Development of a 3D in vitro model of cancer progression by Magdeldin, T
  
 
 
 
 
Development of a 3D in vitro model of 
cancer progression 
 
 
Tarig Magdeldin 
 
 
Submitted in partial fulfillment of the requirements for the 
degree of Doctor of Philosophy  
 
Division of Surgery and Interventional Science 
University College London 
 
April 2016 
 
 
 
 
 
  
 
 
I, Tarig Magdeldin, confirm that the work presented in this thesis is my own.  
Where information has been derived from other sources, I confirm that this has been 
indicated in the thesis. 
 
 
 Signed ……………………………………… 
 
 
 
 
 
 
 
 
 
 i 
 
Acknowledgements 
I would like to express my most sincere gratitude to my supervisors, Dr. Umber 
Cheema and Professor Marilena Loizidou for their endless support, guidance and 
friendship over the duration of this work. You were always there to offer words of 
encouragement and a little dose of optimism when I needed it most. Your stimulating 
suggestions have always taught me to think outside the box and for that I am 
eternally thankful.  
I am grateful to TAP Biosystems for their financial contributions to this project, 
which without this research would not have been possible. I would also like to thank 
Dr. Rosemary Drake, Dr. Grant Cameron and Dr. Cécile Villemant for their 
overwhelming support and thoughtful discussions from the outset of my PhD and 
throughout. 
I would also like to thank all of my friends and colleagues at the Institute of 
Orthopeadics and the Royal Free Hospital for their support, expertise and friendship, 
Ms. Rebecca Porter, Ms. Claire Walsh, Dr. Katerina Stamati, Dr. Noah Tan, Dr. 
Hazel Welch, Dr. Kate Ricketts, Dr. Bala Ramesh and Ms. Stephanie Bogan. A 
special thanks to Dr. Víctor López-Dávila who taught me the importance of laughter 
and sanity when it seemed all hope was lost.  
I owe a great deal of thanks to Cheryl Teoh, whom without this thesis would not 
have been possible. You always believed in me and helped me realize the best in my 
abilities. Thank you for your kindness, support, patience and care. 
Most of all, I would like to thank my family for the endless love, support and 
motivation through this journey. Your confidence and belief in me is the main reason 
for all of my achievements. Your sacrifices have brought me to this point and this 
PhD belongs to you as much as it does to me. Thank you for everything. 
 ii 
Abstract 
The hallmark of cancer is the ability of cancer cells to disseminate and invade to 
distant organs. Metastasis accounts for over 90% of cancer related deaths and 
therefore requires a better understanding of the metastatic cascade to develop better 
therapeutic regimens. The metastatic process is heavily influenced by the 
extracellular matrix (ECM) density and composition of the surrounding tumour 
microenvironment. These microenvironmental cues also regulate the angiogenic 
processes within a tumour, facilitating the spread of cancer cells. The aim of this 
thesis was to develop a biomimetic 3D in vitro model of colorectal cancer with 
controllable matrix parameters that regulate cancer invasion, the formation of a 
primitive vascular network and response to targeted drug treatment. 
A novel 3D in vitro cancer model was established based on the removal of interstitial 
fluid in collagen type I hydrogels. Colorectal cancer cells cultured in dense collagen 
gels formed well-defined cellular aggregates mimicking avascular micrometastases 
observed in vivo. Cancer cells invaded from the artificial cancer mass (ACM) into 
the stromal surround in cell specific patterns, either as spherical aggregates or cell 
sheets. Invasion into a denser collagen matrix altered the migration pattern 
predominantly to cell sheets. Laminin was found to enhance the invasion profile of 
colorectal cancer cells independent of stromal matrix density. The pro-invasive and 
epithelial-mesenchymal transition (EMT) markers MMP7 and vimentin were 
upregulated in 3D cultures in comparison to 2D monolayers. 
Stromal cultures containing fibroblasts and endothelial cells formed highly branched 
end-to-end vascular networks in the presence of laminin. The addition of cancer cells 
produces significantly longer but substantially less interconnected vascular networks 
mimicking in vivo ‘leaky’ tumour vasculature. The loss of CK20 by invading cancer 
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cells significantly correlated with the overall distance of invasion into the stromal 
surround. Although the expression of the biomarker EGFR was upregulated in 3D, 
targeted treatment using cetuximab lead to a greater inhibition profile in 2D 
monolayers than in 3D cultures. Drug resistance in 3D cultures corresponded with 
the presence of cancer stem cells. 
These findings signify the importance of 3D in vitro cancer models as important 
tools to study the effect of microenvironmental conditions on tumour malignancy. 
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Chapter 1 Literature review 
 
 
Chapter One 
 
Literature Review 
 
1 Introduction  
Colorectal cancer (CRC) is the third most common diagnosed cancer and is 
responsible for around 12% of all cancer related deaths annually worldwide[1]. The 
incidence rate of CRC varies enormously with the highest reported cases occurring in 
more developed regions such as North America, Europe and Oceania[2]. High risk 
factors in these regions are mainly attributed to a bad diet (high in animal fat, low in 
fibre), a lack of physical activity, obesity and smoking[3]. Cancer outcomes would be 
more successful with improved imaging techniques, which would both accurately 
define the extent of disease progression at primary detection and follow up progress 
after treatment; and secondly, better therapeutic regimens to be used when the 
disease cannot be managed by surgical resection alone. The majority of current 
cancer models used for developing novel therapeutics at the pre-clinical stage 
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involve either two-dimensional (2D) in vitro reductionist cell culture or injecting 
cancer cells into genetically engineered severe combined immunodeficiency (SCID) 
animal models. Underlying mechanistic investigations are not always easy in these 
models due to the absence of extracellular matrix (ECM) interactions associated with 
the local tumour microenvironment or the biological complexity of in vivo animal 
models. The ECM is vital to cancer initiation and progression as it provides cells 
with physical, chemical and biomechanical cues that regulate the growth of a tumour. 
During the growth of a tumour, the ECM becomes highly deregulated and promotes 
the migration of cancer cells to distinct regions through the disorganized tumour 
vascular supply. In order to understand the growth of CRC, an understanding of the 
molecular basis of CRC initiation and progression and the role of the tumour 
microenvironment is required. 
 
1.1 The pathogenesis of colorectal cancer 
The majority of CRC cases are adenocarcinomas that originate from colonic 
epithelial cells. In addition to the significant lifestyle and environmental risk factors, 
there has been considerable progress in pinpointing specific genetic mutations that 
contribute to or underlie the progression of CRC. Structurally, the colon contains 
columnar and mucinous cells (glands/crypts) that are approximately 40-60 cells 
deep. In healthy colonic tissue, proliferation of epithelial cells is restricted to the 
lower portions of the glands and cells migrate toward the upper mucosal surface[4]. 
During the initiation of tumourigenesis, epithelial cells become incapable of 
implementing the normal cellular apoptotic signal during migration from the base to 
the glands and develop an increased proliferative profile[5]. This cellular dysfunction 
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begins with complications in cell division and subsequently differentiation that leads 
to the progression of morphologic lesions such as adenomas, aberrant crypt foci 
(ACF), polyps and ultimately tumours.  
The development of CRC occurs through a sequence of well characterized 
histopathological changes from adenoma to carcinoma (Figure 1.1) caused by an 
accumulation of genetic and epigenetic mutations[6].  
 
 
Figure 1.1: The adenoma – carcinoma sequence during CRC development. Histological panels 
that show the morphological characteristics of lesions at each step. (Image adopted from [7]) 
 
Sporadic CRC makes up ~85% cases and contain an abnormal molecular profile 
including chromosomal imbalances in chromosomes 5q, 8p, 17p and 18q which 
contain important oncogenes and tumour suppressor genes that contribute to 
carcinogenesis[8]. On the other hand, genetic cases (~15% cases) are usually linked 
with syndromes such as familial adenomatous polyposis (FAP) and Lynch syndrome 
(LS), which carry a significant increased risk of the development of CRC. FAP is an 
inherited disorder that involves the presence of numerous adenomatous polyps 
scattered through the intestinal mucosa[9]. Although these polyps are initially benign, 
without treatment they are highly likely to become malignant and are recognized as 
major predispositions to CRC initiation. Many of the key genes involved in 
colorectal carcinogenesis include the oncogene KRAS and the tumour suppressor 
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genes P53, SMAD4 and APC[10]. Mutations in the APC gene are the most common 
prerequisite for CRC development and the risk by the age of 40 years for carriers of 
the mutated version is almost 100%[11]. APC mutations are found in the earliest 
stages of the adenoma to carcinoma sequence and help to form ACF, which are 
precursors to the development of colonic polyps. APC is an important regulator and 
binding partner of the cellular adhesion molecule β-catenin[12]. When mutated, APC 
cannot bind to β-catenin, which leads to the accumulation of intracellular β-catenin 
levels. This rise in β-catenin levels constitutively activates the Wnt signaling 
pathway, a key signal transduction pathway involved in the homeostasis of the 
colonic epithelium[13]. Wnt signaling molecules have been implicated in tumours of 
the breast, prostate, brain and colon[14]. More recently it has been implicated in 
critical aspects of normal cellular function such as cell proliferation, migration, 
polarity and organogenesis during embryonic development[15]. Due to its critical 
function in embryonic development, defects in the Wnt pathway are characteristically 
associated with many cancers. 
In LS (also known as hereditary nonpolyposis CRC, HNPCC) the molecular 
mechanisms vary slightly, with a high occurrence of frameshift mutations and base 
pair substitutions that appear in microsatellites. Microsatellites are repeating 
sequences of DNA, largely between 1-6 base pairs in length and occur throughout 
the genome. This microsatellite instability (MSI) is mainly characterized by 
mutations involved in mismatch repair (MMR) proteins that initiate repair of 
nucleotide errors during DNA replication such as MLH1, MSH2, MSH6 and 
PMS2[16,17]. Mutations in MLH1 are also responsible for ~12% of sporadic CRC. 
This is due to hypermethylation of the CpG islands in the promoter region of MLH1, 
which prevents MLH1 transcription ultimately leading to deficient MMR and high 
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levels of microsatellite instability (MSI-H)[17]. 
 
 
1.1.1 The EGFR pathway in colorectal cancer 
EGFR is a 170-kDa growth factor receptor tyrosine kinase (RTK) that belongs to the 
ErbB family of cell membrane receptors. Its main autocrine ligands are EGF and 
transforming growth factor-alpha (TGF-α), which have been shown to be activators 
of cell proliferation in CRC[18]. Ligand binding of EGF induces dimerization of 
EGFR leading to autophosphorylation of intracellular tyrosine kinases. This initiates 
two main pathways known as the mitogen-activated protein kinase (MAPK) pathway 
and the phosphatidylinositol 3-kinase (PI3K) pathway (Figure 1.2). The activation of 
downstream transcription factors results in increased cell proliferation, adhesion, 
migration and angiogenesis[19]. 
EGFR is commonly overexpressed in a number of cancers including ovarian, 
cervical and bladder carcinomas with a strong association between overexpression 
and poor patient outcome[20]. In CRC, the clinical significance of EGFR is not as 
clear. Some studies have found a strong correlation between EGFR overexpression 
and poor survival[21] while other studies have reported conflicting findings[22]. Due to 
the pro-tumourogenic properties of EGFR, therapies targeting this receptor have 
gained significant attention in recent years[23,24]. 
While the use of cetuximab has led to great success in the treatment of CRC, the 
exact molecular mechanism underlying the clinical response remains largely 
unknown. Mutations within the EGFR pathway affect the response of this targeted 
therapy and it remains largely ineffective in a subset of KRAS and BRAF mutant 
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tumours[25,26]. This is typically due to constitutive activation of both the RAS and 
RAF proteins downstream of EGFR. 
Approximately 40% of all CRC patients carry a KRAS mutation, where 90% of these 
mutations occur in codons 12 and 13[27]. Mutations in these codons lead to 
continuous activation of the MAPK pathway regardless of upstream EGFR signaling. 
There have been several studies in recent years which have shown that KRAS 
mutations are significantly associated to anti-EGFR therapy resistance and poor 
overall patient survival[7,26,27]. 
On the other hand, BRAF mutations occur in around 5-10% of all CRC cases and 
V600E mutations represent 90% of all BRAF mutations[28]. While mutations in KRAS 
occur more specifically in CRC, BRAF mutations occur in a variety of different 
cancers including ovarian, thyroid and particularly melanomas[29]. While BRAF 
mutations have been associated with poor patient outcome, the therapeutic efficacy 
of anti-EGFR treatment on BRAF mutant tumours has been contradictory[30]. It is 
routinely accepted that KRAS and BRAF mutation status should be tested as 
prognostic biomarkers instead of EGFR expression levels[27]. 
 7 
 
 
Figure 1.2: The EGFR signaling pathway. Binding of the extracellular ligands to EGFR stimulates 
downstream signaling to regulate cell proliferation, migration and survival via the MAPK signaling 
pathway. 
 
 
1.1.2 The tumour microenvironment 
The tumour microenvironment consists of a variety of cell types including 
fibroblasts, endothelial cells (ECs) and immune cells such as macrophages and 
lymphocytes. Other non-cellular components include the ECM, which is a large 
assortment of proteins, glycoproteins and polysaccharides, ECM remodeling proteins 
such as MMPs, soluble growth factors such as growth factors (VEGF, PDGF and 
FGF) and cytokines (TGFβ, TNFα and IL-6 and 10)[31,32]. The ECM not only 
provides structural support for cells but also directs their proliferation, differentiation 
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and migration through a series of chemical and biomechanical cues via integrins and 
discoidin domain receptors[33].  
In healthy colonic tissue, the local microenvironment acts as a physical barrier 
against carcinogenesis and promotes normal tissue function and homeostasis[34]. In 
CRC, the sequence of adenoma to invasive carcinoma is mediated via the 
surrounding tumour microenvironment. Neoplastic epithelial cells modulate the 
expression of ECM remodeling proteins, which are mainly produced by adjacent 
stromal cells to promote their own growth, survival and invasion. Initially, these 
stromal cells are not tumour-promoting cells, and it has been shown before that they 
may confer anti-tumourogenic properties[35]. However, as a tumour grows the cancer 
cells exploit the stromal cells function to remodel the ECM to stimulate a pro-
tumourogenic environment. This deregulation of the surrounding ECM extensively 
modifies the structure, composition and stiffness of the microenvironment and is 
understood as a necessary event for the dissemination of cancer cells to distant 
sites[36]. The increase in ECM stiffness is due to increased cross-linking of collagen 
that alters the biomechanical properties, which cells respond to by exerting markedly 
different forces in response[37]. Changes in the stiffness alter gene expression profiles 
through mechanotrasnduction pathways and directly impacts how migratory cancer 
cells interact with the surrounding ECM[38]. 
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Figure 1.3: Structural differences between healthy tissue and the tumour microenvironment. 
The tumour microenvironment contains increased ECM deposition, disorganized blood vessels and 
chronic inflammation that leads to the recruitment of immune cells. (Image adopted from [39]). 
 
 
1.1.3 Mechanisms of cancer cell invasion 
Despite the advances in treatment modalities, metastasis, the spread of cancer cells 
from the primary tumour site to distant organs, remains the foremost cause of cancer 
related mortality[40]. The transformation of cancer epithelial cells is plays a vital role 
in the development of secondary tumour sites[41]. This highly conserved process, 
known as the epithelial to mesenchymal transition (EMT) governs a variety of 
normal cellular processes in embryonic development and tissue repair[42]. In 
carcinomas, the EMT process leads to a shift in cell phenotype resulting in the loss of 
cell-cell adhesion, apico-basal polarity and active remodeling of the actin 
cytoskeleton required for motility. Simultaneously, the increased expression of the 
mesenchymal marker vimentin and deceased expression of the epithelial marker e-
cadherin gives rise to the elongated spindle-like morphology that is often associated 
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with increased migration and invasiveness[43].  
Cell migration is a highly complex and coordinated process which involves an 
intricate series of interactions between tumour cells and the tumour 
microenvironment that facilitate both breakdown of the surrounding ECM and 
subsequent invasion. There are three described mechanisms by which tumour cells 
invade. Tumour cells can migrate either in a mesenchymal or collective type of 
invasion and an amoeboid type of movement[44].  
One example of cancer cell invasion which occurs within the gastrointestinal tract 
gives rise to small clusters of cancer foci are often seen at the invasive front of 
carcinomas[45]. This process of tumour budding can often be quantified on 
histological samples and is routinely used in the clinic to assess tumour 
aggressiveness[46]. The migration of tumour buds is thought to be largely mediated 
by activation of signalling cascades controlled by integrins; adhesion molecules that 
facilitate cell-cell and cell-matrix interactions, combined with the action of matrix 
metalloproteinases (MMPs) to enable basement membrane penetration. This 
mechanism of invasion is suggested to be representitive of the EMT process in 
carcinomas and is associated with higher tumour grade and lymph node 
metastases[47].  
Another pattern of migration exhibited by cancer cells is the movement of whole cell 
sheets. In cancer, this mechanism of migration is exclusive to carcinomas and is 
thought to be, at least in part controlled by the active proteolysis of the basement 
membrane barrier by MMPs[48,49] followed by collective migration. Cells maintain 
their cell-cell junctions in order to move as a cohesive unit. Although, the precise 
molecular pathways are not well understood it is likely they would mimic epithelial 
cell sheet migration during embryonic development[50]. One member of the MMP 
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family which is expressed by epithelial cells and has been implicated in colorectal 
cancer invasion is MMP7[51]. MMP7 is involved in the degradation of a range of 
ECM proteins including collagens and laminin and is often expressed solely by 
tumour cells whereas most MMPs are expressed by adjacent stromal cells[52].  
While tumour budding and collective migration follow a mesenchymal pattern, the 
migration of single cells follows an amoeboid mechanism[53]. This type of migration 
is thought to be the fastest mechanism of cancer cell migration with reported speeds 
of up to 4µm/min observed in vivo[54]. Amoeboid migration is utilized by leukocytes 
and it is thought invasive cancer cells can hijack the same mechanism to 
metastasize[55]. Recent studies have shown that amoeboid migration is independent 
of the activity of proteases and cells migrate by squeezing through gaps within the 
fibrillar collagen network[53]. The activation of chemoattractant receptors on the 
membranes of cells triggers actin polymerization and the formation of pseudopods. 
Contraction of the cortical actin networks driven by Rho-ROCK signaling promotes 
the remodelling of the cell cortex ultimately generating an irregular morphology 
characteristic of amoeboid migration[56]. Mesenchymal and amoeboid mechanisms of 
cancer are mutually interchangable highlighting the plasticity and complexity of 
tumour invasion mechanisms[57]. 
 
Figure 1.4: The plasticity of tumour invasion mechanisms. Cancer cells can undergo changes in 
motility in response to their environment. (Image adopted from [57]) 
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1.2 Neovascularization 
The development of an adequate blood supply is essential to a growing tumour as it 
provides nutrients, oxygen and aids in the removal of waste products[58]. The process 
of developing new blood vessels is known as neovascularization and occurs mainly 
by three main mechanisms; vasculogenesis, arteriogenesis and angiogenesis. This 
section will focus mainly on vasculogenesis and angiogenesis, as these are the most 
well understood processes in both embryonic and adult blood vessel development 
and in the development of diseases such as cancer. 
 
 
1.2.1 Vasculogenesis 
Vasculogenesis is the formation of new blood vessels by a de novo production of 
endothelial cells (ECs). Typically, vasculogenesis occurs during development of the 
mammalian embryo where angioblasts differentiate into ECs that assemble into 
vascular networks (Figure 1.5a)[58]. There are five main processes that occur during 
vasculogenesis; the birth of angioblasts, the end to end aggregation of angioblasts, 
angioblast elongation and the assembly of cord-like structures, the amalgamation of 
individual vascular networks to form capillary-like networks and finally the 
endothelialization and lumenization of these networks[59]. Both cytokine-mediated 
interactions and a sophisticated series of cell-cell and cell matrix interactions 
regulate these processes. These growth factors include vascular endothelial growth 
factor (VEGF) and its receptor VEGFR-2, which regulate differentiation of 
mesenchymal progenitors down an endothelial lineage, CD31 and CD34 which 
establish strong cell-cell interactions, VEGFR-1 involved in lumen formation, 
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angiopoietin-1 (Ang-1) and its receptor Tie2 involved in blood vessel maturation and 
integrins that are essential in regulating cell shape and migration[59,60]. The 
importance of these molecules have been implicated in gene knockout studies in 
mice[61–64]. 
 
 
1.2.2 Angiogenesis 
On the other hand, angiogenesis is the sprouting of new blood vessels from pre-
existing vasculature (Figure 1.5b). It is the best understood of all the 
neovascularization processes due to its presence of in a variety of diseases such as 
ischemia, wound healing, cancer and inflammatory disorders[65]. Angiogenesis 
begins with vasodilation in pre-existing blood vessels, a process that involves nitric 
oxide[66]. The upregulation of VEGF in the local microenvironment by ECs and 
stromal cells leads to an increase in vascular permeability. This permeability coupled 
with MMP degradation of the basement membrane recruits pericytes and smooth 
muscle cell migration. Strict regulation of this proteolytic degradation is fundamental 
as excessive degradation of the ECM leaves behind too little matrix support for the 
new branches to sprout. Pro-angiogenic molecules such as VEGF and basic 
fibroblast growth factor (bFGF) are further released through paracrine signaling 
pathways by stromal cells. The increase of pro-angiogenic stimuli guides EC 
migration that occurs through tip and stalk cells[65]. Tip and stalk migration is 
regulated through Notch signaling which plays a key role in directing EC behaviour 
during vessel patterning[67]. Microenvironmental cues then regulate the position of 
tip cells and drive them to migrate to the new blood vessel where they fuse to extend 
the vascular network[58]. The final step of blood vessel maturation requires the 
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autocrine production of platelet derived growth factor (PDGF) by ECs that recruits 
pericytes and smooth muscle cells to coat the vessel wall[68]. 
 
 
 
Figure 1.5: Hallmarks of blood vessel formation. A schematic diagram depicting (a) the 
vasculogenic process during blood vessel formation where angioblasts differentiate into ECs, form 
vascular cords and acquire a lumen, (b) the angiogenic process depicting vessel sprouting, tip cell 
migration and fusion followed with lumen formation, (c) the sequential steps involved in vascular 
remodeling of blood vessels. (Image adopted from [65]) 
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1.2.3 Tumour induced angiogenesis 
As described in Section 1.2, angiogenesis is a highly regulated process that involves 
VEGF, angiopoietins, Notch and the integrin family of receptors. During normal 
embryonic development there is a delicate balance between these pro-angiogenic and 
anti-angiogenic factors that creates healthy functional blood vessels. During normal 
embryonic development, there is a temporary shift towards pro-angiogenic signaling 
this is kept in check by inhibitory mechanisms such as endostatins and 
angiostatins[69,70]. During the growth of a tumour, this balance is lost resulting in a 
range of morphological and functional differences between normal and tumour 
vasculature.  
Tumour vasculature is made up of a highly disorganized, hyperpermeable, immature 
blood vessel network consisting of abnormal vessel dynamics (figure 1.6)[71]. There 
is a loss of the vascular hierarchy whereby capillaries, arterioles and venules are 
indistinguishable from one another by immunohistochemical analysis[72]. 
Furthermore, the diameters of blood vessels is often irregular and are an inconsistent 
shape with the endothelial layer containing spaces that contribute to the leakiness of 
blood vessels[73]. Adjacent proliferating tumour cells cause compression of the 
vascular walls of the blood vessels increasing the interstitial pressure[74]. This 
disorganization of the vascular supply surrounding a tumour results in an inability to 
supply oxygen and remove waste products efficiently leading to hypoxia and 
acidosis in the local microenvironment[75,76]. Understanding some of the molecular 
mechanisms involved in how the tumour vasculature is disorganized is essential to 
developing novel strategies to improve the delivery of anti-cancer therapies. For 
example, micro-regional hypoxia is associated with resistance to both chemotherapy 
and radiotherapy[77,78]. Hypoxia inducible factor -1 (HIF-1) is an important regulator 
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of the hypoxic response in a tumour. Under hypoxic conditions, HIF-1α dimerizes 
with HIF-1β, creating a dimer complex which then translocates to the nucleus 
leading to increased VEGF transcription[79]. 
Of all the molecular markers involved in angiogenesis, none have gained more 
attention than the VEGF family and their receptors (Figure 1.6). However, the role of 
VEGF is not only limited to angiogenesis and vascular permeability and has been 
shown to regulate the function of cancer cells[80]. For example, there have been 
significant amounts of VEGFR found on cancer cells of the breast and colon[81,82]. It 
is thought that overexpression of VEGF in response to the local hypoxic environment 
may stimulate the production of VEGFR on cancer cells which respond to other 
VEGF ligands to support tumour growth. Therefore, the overexpression of VEGF in 
a variety of tumours implies the presence of an autocrine VEGF/VEGFR signaling 
loop. This has been demonstrated in subgroups of leukemia whereby disrupted 
VEGF/VEGFR2 autocrine loops induce cancer cell apoptosis and inhibit cancer cell 
migration[83]. Recent studies have shown in a model of colorectal cancer that 
VEGFR1 activation by the VEGF-A or VEGF-B ligands lead to activation of the 
MAPK pathway ultimately stimulating cell proliferation, migration and invasion[84]. 
It is postulated that VEGF may promote growth by directly acting on receptors via an 
EC independent manner opening up a new avenue of anti-cancer therapies that target 
VEGFR on cancer cells. 
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Figure 1.6: The role of VEGF in tumour induced angiogenesis. VEGF ligands expressed by cancer 
and stromal cells stimulate VEGFR expression by lymphendothelial, endothelial or hematopoietic 
cells. The presence of VEGF enhances the proliferation, survival, and migration of cells in the tumour 
microenvironment. (Image adopted from [85]) 
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1.3 Three dimensional in vitro models of cancer 
Until recently, the gold standard for in vitro pharmacological testing of anti-cancer 
drugs has been reductionist 2D cell culture. Classical 2D monolayer studies have 
proven invaluable for dissecting cancer cell behaviour to a certain degree. However, 
a large body of evidence demonstrates that 2D cell culture does not accurately reflect 
the 3D in vivo tumour microenvironment[86–88]. This is particularly relevant for 
oxygen and nutrient gradients, drug pharmacokinetics and gene expression profiles. 
The lack of a clear understanding of how cell-cell and cell-matrix interactions 
influence the progression of a tumour has prompted development of novel 3D in 
vitro cancer models to address this issue. Another incentive to develop 3D in vitro 
models is to replace, reduce and refine the use of animal models in research in line 
with the NC3R initiative. 
Many recent studies have demonstrated that the unnatural flat 2D surface which 
basic cancer research is carried out may be inadequate for accurate drug testing[89]. 
Therefore, a wide generation of new sophisticated organotypic 3D cell culture 
systems have been adopted to improve efficacy outcomes of new therapeutics. The 
use of these in vitro 3D culture models helps bridge the gap between conventional 
2D cell culture studies and animal models, improving the pre-clinical selection 
process of new chemotherapeutics while simultaneously lowering the development 
costs. Development of these models is essential in constructing physiologically 
relevant models to study the underlying mechanisms of cancer progression.  
The tumour stroma has also been identified as an important regulator of 
tumourigenesis[90]. This includes stromal cells such as fibroblasts, endothelial cells 
and immune cells that often interact close to and around tumours in vivo. The tumour 
vasculature, which is often leaky for example, can influence the distribution of a 
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pharmaceutical agent, as it needs to penetrate vessel walls before it can permeate 
sufficiently through the tumour tissue. In comparison to normal healthy tissues the 
tumour stroma, consists of a distorted ECM and an increased number of stromal cells 
that release MMPs that facilitate tumour progression[91]. As tumours are 
heterogeneous in nature[92], drug distribution throughout them is often also thought to 
be heterogeneous. Within the tumour microenvironment, differing regions of 
hypoxia and pH in addition to the increases in the interstitial fluid pressure can all 
affect the macromolecular penetration of drug through the tissue.[93] Therefore, 
improving drug bioavailability and delivery is essential to sustaining adequate 
exposure of cancer cells to toxic agents.  
Cell growth and function lies within a continuous intricacy of cell-cell and cell-
matrix interactions facilitated by the ECM - a heterogeneous collection of 
interlocking macromolecules of collagens, proteoglycans, polysaccharides and 
various other soluble matrix proteins[94]. The ECM mediates many cellular functions 
through focal adhesions found on the cell membranes of cells. These focal adhesion 
points are composed of cytoplasmic proteins and cell membrane receptors that 
interact with the cell cytoskeleton to activate mechanotransduction pathways to 
regulate gene expression[38]. Biomaterials aim to mimic these functions of the ECM. 
From a scaffold perspective, fundamental design principles include good mechanical 
properties that support and maintain cellular function, biocompatibility to support 
cell viability (of cancerous and stromal cells) and biodegradability to be able to 
mimic cancer invasion and ECM degradation[95].  
Although tumours are disorganized organs, there is still an inherent level of 3D 
structure due to tumour cells interacting with the surrounding ECM. One of the most 
striking differences between 2D and 3D cultures is the morphological differences 
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caused by the presence of the ECM. Cells in monolayer culture adhere and spread on 
flat surfaces in 2D dimensions, i.e. only in the horizontal plane. For example, the 
absence of movement in the vertical plane forces apical-basal polarity which may be 
important for cell types such as epithelial cells but not for others such as fibroblasts, 
which prefer a front to rear polarized shape necessary for cell migration[96]. For 
example, these interactions define cell polarity and geometry, which are critical for 
normal cellular function. Weaver and colleagues have demonstrated that the 
formation of polarized 3D structures by both normal and malignant epithelial cells, 
protected cells against apoptosis whereas non-polarized cells remained sensitive to 
apoptosis[97]. Apart from the mechanical support, the ECM also regulates the 
distribution of nutrients, cytokines and gases such as oxygen and carbon dioxide, 
which are all necessary for processes such as angiogenic sprouting and wound 
healing[98]. In monolayer cultures, nutrients and soluble factors diffuse freely 
throughout the culture medium and it is difficult to replicate the gradients that are 
present in tissues. Due to the structural organization present in 3D cultures, this can 
act to hinder the penetration of soluble factors, creating an oxygen or nutrient 
gradient that can regulate long-term morphogenetic events such as the presence of 
hypoxia[99].  
The following section aims to discuss some of the 3D in vitro cancer models used in 
recent years. They are classified broadly into two categories; scaffold free and 
scaffold based culture systems. Scaffold free approaches include the use of 
multicellular spheroids and scaffolds based approaches aim to mimic the 
macromolecular structure of the ECM and fall under two main categories: natural 
scaffolds and synthetic polymers.  
More complex in vitro tumour modelling has prompted the use of biomaterial-based 
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approaches for tissue engineering. This has prompted the use of both natural and 
synthetic matrices with customizable properties to mimic the 3D microenvironment 
in vivo. Although many of these materials were initially intended for in vivo tissue 
engineering and regenerative medicine, many have recently been applied to cancer 
research as established 3D cell culture models.  
 
 
1.3.1 Multicellular tumour spheroids 
Scaffold free 3D in vitro cancer models mainly includes multicellular tumour 
spheroids, which are three-dimensional assemblies of cancer cells[100]. They are the 
most widespread 3D in vitro models used for drug testing. These are aggregates of 
cancer cells, and due to their cellular organization have been shown to mimic the 
phenotype and gene expression profile of tumours in vivo[101]. They comprise of 
actively proliferating surface exposed cells with nutrient deprived hypoxic quiescent 
cells in the inner region of the spheroid (Figure 1.7). Multicellular spheroids can be 
formed using a variety of different techniques. These include the hanging drop 
method, spinner flask cultures and culturing cells on non-adherent surfaces such as 
those pre-coated with agar[100]. The hanging drop method is the most common 
method used and involves pipetting cells in small volumes of media on the inner side 
of a petri dish lid and inverting the lid upside down. Under the force of gravity, this 
causes cells to aggregate at the bottom of the hanging drop and spheroids can 
typically take 24 hours to form for a variety of different cancer cell lines[102].  As 
drug efficacy is usually lost at the 3D pathophysiological level due to inadequate 
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penetration of the drug molecule, spheroids are often the cheapest and simplest 
models to employ to test new drugs as a precursor to animal studies[103]. 
 
Figure 1.7: Gradient formation in vivo and in multicellular tumour spheroids.  A schematic 
diagram depicting the oxygen and nutrient gradients in a tumour compared to multicellular spheroids. 
(Image adopted from [104]) 
 
With regards to multicellular spheroids, the most suitable model of cancer must be 
carefully chosen to match the requirements of the investigation. For instance, 
spheroid monocultures have long been used to identify new mechanistic pathways 
involved at the 3D cellular level, whereas spheroid co-cultures have been used to 
explore combinations of therapies such as radiotherapy and anti-neoplastic drugs[105]. 
Spheroids have recently been employed to evaluate the anti-proliferative effects of 
two anti-cancer drugs with distinctive activity profiles; 5-fluorouracil (5-FU) that 
targets actively proliferating cells and tirapazamine (TPZ), a hypoxia-activated 
toxin[106]. Following drug incubation, 3D spheroids displayed remarkable resistance 
to 5-FU in comparison to their 2D counterparts whereas TPZ induced a far greater 
reduction in cell viability in 3D spheroids than 2D cultures. These differences in 
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chemosensitivity may be attributed to the fact 5-FU actively targets proliferating 
cells and not the quiescent cells within the spheroids, while TPZ targets hypoxic cells 
known to be present within spheroids.[107] This study further highlights the 
differences of cytotoxicity treatment when the 3D physiological environment is 
enhanced. 
With regards to drug evaluation, spheroids are inherently limited by several factors. 
As there is no external bulk ECM component present in spheroid cultures, it is 
difficult to model cancer invasion without nesting the spheroids within a matrix to 
which they can invade. However, cells cultured in 3D have also been shown to 
endogenously secrete various ECM proteins such as collagen and laminin[108]. While 
cells cultured in 2D also secrete ECM proteins, they are typically upregulated in 3D 
culture systems. This has been demonstrated in a 3D model of pancreatic ductal 
adenocarcinoma (PDAC) where the authors postulated the increase in matrix 
production was strongly correlated to the sphere formation and compaction of these 
cells in a 3D spatial configuration[109]. Due to the lack of an adequate vascular 
system, oxygen, nutrients and other compounds diffuse through the spheroids 
creating a concentration gradient limiting these compounds to the outer most 
cells[100]. This not only limits the maximum size of spheroids to ~500µm, but also 
prevents sufficient distribution of most drugs, which tend to be molecules larger than 
oxygen or carbon dioxide for instance. The diffusion properties of new prospective 
anti-cancer drugs are occasionally overlooked when they are assessed and therefore, 
more detailed pharmacokinetic studies are required to distinguish between general 
lack of efficacy of the agent and insufficient drug penetration. Nonetheless, there has 
been noteworthy progress in this field. A recent study reported exploiting diffusion 
gradients within spheroids to evaluate penetration of large antibody molecules such 
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as the anti-mesothelin immunotoxin SS1P[110]. The fluorescently labelled SS1P 
showed limited penetration that plateaued after 4 hours of incubation, which matched 
the reduced cytotoxicity observed in spheroids compared with 2D monolayers. 
However, this also reiterates the need for a standard analytical endpoint assay and 
furthermore, an accurate means for testing cell viability in spheroid cultures and in 
other 3D in vitro disease models. The assays must provide suitable accuracy, 
sensitivity and reproducibility while testing a robust variety of compounds. 
Classically, the same methods used to assess cell viability in 2D monolayer are used 
for spheroid cultures[111,112]. As there is currently no universal endpoint assay; a 
variety of different methods can be employed in combination to provide the 
appropriate results.  
 
1.3.2 Natural scaffolds 
Natural scaffolds are composed of ECM components that make up an interlocking 
mesh of fibrous proteins and glycosaminoglycans (GAGs) including collagens, fibrin 
and hyaluronic acid[113,114]. They provide tissues and cells with mechanical stability 
and enable cell-matrix interactions to regulate normal tissue function. When used for 
in vitro 3D cell culture, these scaffolds exist as cross-linked networks of ECM 
proteins known as hydrogels. Although one of their main disadvantages is their high 
water content (upwards of 99%), they are still extremely useful for mechanistic 
investigations as they are entirely malleable by cell behaviour. Natural scaffolds are 
also biologically active and promote excellent cell adhesion and growth[115].  
Collagen type I is the current gold standard for 3D in vitro cell culture as collagen 
type I is the main constituent within the in vivo ECM[116]. Despite its poor 
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mechanical strength, it is the most widely used natural scaffold for 3D in vitro cell 
culture. It can be used either on its own or in combination with other ECM proteins 
such as glycosaminoglycan or laminin[115,117]. Using a collagen type I scaffold, recent 
studies have reinforced the importance of the tumour microenvironment, particularly 
in terms of specific populations of cells, such as CAFs[118]. The presence of CAFs 
instead of normal fibroblasts was found to disrupt dual cell co-unit formation in a 
heterotypic model of breast cancer. This was due to the release of high levels of 
MMPs into the surrounding cell culture medium, which led to the breakdown of the 
ECM and subsequent disruption and invasion of cancer cells. Collagen gels have also 
been used to identify novel invasion mechanisms involving Gα13 and discoidin 
domain receptor 1 (DDR1) exploited by pancreatic cancer cells to differentially 
regulate cell-cell junctions promoting cell migration[119]. 
The collagen used throughout this study is acetic acid solubilized rat-tail collagen 
type I. As the collagen is neutralized with sodium hydroxide to a neutral pH, 
fibrillogenesis is initiated and cells are embedded within a random organization of 
collagen fibers[120]. Collagen is highly conserved across entirely different species 
from sponge to human and has undergone very little evolutionary changes over 
time[121]. While the mechanical strength of these hydrogels is weak, plastic 
compression can increase the collagen density and mechanical strength to mimic the 
in vivo tissue barrier. 
Hyaluronic acid (HA) has also been extensively used as a scaffold for 3D cell culture 
of cancer cells. It is a major component of the ECM and plays a key role in cell 
proliferation and migration. Its main receptors CD44, RHAMM and hyaluronidase-1 
(HYAL-1) have been shown to be highly involved in tumour growth and progression 
in a range of different cancers[122]. Porous scaffolds such as HA make excellent in 
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vitro culture models of glioblastoma, as it is the major GAG component of the brain 
ECM[123]. However, HA is negatively charged and prevents optimum cell adhesion. 
This has led to the incorporating of other materials such as chitosan to increase the 
scaffold properties. The development of hybrid scaffolds such as chitosan-HA 
hydrogels have been recently employed to model the microenvironment of 
glioblastoma multiforme (GBM)[124]. GBM cells cultured in chitosan-HA hydrogel 
were highly resistant to doxorubicin and temozolomide in comparison to 2D cultures 
and upregulated a number of stem cell like markers including CD44, Nestin and 
GFAP. Other hybrid materials include HA chemically bound to acrylate groups or 
reactive thiols to increase crosslinking and have been used to test novel nanoparticle 
therapies in a model of prostate cancer[87].  
Another scaffold often used for in vitro tumour modeling and angiogenesis studies is 
the commercially available ECM and basement membrane extract from the 
Engelbroth Holm sarcoma mouse, Matrigel®[125,126]. It is a matrix rich in ECM 
proteins including laminin, enactin and collagen IV, which are the main constituents 
of the basement membrane[127]. However, the exact protein composition is not known 
and it usually contains additional growth factors and cytokines[128]. When used for 
angiogenic assays, the presence of these growth factors induces EC tubule formation 
within hours of encapsulating ECs within the matrix[129]. For tumourogenic studies, 
human mammary fibroblasts and breast cancer cells have been co-cultured in a 
model of Matrigel and collagen and demonstrated the progression from ductal 
carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC)[130]. Other studies 
utilizing Matrigel have shown that CAFs co-cultured with breast cancer cells 
contribute to cancer invasion by upregulating MMP-9 which specifically degrades 
the BM[131]. The presence of ECs in the co-culture also resulted in a significant 
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increase in proliferation and branching ductal alveolar morphology of the 
preneoplastic breast epithelial cells.  
 
1.3.3 Synthetic scaffolds 
The recent increase of synthetic polymers for tissue engineering and regenerative 
medicine applications has prompted the development of more biocompatible and 
biodegradable synthetic scaffolds that can be used as matrices for 3D cancer models. 
Synthetic polymers used for cancer studies include poly (lactide-co-glycolide) 
(PLG), polyethylene glycol (PEG) and poly (ε-caprolactone) (PCL)[132–134]. These 
synthetic matrices aim to mimic the fibrous and interconnected macromolecular 
structures of the ECM. They exist in many different forms including fibers, meshes 
and sponges. Synthetic scaffolds are mechanically stronger in comparison to natural 
scaffolds making them ideal for simulating the dense microenvironment of a tumour. 
Although they are not without their disadvantages and often tend to have poor cell 
adhesion and must undergo surface property modifications to improve their 
biocompatibility and functionality[135]. Biofunctionalization of polymers can include 
surface modifications such as adding ECM components such as collagen, fibronectin 
or laminin to improve cell adhesion[136]. Customizable features such as matrix 
composition, organization, stiffness and orientation make synthetic scaffolds ideal 
for use as scaffolds for 3D cancer models. 
Synthetic hydrogel matrices such as PEG have been recently modified with the 
integrin-binding motif Arg-Gly-Asp (RGD) and MMP sensitive substrates to mimic 
certain degradability aspects of the ECM[137]. Epithelial ovarian cancer cells seeded 
in this scaffold formed aggregates of cells that resemble tumour masses found in the 
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peritoneal cavity of patients with advanced disease. Matrix stiffness was also found 
to regulate the proliferation of these cancer cells. PEG hydrogels have also been used 
to investigate the motility profile between normal and cancerous cells by tuning the 
mechanical properties of the scaffold, including the microarchitecture and the overall 
material stiffness[138]. Controlling pore size and density of the material is critical to 
understanding some of the molecular mechanisms involved in metastases[139]. 
The co-polymer, PLG which is FDA approved has also been used as a model of oral 
squamous carcinoma[126]. This model demonstrated the presence of central hypoxia 
where oxygen measurements revealed similar oxygen concentration levels to those of 
in vivo tumour masses. Several genes including VEGF, IL-8 and bFGF that are 
associated with hypoxia were found to be upregulated in comparison to 2D cultures. 
Other co-polymers with high mechanical strength include poly (lactic acid) (PLA) 
used as microparticles containing a chemically bound mixture of poly vinyl alcohol 
(PVA) and chitosan[140]. Breast cancer cells were shown to grow as spheroids on the 
surface of the porous microparticles and formed tumour like structures in vitro with 
reduced drug efficacy suggesting the role of cellular architecture on drug 
distribution.  
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1.4 Aims and objectives 
The aim of this research was to apply the principles of tissue engineering and cancer 
biology to develop a spatially relevant collagen based biomimetic three-dimensional 
(3D) in vitro model of cancer, termed a ‘tumouroid’ that aims to mimic important 
aspects of the in vivo tumour microenvironment. The main objective was to 
reproducibly develop a 3D in vitro cancer model with the ultimate aim of providing 
results relevant to the in vivo scenario. ECM stiffness and composition are factors 
that are often overlooked in cancer research but have more increasingly been 
implicated as significant factors involved in cancer progression[41]. Utilizing collagen 
type I hydrogels, we used plastic compression (PC) to increase and control the matrix 
density to mimic the dense nature of in situ tumours. The effect of matrix stiffness on 
cancer invasion was investigated. The stromal compartment was also populated with 
the basement membrane protein laminin, and stromal cells such as fibroblasts and 
endothelial cells, which are found in the local tumour microenvironment. The 
interplay between cancer cells and stromal cells is a critical step in the metastatic 
cascade. The development of a primitive vascular network was also explored due to 
the presence of the endothelium adjacent to a tumour in vivo, as these cell-cell 
interactions have been shown to promote tumourigenesis. Finally, we investigated 
targeted treatment using the clinically used anti-epidermal growth factor receptor 
(EGFR) inhibitor cetuximab to validate the tumouroids as a suitable in vitro drug-
screening platform. 
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1.5 Hypotheses under test 
1. Increases in collagen type I density and concentration will enhance colorectal 
cancer cell migration. 
2. The attachment factor and BM protein laminin will increase colorectal cancer 
cell migration. 
3. The presence of an active stroma (the presence of fibroblasts and ECs) will 
enhance colorectal cancer cell migration. 
4. ECs will form end-to-end vascular networks in the presence of fibroblasts in 
dense collagen type I gels. 
5. The biomarker EGFR will be significantly upregulated in tumouroids in 
comparison to 2D monolayers. 
6. The effect of targeted treatment of EGFR will be hindered in tumouroids in 
comparison to 2D monolayers. 
 
 
1.6 Thesis overview 
Chapter one focuses on the pathogenesis of colorectal cancer, an overview of the 
neovascularization process and the current 3D in vitro models that have been 
successfully utilized to date. This includes the use of multicellular spheroids, natural 
and synthetic scaffolds. Chapter two will focus on the general materials and methods 
that have been used throughout the experiments in this thesis. Chapter three focuses 
on controlling matrix stiffness and composition to regulate cancer invasion. This will 
also include investigations into the molecular mechanisms and morphological 
changes that contribute to an invasive phenotype. Chapter four will present the 
development of a primitive vascular network within the tumouroids and the influence 
of stromal cells on cancer invasion. Chapter five will explore the expression of 
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EGFR as a potential biomarker and its suitability to anti-EGFR therapy in 
conventional monolayer cultures and in tumouroids. 
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Chapter 2 Material and 
Methods 
 
Chapter Two 
 
Materials and Methods 
 
2.1 Introduction 
This Chapter includes a description of the general methodologies used throughout 
the thesis. Specific experimental protocols are outlined in the materials and methods 
of each respective Chapter. 
 
2.2 Cell maintenance of cancer cells 
Two colorectal cancer cell lines were used throughout this thesis. The HT29 human 
colorectal adenocarcinoma cell line and the HCT116 human colorectal carcinoma 
cell lines were obtained from the European Collection of Cell Cultures (Sigma 
Aldrich, Dorset, UK). Cells were routinely cultured in 2D monolayers in Dulbecco’s 
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modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 
100 units/ml penicillin and 100µg/ml streptomycin (1% P/S) (all from Invitrogen, 
Paisley, UK). Cells were maintained at 37°C and 5% CO2/air. 
HT29 and HCT116 cells were cultured in T75cm2 flasks. Cells were allowed to reach 
90% confluency before being passaged using a 1:5 ratio. Briefly, the medium was 
aspirated from the flasks before being washed once with 10ml phosphate buffered 
saline (PBS) (Lonza, Slough, UK). Cells were detached by incubating the flasks with 
3ml of 0.25% trypsin/EDTA (Sigma) at 37°C for 5 minutes and by gently tapping on 
the side of the flask to ensure all the cells were floating. For neutralization, 7ml of 
fully supplemented DMEM was added and mixed thoroughly by pipetting up and 
down several times. Subsequently, 2ml was added to a fresh flask containing 
medium. 
For experiments, cells were prepared for counting after neutralization by adding 50µl 
of the cell suspension and 50µl of PBS (1:2 dilution) into a fresh eppendorf tube. 
This was vortexed briefly (3-4 seconds) to break up any clumps of cells. Cells were 
counted by adding 10µl of the PBS-cell suspension into a haemocytometer. The 
number of cells in the four quadrants of the haemocytometer was counted and the 
total cell number was calculated using the following formula: N = M x V x D x 104 
cells/ml.  M denotes the average number of cells, V the volume of medium the cells 
were re-suspended in and D the dilution factor (1:1 cells and PBS). The cells were 
then centrifuged at 1500rpm for 5 minutes. The supernatant was discarded and the 
cells resuspended in the appropriate volume required for experiments. Cells were 
used up to passage 40. 
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2.3 Cell maintenance of endothelial cells 
Human umbilical vein endothelial cells (HUVECs) were purchased from Promocell 
(Heidelberg, Germany). HUVECs were cultured in 2D monolayers in complete 
endothelial growth medium (EGM) (Promocell, Heidelberg, Germany) supplemented 
with 10% fetal bovine serum and 100 units/ml penicillin and 100µg/ml streptomycin 
(all from Invitrogen, Paisley, UK) and maintained at 37°C and 5% CO2/air.  
HUVECs were routinely cultured in T75cm2 flasks and were allowed to reach ~95% 
confluency before being passaged at a 1:4 ratio. The EGM was removed and flasks 
were washed once briefly in PBS-EDTA (Ethylenediaminetetraacetic acid) 
(Invitrogen, Paisley, UK). The cells were then detached using 3ml of 0.25% 
trypsin/EDTA for 2-3minutes. To ensure the cells were detached, they were checked 
under a light microscope and gently tapped on the side of the flask. To neutralize, 
7ml of EGM was added to the flask and mixed well. 2.5ml was then added to a new 
flask containing medium and returned to the incubator.  
For experiments, cells were trypsinized and counted as described in Section 2.1. 
Cells were used up to passage 5 for experiments. 
 
2.4 Cell maintenance of fibroblasts 
Adult human dermal fibroblasts (HDFs) were purchased from Invitrogen (Paisley, 
UK). HDFs were cultured in 2D monolayers in high glucose DMEM supplemented 
with 10% FBS and 100 units/ml penicillin and 100µg/ml streptomycin (all from 
Invitrogen, Paisley, UK) and maintained at 37°C and 5% CO2/air. HDFs were 
cultured in T75cm2 or T225cm2 flasks depending on the number of cells required for 
experiments. HDFs were trypsinized, neutralized and counted as described in Section 
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2.1. Cells were used up to passage 12 as recommended by the manufacturer’s 
instructions. 
 
2.5 Fabrication of 3% matrix tumouroids 
The same basic formula was used to create 3% matrix tumouroids throughout. A 
total volume of 4ml was prepared for the ACM comprising 3.2ml of acid soluble rat 
tail collagen type I (protein concentration 2.05mg/ml in 0.6% acetic acid, First Link, 
Wolverhampton, UK), 0.4ml 10X Minimum Essential Medium (MEM, 10X with 
Earle’s Salts, without L-glutamine and without sodium bicarbonate, Invitrogen, 
Paisley, UK), 0.4ml of the appropriate colorectal cancer cell suspension at a ratio of 
8:1:1. Collagen type I was mixed with 10X MEM and neutralized dropwise with 5M 
NaOH and then 1M NaOH to reach a pH ~7.4. Once neutralized the collagen-MEM 
mixture colour changed yellow to pink following gentle agitation. The cell 
suspension was immediately added and mixed thoroughly to ensure the cells were 
even distributed within the viscous collagen solution. Using a pasteur pipette, the 
collagen-cell solution was transferred into a mould resting on top of a glass slide 
with 30nm filter paper on the underside. The solution was left to compress under its 
own weight for 30 minutes at room temperature. The mould was then transferred to a 
nylon mesh resting on top of a 165µm stainless steel mesh and 30nm filter paper at 
the base (Figure 2.1 and 2.2). The gel was compressed under a load (weight = 175g) 
for 1 minute at room temperature. This compression process was also carried out for 
the other side of the gel to create the ACM (Figure 2.2b). The mould was removed 
and the resulting collagen gel (22 x 10 x10mm) was cut into 4 equal pieces (~5.5 x 
10 x 10mm) using a sterile surgical knife (Figure 2.2c). A few drops of DMEM was 
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added to each piece and placed in the incubator. To create the acellular stromal 
surround, 4ml of acellular collagen was prepared as described above with 0.4ml 
DMEM substituted for the cell suspension. The collagen solution was pipetted (1ml 
was added to each well) in a 12 well plate and each ACM was nested within the 
collagen hydrogel and placed in the incubator for 30 minutes to initiate 
fibrillogenesis. Once the gel had formed, 1ml of fully supplemented DMEM was 
added to each well and returned to a humidified incubator set at 37°C. 
 
Figure 2.1: A schematic illustrating how 3% matrix tumouroids are fabricated: Collagen and 
10X MEM were mixed and neutralized with 5M and 1M NaOH on ice. Once the solution was 
neutralized, observed by a colour change from yellow to pink, the cell suspension was added and 
mixed thoroughly. The collagen – cell mixture was then added into a mould and allowed to gel at 
room temperature for 30 minutes. A plunger (175g) was then used to compress both sides of the 
collagen gel for 30 seconds each. The resulting ACM, containing the cancer cells was cut into 4 equal 
pieces and nested into an acellular collagen hydrogel surround set in a 12-well plate for 20 minutes in 
the incubator set at 37ºC before 1ml of fully supplemented DMEM was added to each tumouroids to 
fully immerse the culture. 
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Figure 2.2: Plastic compression of a collagen gel to create 3% matrix tumouroids (a) The 
collagen-cell solution was added to the mould and compressed with a load (175g) for 30 seconds on 
each side (b) The ACM after compression on both sides (c) The ACM divided into four equal pieces. 
 
2.6 Fabrication of 10% matrix tumouroids 
High density ACMs were prepared using the RAFT™ 3D cell culture system in 96 
well plates as detailed by the manufacturer’s instructions (TAP Biosystems, Royston, 
UK). A full 96 well plate was never populated with 96 RAFT™ gels, as this was 
never required at once. The manufacturer’s instructions detailed the different reagent 
volumes required to create different numbers of wells of a 96 well plate. The 
volumes required were pre-established in the manufacturers protocol. For example, 
experiments that required 10 wells, 0.3ml of 10X MEM, 2.7ml of rat tail collagen 
type I, 0.197ml neutralizing solution and 0.143ml cell stock solution (1.98 x 106 
cells/ml for 20,000 cells per well or 4.96 x 106cells/ml for 50,000 cells per well) 
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were added in that order and mixed thoroughly to create a final volume of 3.4ml. 
From this solution, 240µl was pipetted into 10 wells in a 96 well plate and placed on 
a plate heater (Tap Biosystems, Royston, UK) set at 37°C for 15 minutes to initiate 
fibrillogenesis. While still on the plate heater, biocompatible hydrophilic RAFT™ 
absorbers were placed on the hydrogels and left for 15 minutes to remove some 
interstitial fluid to create a high density ACM. The absorbers were then removed and 
fully supplemented DMEM was added to each well. To create the stromal surround, 
acellular collagen gels were prepared as described in Section 2.5. 500µl of acellular 
collagen was cast in a 24 well plate and placed on a plate heater for 5 minutes at 
37°C to begin gelation. Each RAFT gel was then carefully removed from the 96 well 
plate using a fine tip stainless steel forceps and placed on top of the collagen 
hydrogel. 200µl of the acellular collagen solution was then added on top of the 
RAFT gel to fully encapsulate it. The 24 well plate was returned to the incubator for 
15 minutes to gel the stromal surround. Fully supplemented medium was added 
immediately after and returned to a humidified incubator set at 37°C. 
 
2.7 Basement membrane incorporation into tumouroids 
To investigate the effect of laminin on cancer cell morphology and invasion, 50µg/ml 
of laminin (mouse, BD Biosciences) was added to the collagen-MEM mixture prior 
to neutralization. This concentration was based on information from the 
literature[117,141,142]. Laminin was only added to the stromal surround for experiments. 
The stromal surround collagen-laminin hydrogel was prepared as described above by 
casting hydrogels in 12 or 24 well plates. 
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2.8 Physiological stromal surround 
In order to test the effect of matrix density on cancer cell morphology and invasion, 
the stromal surround was compressed for a series of experiments in 10% matrix 
tumouroids. Collagen gels with or without laminin were prepared as described in 
Section 2.6. Briefly, 500µl of neutralized acellular collagen ± laminin was cast in 24 
well plates and allowed to gel for 5 minutes on a plate heater (TAP Biosystems) set 
at 37°C. RAFT cultures were then placed on the gel before 500µl of acellular 
neutralized collagen ± laminin was added on top to fully immerse the RAFT 
construct containing the cancer cells. This was allowed to gel for 10 minutes at 37°C 
before being compressed for 15 minutes under biocompatible hydrophilic RAFT 
absorbers to produce the dense stromal component. 
 
 
Figure 2.3: The morphological appearance of 10% matrix nested tumouroids. (a) A schematic 
diagram illustrating how tumouroids are made and (b) the gross appearance of the ACM containing 
cancer cells nested within the stromal component after 21 days in culture. Scale bar – 1cm. 
 
2.9 ImageJ analysis 
The total surface area (µm2) of cell aggregates was measured using the ImageJ 
software version 1.47 (National Institute of Health, USA). All analysis was done 
manually. Cancer invasion was defined as cell aggregates detaching and invading the 
stromal surround or cell sheets growing outwards from the ACM. The freehand line 
tool was used to trace around the cellular aggregates and the surface are was 
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calculated using a pre-set scale set in ImageJ. HCT116 epithelial cell sheet invasion 
was measured using the straight-line tool. The furthest distance the cell sheet had 
migrated from the ACM was taken as a single measurement as shown in Figure 2.4.  
 
 
 
Figure 2.4: ImageJ analysis of tumouroid invasion. To quantify aggregate size and cancer invasion, 
the freehand line and straight-line tools of ImageJ were used to trace around HT29 cellular aggregates 
and HCT116 cell sheets respectively. The sizes and distances were measured and the average was 
calculated. Ten random aggregates or cell sheets were analyzed per well. (n=4). Scale bar – 100µm. 
 
2.10 Statistical analysis 
The data shown throughout this thesis is displayed as the mean ± standard deviation 
(SD) and was calculated using GraphPad Prism 6 software (GraphPad, San Diego, 
CA). Statistical analysis was carried out on original data values where the data was 
converted to percentages. Data points (n numbers) are displayed for each respective 
experiment in the figure legend. Data comparisons for two sets of data were analyzed 
for statistical significance by Students T-test analysis. Vascular network analysis 
among different groups was carried out using one-way analysis of variance 
(ANOVA) followed by post hoc analysis using Tukeys multiple comparisons test. 
HT29% HCT116%
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Drug treatment experiment datasets were analyzed using ANOVA followed by post 
hoc analysis using Dunnett’s test. Significance was taken at p<0.05. 
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Chapter 3 Colorectal cancer cell 
morphology and invasion 
 
Chapter Three 
 
Colorectal cancer cell morphology and 
invasion 
 
3.1 Introduction 
Understanding the more complex mechanics of tumour cell migration within 
conventional 2D in vitro models has proved challenging. As a result, there has 
recently been an increase in tissue engineered solutions to address this problem. One 
avenue, not often explored within 3D in vitro models, is the effect of the tumour 
stroma on cancer growth and invasion.  
We previously described the development of a novel 3d in vitro model of colorectal 
cancer (tumouroid) based on the removal of interstitial fluid in collagen 
hydrogels[143–145]. Our tumouroid model is spatially accurate. It is based on a dense 
ACM which contains colorectal cancer cells, nested within a collagen hydrogel that 
represents the tumour stroma. Although, tumouroids are formed entirely with 
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collagen type I, we also added the basement membrane (BM) protein, laminin, to the 
stromal component to investigate the effects on cancer invasion.  
The aim of this Chapter was to characterize the effect of matrix composition and 
matrix density on cancer cell morphology and invasion both within the cancer mass 
and within the stroma. Providing further insight into the effect of matrix density and 
composition on cancer cell migration particularly, investigating the onset of EMT 
and subsequent invasion of cells could open up a new avenue of therapeutics that 
targets not only the cancer cells but also the adjacent tumour stroma.  
The effect of matrix density on cancer cells cultured in two ACMs of different 
densities was also investigated. Section A in this Chapter relates to preliminary work 
carried out on 3% matrix tumouroids nested in 0.2% matrix collagen gels using both 
HT29 and HCT116 cell lines. Section B describes HT29 and HCT116 cell behaviour 
in 10% matrix tumouroids nested in both stromal matrices of 0.2% and 10% 
collagen. The effects of the BM extract, laminin, on cancer cell invasion were also 
investigated in both stromal surrounds.  
 
3.2 Materials and Methods 
3.2.1 Cell Maintenance 
The colorectal cancer cell lines HT29 and HCT116 were routinely cultured as 
described in Chapter 2. Cells were maintained routinely in culture and appropriate 
cellular concentrations were prepared for the experiments described below. 
 
3.2.2 Collagen gel density measurement 
The density of collagen gels was assessed using the freeze-drying method. Acellular 
 44 
collagen gels were prepared and compressed under various weights as described in 
Section 2.5 and 2.6. Collagen gels (uncompressed), partially compressed gels 
(compressed with 175g weight for 1 minute) and fully compressed gels (removal of 
interstitial fluid using RAFT hydrophilic absorbers for 15 minutes). Once the gels 
were prepared, DMEM was added to each sample for 24 hours to accommodate a 
bounce back effect from the collagen gels (reabsorption of fluid). The gels were then 
washed with phosphate buffered saline (PBS, Sigma Aldrich) followed by a thorough 
wash in distilled water in until all the salts within the gel were removed. This was 
estimated by a colour change of the collagen gel from pink to colourless. The gel 
weight was then measured using a balance to calculate the wet weight of the gel. 
Each gel was then frozen at -20°C for 1 hour before being freeze-dried overnight and 
the weight of the dry gels was measured again. The difference between the wet and 
dry weights was then used to calculate the overall collagen content within the gels 
once the water had been removed. 
 
3.2.3 Proliferation assay 
The alamarBlue assay was used to assess proliferation in 3% and 10% matrix 
tumouroids. AlamarBlue measures the chemical reduction of resazurin to resorufin 
by mitochondrial activity and provides an indicator of metabolic activity. This 
metabolic activity was taken as an indicator of cell proliferation within the 
tumouroids. AlamarBlue was diluted 1:10 in phenol red free media and added to 
each well. Plates were covered in tin foil, as alamarBlue is photosensitive and placed 
in an incubator set at 37ºC, 5% CO2/air for 4 hours. Following incubation, 100µl of 
solution in each well (n=4) was transferred to a blank 96 well plate (Nunc, 
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Loughborough, United Kingdom). The absorbance was recorded at excitation 530nm 
and emission 620nm.  
 
3.2.4 Haematoxylin and Eosin staining 
Haematoxylin and eosin (H&E) staining was used to evaluate cell morphology, 
proliferation and migration. 3% matrix tumouroids were cultured for up to 21 days 
and fixed on days 1, 7, 14 and 21 in 10% formalin for 1 hour at room temperature. 
The samples were then washed with PBS three times for 5 minutes each and 
dehydrated through increasing alcohols and chloroform in an automated tissue 
processor (Shandon Citadel 2000TM Tissue Processor, Ramsey, Minnesota, USA) 
overnight for paraffin wax embedding. Dehydrated samples were then placed in 
metal moulds and filled with paraffin wax and set on a cold plate overnight to 
solidify. Paraffin wax embedded sections were cut (10µm thick) using a microtome 
and dipped in 20% ethanol before being placed in a hot water bath set at 37ºC to 
soften the wax. Microscope slides were used to lift the sections out of the water bath 
and left to dry on a rack at room temperature overnight. Prior to staining, the 
microscope slides were placed in an oven set at 60ºC for 20 minutes to soften the 
wax. The following procedure for staining was carried out (Figure 3.1) and slides 
were then mounted with coverslips using DPX mounting media and imaged using an 
EVOS XL Core Cell Imaging System (Life Technologies). 
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Figure 3.1: The rehydration, staining and dehydration process involved in haematoxylin and 
eosin staining. 
 
 
3.2.5 Immunofluorescence 
Immunofluorescent staining of tumouroids was carried out using a slightly modified 
protocol that was previously established[144]. Briefly, collagen gels were fixed in 10% 
formalin for 1 hour and washed three times for 5 minutes with PBS. The gels were 
then permeabilised with 0.2% Triton X-100 (TX-100, Sigma) for 30 minutes and 
washed with PBS (3 x 5 minutes). Each gel was then incubated with a Rhodamine 
Phalloidin conjugated to an Alexa Fluor 488 fluorescent antibody (Life technologies) 
for 1 hour at room temperature. The samples were then washed in PBS thoroughly 
and Hoechst 33342 was added to counterstain the cell nuclei. The gels were then 
imaged using an EVOS FL imaging microscope (Invitrogen).  
Rehydration 
Solvent           Duration 
Xylene x3         4 minutes 
100% alcohol         4 minutes 
70% alcohol         1 minute 
Tap water         1-2 minutes 
Staining 
Solvent           Duration 
Haematoxylin         8 minutes 
Tap water         1 minute 
1% acid alcohol         20 seconds 
Tap water         1-2 minutes 
Scott’s tap water         30 seconds 
Eosin          5 minutes 
Dehydration 
Solvent           Duration 
Tap water         1 minute 
70% alcohol         2 minutes 
90% alcohol         1 minute 
100% alcohol         1 minute 
Xylene x3         4 minutes 
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3.2.6 Protein extraction and quantification 
For 2D cultures, HT29 or HCT116 cells were plated on 6 well plates at a density of 
300,000 and 250,000 cells per well. The plates were then placed on ice and washed 
with PBS twice. For 3D cultures, collagen gels were washed with PBS twice and 
digested with collagenase type I (Invitrogen) at a concentration of 500 units/ml for 1 
hour. The sample was pipetted up and down to help speed up the degradation 
process. Once the gel was visibly degraded, the cells were then removed, 
resuspended in FBS supplemented DMEM to neutralize the collagenase and 
centrifuged at 377G for 5 minutes to create a cell pellet. Cells were lysed with 250µl 
of RIPA lysis buffer (Sigma) containing 1x protease inhibitor (Sigma). Cells cultured 
in 6 well plates were lysed within the plate and the supernatant subsequently 
transferred to 1.5ml eppendorf tubes. Protein concentration was calculated using the 
Pierce™ Modified Lowry Protein Assay Kit (Thermo Scientific) using a bovine 
serum albumin (BSA) standard curve according to the manufacturers protocol. Each 
standard and protein sample was measured at 750nm using Genova Plus 
Spectrophotometer (Jenway). 
 
3.2.7 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
and Western Blot 
Equal amounts of protein (35µg) were calculated in a final volume of 30µl. The 
loading dye was prepared by mixing 1.2µl of β-Mercaptoethanol and 8.8µl of 4 x 
Sample Buffer per sample. 10µl of the loading dye was mixed to each sample 
thoroughly to ensure it was mixed well before being heated at 95°C for 5 minutes to 
denature the samples. 15µl of the SeeBlue Plus2 Pre-stained protein standard 
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(Invitrogen) was added as a protein ladder and 40µl of each sample containing the 
loading dye was added to each well. SDS-PAGE gels were run at 150V for 60 
minutes and proteins transferred to PVDF (Polyvinylidene fluoride) membranes at 
30V for 90 minutes. 
Membranes were blocked for 30 minutes in 2.5% BSA and 0.05% Tween 20 in PBS. 
Antigens were detected using mouse monoclonal antibodies against MMP-7 and 
vimentin (both at 1:1,000, Santa-Cruz Biotechnology, Santa Cruz, CA) and 
incubated with a goat anti-mouse IgG-HRP (Santa Cruz) secondary antibody at room 
temperature for 30 mins. Blots were developed using the Clarity™ Western ECL 
Substrate (Bio-Rad, Hertfordshire) and visualized using the ChemiDoc™ XRS+ 
System (Bio-Rad). 
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3.3 Results 
Section A 
3.3.1 Collagen gel density measurement 
The matrix density of collagen gels was evaluated by freeze-drying acellular 
collagen gels under a variety of methods which remove the interstitial fluid within 
the gels. Partially compressed gels were prepared as described previously (Section 
2.5) and were compressed with a 175g weight for a total of 1 minute. Partial 
compression of the collagen gels revealed a 13-fold increase (2.63% ± 0.32%) in 
collagen density in comparison to standard uncompressed collagen gels (0.2%) (p < 
0.05) (Figure 3.2). Fully compressed gels were prepared by compressing the collagen 
gels with a 175g weight for a total of 10 minutes. Full compression using this method 
revealed a 35-fold increase in collagen density (6.98% ± 1.24%) in comparison to 
collagen hydrogels. The removal of fluid in fully compressed gels was also carried 
out for 15 minutes under hydrophilic RAFT absorbers, which absorbs the interstitial 
fluid to create a dense collagen matrix. RAFT absorbers produced a matrix with a 
48-fold increase in collagen density (9.59% ± 1.28%) (p < 0.05) in comparison to 
uncompressed collagen gels. From this point, partially compressed gels and RAFT 
gels will be referred to as 3% and 10% matrix respectively. The protein 
concentration of uncompressed collagen gels, partially compressed gels, fully 
compressed gels and RAFT gels was 2.04mg/ml, 26.52mg/ml, 71.4mg/ml and 
97.81mg/ml respectively. 
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Figure 3.2: Collagen density of acellular gels. Matrix densities (mean ± SD) of collagen gels under 
various compressions as a % w/v. (n=4) *p < 0.05; **p < 0.0001. 
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3.3.2 Colorectal cancer cell proliferation and morphology in 3% matrix 
tumouroids 
The proliferation rate of HT29 and HCT116 cells was tested in 3% matrix 
tumouroids over a 14-day period. To assess the proliferation profile of cells cultured 
in 3D, the alamarBlue assay was used. The advantage of using the alamarBlue assay 
lies in the fact that the assay is non-toxic and therefore the same construct can be 
measured on a timescale. The optimum cell density for 3% matrix tumouroids has 
been established previously[145]. Both HT29 and HCT116 cell lines were cultured in 
3% matrix tumouroids at a density of 1.6 x 106 cells/ml (to make up a total of 4ml). 
HT29 cells cultured in 3% matrix tumouroids displayed no significant increase in 
proliferation over the 14-day period (Figure 3.3), as the cells appeared to slow down 
metabolically. However, HCT116 cells had a much higher proliferation profile in 
comparison to HT29 cells. Interestingly, while the overall growth pattern of HCT116 
cells increased over 14 days, there was a significant drop in the proliferation readings 
at day 7 indicating a state of cellular quiescence. By day 7 and significantly more so 
by day 14, cells aggregated together to form spheroid like structures in both HT29 
and HCT116 cells (Figure 3.4a) On day 21, HT29 cells formed aggregates that were 
31,337.6µm2 ± 9438.8µm2 and HCT116 cells formed aggregates that were 
34,791.2µm2 ± 9378.4µm2 (Figure 3.4b). It is interesting to note that although 
aggregates formed 3D cellular structures, the quantification of these structures was 
carried out in two-dimensions. The surface area of the largest area was measured and 
taken as an indicator of growth over time. This is because volumetric measurements 
were difficult to quantify using microscopy. 
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Figure 3.3: Growth kinetics of colorectal cancer cells cultured in 3% matrix tumouroids. The 
alamarBlue assay was used to measure the metabolic activity of HT29 and HCT116 cells over a 14-
day period. Data is presented as mean ± SD (n=4). 
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Figure 3.4: Cell morphology of colorectal cancer cells in 3% matrix tumouroids. (a) Bright field 
microscope images at the interface between the ACM and the stromal surround over a 21 day period. 
(b) Quantification of the size of HT29 and HCT116 aggregates as measured by ImageJ of 10 random 
cellular aggregates (n=4). Data is presented as mean ± SD. Scale bar – 100µm. 
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3.3.3 The morphology of invading cancer cells from the ACM is cell specific 
H&E staining was used to analyze cell distribution and the morphology of colorectal 
cancer cells within the ACM of 3% matrix tumouroids for HT29 and HCT116 cells. 
H&E stains the cell nuclei blue and can distinguish cells from the collagen matrix by 
staining the matrix pink.  
Histological analysis of HT29 and HCT116 tumouroids revealed an equal 
distribution of cells throughout the ACM at day 1 (Figure 3.5). By day 7, cells had 
formed small aggregates of cells similar to those observed using light microscopy in 
Figure 3.4a. However, all of the larger aggregates were localized to the boundary 
between the ACM and the surrounding stroma. Increasingly, by day 14, HT29 cell 
aggregates had invaded out of the ACM as aggregates whereas HCT116 formed 
dense cell sheets. After 21 days, it was evident that the invasion profile of each cell 
line was significantly different from each other with HT29 cells remaining as 
aggregates within the ACM and the surrounding stroma whereas HCT116 cells, 
which still formed aggregates in the ACM, invaded exclusively as cell sheets.  
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Figure 3.5: Morphology of colorectal cancer cells in 3% matrix tumouroids. H&E staining was 
used to evaluate cell distribution, morphology and cancer invasion in 3% matrix tumouroids. (a) HT29 
cells and HCT116 migrated towards the edge of the ACM by day 1 which increased by day 7. Both 
cell lines formed cellular aggregates by day 7 which were mostly localized to the interface between 
the ACM and the acellular stromal surround. At day 14, HT29 cells invaded into the stroma as 
a"
b"
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aggregates while HCT116 invaded as cell sheets. By day 21 there was a marked presence of HT29 
cellular aggregates and HCT116 cell sheets in the stromal surround. (b) Higher magnification images 
of the ACM stromal interface. Black arrows represent invading HT29 aggregates and HCT116 cell 
sheets.  Scale bars – 100µm. 
 
 
 
3.3.4 Cancer invasion in 3% matrix tumouroids 
The invasive capacity of HT29 and HCT116 cells in 3% matrix tumouroids was 
further established using bright-field microscopy. This was carried out to evaluate 
the migration of cells in real time. HT29 and HCT116 cell invasion was observed at 
day 12 and day 11 respectively with prominent invasion shown at day 14 (Figure 
3.6a). HT29 cells invaded from the ACM as spherical cellular aggregates. The 
distance of aggregate invasion was then quantified using the ImageJ software. There 
was no statistically significant difference in the distance of invaded aggregates 
between day 14 and day 21. However, while the distance was not significant, the size 
of the aggregates increased over time indicating that the aggregates continued to 
proliferate in the stromal surround at a much faster rate than within the ACM (Figure 
3.6a). The addition of laminin did not appear to enhance the size or the distance of 
the invaded aggregates in the stromal surround. HCT116 cells, which also formed 
aggregates within the ACM invaded as epithelial cell sheets contiguous from the 
ACM. Over time, secondary cell sheets were observed to detach from the primary 
invading cell sheet and form and continue to proliferate within the stromal surround 
(Figure 3.6b). Although it was not statistically significant, laminin slightly increased 
the overall distance migrated of the cell sheets in comparison to the collagen only 
stromal surround. 
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Figure 3.6: Invasive profile of colorectal cancer cells in 3% matrix tumouroids. (a) Phase contrast 
images of HT29 cancer cells invading as a cell aggregate from the ACM into the stromal surround. 
Quantification of the distance travelled by the invading HT29 aggregates from the ACM and the 
average size of the aggregates both in a collagen only stromal surround and a collagen + laminin 
stromal surround. (b) Phase contrast images of HCT116 cancer cells invading as an epithelial cell 
sheet, forming secondary cell sheets, within the stromal surround. The total distance migrated of the 
cell sheet from the ACM was also quantified in collagen and collagen and laminin gels. Data is 
presented as the mean ± SD. * p < 0.05. Scale bars – 100µm. 
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3.4 Results 
Section B 
3.4.1 Colorectal cancer cell morphology in 10% matrix tumouroids 
The proliferation profile of HT29 and HCT116 cells was also measured in 10% 
matrix tumouroids that were cultured at a density of 2 x 104 cells per well. These 
differences in cell number are due to the volumetric differences taken into 
consideration between 3% and 10% matrix tumouroids.  
In 10% matrix tumouroids, HT29 cells displayed a steady increase in metabolic 
activity that appeared to plateau at day 14 (Figure 3.7).  Morphologically, the size of 
the cellular aggregates grew in size in line with the proliferation measurements. 
Similarly to 3% matrix tumouroids, HCT116 cells cultured in a 10% matrix 
displayed a drop of metabolic activity by day 7. Conversely, bright field microscope 
images (Figure 3.8a) of HCT116 aggregates showed no decline in growth between 
day 3 and day 7; therefore any state of biochemical quiescence did not result in any 
associated decrease in aggregate size. On day 21, HT29 cells formed aggregates of 
32,565.2µm2 ± 5993.4µm2 and HCT116 cells formed aggregates of 35,847.8µm2 ± 
5536.8µm2 (Figure 3.8b). Overall, HCT116 cells formed slightly larger aggregates 
than HT29 cells in 10% matrix tumouroids; however this appeared to follow a trend, 
which was not statistically significant. 
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Figure 3.7: Growth kinetics of colorectal cancer cells cultured in 10% matrix tumouroids. The 
alamarBlue assay was used to measure the metabolic activity of HT29 and HCT116 cells over a 14-
day period. Data is presented as the mean ± SD (n=4). 
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Figure 3.8: Cell morphology of colorectal cancer cells in 10% matrix tumouroids. (a) Phase 
contrast images of HT29 and HCT116 cells cultured in 10% matrix tumouroids over a 14-day period. 
Single cell proliferate and migrate to form cellular aggregates. (b) Quantification of the size of the 
cellular aggregates as measured by ImageJ of 10 random cellular aggregates (n=4). Data is presented 
as mean ± SD. Scale bar – 50µm. 
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3.4.2 Extracellular matrix density and composition of the stroma regulates 
cancer cell invasion 
During the metastatic cascade, cancer cells must first detach from the primary 
tumour site where they invade the surrounding stromal tissue and adjacent 
parenchyma. Subsequently, cancer cells then break through the basement membrane 
where they enter the circulating blood flow and travel to distant organs. The aim of 
these experiments was to examine the influence of cell-matrix interactions on the 
migration of cancer cells. We investigated the effect of incorporating the basement 
membrane protein laminin and increasing matrix density of the stromal surround on 
cancer cell invasion. This was demonstrated in 10% matrix tumouroids which have a 
much stiffer ACM than partially compressed tumouroids (see Figure 2.2). 
Similarly to the 3% matrix tumouroids shown in Figure 3.6a, HT29 cells invaded as 
cellular aggregates in 10% matrix tumouroids (Figure 3.9ai). They also detached 
from the ACM as they invaded and migrated into the stromal surround. The addition 
of the attachment factor and basement membrane component laminin, also increased 
the size of the invaded aggregates at day 21 between collagen only (56,615.9µm2 ± 
28,792.6µm2) and collagen + laminin cultures (253,564.6µm2 ± 115,601.8 µm2) 
(Figure 3.9b) (p<0.05). Again, similar to 3% matrix tumouroids there was no 
correlation between the distance migrated by aggregates between day 14 and day 21 
(Figure 3.9c). When the collagen density of the surrounding stroma was increased 
from 0.2% to 10% collagen, HT29 cells began to form additional migratory patterns.  
While cellular aggregates were still distinguishable within the stroma, contigous cell 
sheets also invaded from the ACM (Figure 3.9aiii). Invaded aggregates displayed a 
trend of migrating further in the dense stromal surround in comparison to standard 
uncompressed collagen gels (Figure 3.9c), however this was not statistically 
significant. 
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Figure 3.9: Matrix density changes cancer cell invasion in HT29 tumouroids. (a)i HT29 cells 
cultured in a 10% collagen matrix invade into a collagen hydrogel only stromal surround and a (ii) 
collagen and laminin hydrogel stromal surround. (iii) HT29 cell invasion switches to an epithelial cell 
sheet in a stiff stromal surround and (iv) invasion is enhanced when laminin is added to the stromal 
surround.  (b) Quantification of size of invaded aggregates and (c) the distance that aggregates 
invaded into each respective stromal surround. (n=6). Data is presented as mean ± SD. * p < 0.05. 
Scale bar – 500µm. 
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HCT116 cells, which are the more metastatic than HT29 cells[146], invaded 
exclusively as epithelial cell sheets (Figure 3.10a) under all stromal conditions. The 
addition of laminin to the stromal cultures increased the overall migration distance of 
the epithelial cell sheets between day 7 and day 21 in comparison to collagen only 
stromal surrounds (Figure 3.10b) Interestingly, when the distances of cell sheet 
invasion were quantified in different stromal surrounds, highly different patterns of 
the rate of invasion were observed. In the low density collagen stroma, the invasion 
of the cell sheets appeared slow at first, however between day 10 and day 21, the rate 
of invasion increases in a linear fashion. On the contrary, the invasion pattern of  
HCT116 cells migrating into a dense stromal surround was earlier than the low-
density stroma (Table 3.1). Conversely, at day 14, HCT116 cell sheet invasion 
appears to slow down significantly until day 21 where the presence of laminin 
appears to be the major driving factor in enhancing the total distance migrated 
(Figure 3.10c). 
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Figure 3.10: HCT116 cancer cell invasion rate is dependent on collagen density. (a)i HCT116 
cells cultured in a 10% collagen matrix invade into a collagen only hydrogel stromal surround (ii) and 
a collagen and laminin hydrogel stromal surround as cell sheets. (iii) HCT116 cells invading into a 
collagen only stiff stromal surround and (iv) enhanced invasion when laminin is added. (b) 
Quantification of the total distance of invasion of HCT116 cells into a collagen and collagen/laminin 
hydrogel (0.2% collagen) and (c) a stiff (10% collagen) stromal surround with or without laminin by 
ImageJ. Ten random cell sheets were measured from the ACM to the furthest point. (n=6) Data is 
presented as mean ± SD. * p < 0.05. Scale bar – 500µm. 
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Stromal surround composition Day of invasion 
HT29                    HCT116 
0.2% collagen matrix Day 11 Day 7 
0.2% collagen + laminin matrix Day 10 Day 5 
10% collagen matrix Day 10 Day 6 
10% collagen + laminin matrix Day 10 Day 5 
Table 3.1: The invasion profile of HT29 and HCT116 cells into different stromal conditions. 
 
 
3.4.3 Morphological changes in invading leader cells 
The invasive capacity of HT29 and HCT116 cells was also characterized in a dense 
(~10% collagen) stromal surround. Both cell lines used thus far were highly invasive, 
particularly the HCT116 cells which invaded earlier than HT29 cells in all conditions 
(Table 3.1). The aim of these experiments was to investigate the morphology of the 
invading ‘leader’ cells, which appeared elongated and morphologically distinct from 
the cells that seemed to follow.  
Interestingly, as the cells begin to invade the stromal surround, HT29 cells display 
three different morphologies whereas HCT116 cells displayed only two (Figure 
3.11). However, this was not visible by the light microscope images in Figure 3.9 
and 3.10 and was confirmed by the immunofluorescent staining of the actin filaments 
(phalloidin). Although the location and morphology of the invading cells appeared 
random and unsystematic, there were distinguishable features to each pattern. In 
some instances, HT29 cells protruded outwards from the ACM into the stromal 
surround and formed polarized organized structures as evident by the coordinated 
one-directional organized migration of the invading cell sheet (Figure 3.11a). It is 
worthwhile mentioning that these dense collagen scaffolds were not aligned prior to 
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these experiments and that collagen fibers would have a random non-aligned 
orientation. 
On the other hand, invading HCT116 cell sheets had no structured organization and 
the migration appeared to random and in all directions (Figure 3.11b). Moreover, the 
morphology of the cells at the front of the invading sheets differed greatly from those 
comprising the bulk of the cell sheet. These leader cells were particularly elongated 
for both HT29 and HCT116 cell lines, and appeared morphologically distinct from 
the cells in of the ACM (Figure 3.11c, e) Moreover, HT29 cells also formed cellular 
aggregates, which invaded the surrounding stroma (Figure 3.11e). This feature was 
again, entirely absent from HCT116 tumouroids. 
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Figure 3.11: Different morphologies of invading cell sheets and aggregates in a dense collagen 
stroma. HT29 and HCT116 cells invading into a 10% collagen matrix containing laminin after 14 
days in culture were fixed and stained for F-actin (green - phalloidin). Nuclei were stained with DAPI 
(blue). (a) HT29 cells invading as organized polarized cell sheets into a single direction whereas (b) 
HCT116 invasion was disorganized and was observed to migrate in all directions. The dotted line 
represents the border between the ACM and the stromal surround. The presence of elongated leader 
cells (c, d) at the invading edge of both HT29 and HCT116 cell sheets. (e) A single invaded HT29 
aggregate in the stromal surround. (n=6). Scale bars - 100µm. 
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3.4.4 Induction of EMT corresponds with extracellular matrix remodeling 
In order to validate phenotypic changes associated with cancer cell invasion, we 
examined the presence of EMT and MMP expression involved in ECM degradation. 
Western blotting was used to detect the expression patterns of MMP7 and the EMT 
marker vimentin between cells cultured in 2D and in tumouroids (Figure 3.12). 
MMP7 overexpression has been linked to an increased incidence of metastasis and 
advanced disease in colorectal cancer[51,147]. Although, MMPs are typically expressed 
by stromal cells, MMP7 was chosen due to its previously established expression 
exclusively by carcinoma cells[148]. MMP7 is the smallest member of the MMP 
family and is involved in the degradation of a host of ECM proteins including 
fibronectin, collagen IV and various proteoglycans[149]. Two versions of MMP7 
exist, pro-MMP7 and an active MMP-7. Similarly to all MMPs, pro-MMP7 is 
converted to the active MMP-7 form via various extracellular proteases and 
plasmins[150].  
Densitometry analysis revealed vimentin expression was highly upregulated in both 
HT29 and HCT116 tumouroids in comparison to their monolayer counterparts 
(fourfold and twofold respectively). The expression level of active MMP7 in HT29 
cells was four times higher in tumouroids than in 2D. On the other hand, HCT116 
tumouroids and 2D monolayers did not illustrate a dramatic difference in active 
MMP7 expression.  
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Figure 3.12: Expression of invasive and EMT markers in colorectal cancer tumouroids. Western 
blot analysis demonstrates the expression of the ECM degradation protein MMP7 and the EMT 
marker Vimentin after 10 days in culture in 10% matrix tumouroids. Densitometry analysis using 
ImageJ demonstrated a fourfold and twofold increase in vimentin expression in HT29 and HCT116 
tumouroids in comparison to monolayers.  
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3.5 Discussion 
This Chapter explores the effect of matrix density on cancer cells cultured in 
collagen gels, and how these differences in matrix density influence cancer cell 
morphology and invasion. The method of PC, developed previously in our lab[120], 
was used to expel excess interstitial water and increase the collagen density within 
collagen hydrogels. We have developed a 3D in vitro cancer model and identified 
different mechanisms of invasion between colorectal cancer cell lines. The advantage 
of using tumouroids is that they allow mechanistic investigations such as cell 
migration due to the distinct compartments (the ACM and the stromal surround).   
 
3.5.1 Matrix density of collagen hydrogels 
Collagen is the most abundant protein and constitutes around 30% of the total protein 
content within the human body. Currently, type I collagen hydrogels are the gold 
standard for 3D in vitro cell culture, however their low mechanical strength is not 
representative of in vivo tissue matrix density. PC of collagen hydrogels rapidly 
produces dense collagen constructs that mimic the structural characteristics of in vivo 
tissues without compromising cell viability[120]. These constructs have been shown to 
support the growth and promote the normal phenotypic expression of a variety of 
different cell types including fibroblasts[151], ECs and human bone marrow derived 
stem cells (HBMSCs)[117]. However, one of the major limitations of PC collagen gels 
is the inability to control for fibril diameter or fibril orientation. This is particularly 
relevant with regards to cancer invasion, as recent work published has shown fibril 
diameter and not pore size is the main determinant of cell clustering and invasion[152]. 
There are a variety of different techniques that can be used in conjunction with PC 
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collagen gels to control fibril orientation. A study by Guo et al. in 2007 established a 
simple technique to control collagen fibril orientation, which requires no specialized 
equipment other than streptavidin coated magnetic beads and a magnet[153]. 
Incubating the magnetic beads within the gel and using a relatively weak magnet, the 
authors demonstrated highly aligned collagen 1 hour after fibrillogenesis. Another 
inexpensive technique utilized by Georgiou and colleagues was reported in 2013 and 
involved a method of cellular self-alignment using tethered PC collagen gels. This 
method generated aligned stabilized collagen gels in 24 hours and was found to 
promote neuronal growth during rat sciatic nerve repair[154]. Focusing on developing 
anisotropic biomaterials will provide novel methods of creating aligned scaffolds for 
tissue engineering and regenerative medicine purposes. 
We first examined the matrix density of collagen gels under varying types of PC. 
Partial and full PC under a 175g weight for 1 and 10 minutes, generated matrices of 
2.6% and 6.9% collagen respectively. It is interesting to note that there is a lack of 
information on the matrix density of different tissues. However, due to the soft 
nature of bowel tissue, it is highly unlikely that it contains dense amounts of collagen 
in comparison to bone or tendon. A different method of producing stiff collagen 
constructs was developed recently and works on the principal basis interstitial fluid 
removal using biocompatible hydrophilic absorbers instead of a weight[144]. Using 
this method we were able to generate collagen matrices consistently of 9.6% 
collagen content. One of the disadvantages of creating PC collagen gels lies within 
the uncontrollable heterogeneity during the PC process. The fluid-leaving surface, in 
this instance the top of the construct, always forms compacted lamellae of collagen 
fibrils. This was explained in detail by Brown and colleagues[120]. Other groups have 
made advances in generating more biomimetic collagen scaffolds. Typically, this 
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involves increasing the overall concentration of collagen in the acid solution or using 
reverse dialysis to generate more defined collagen fibril orientations[155]. Developing 
scaffolds with controllable characteristics such as matrix stiffness, pore size or fibril 
orientation will provide the foundation of the next generation of biomimetic 
scaffolds. 
 
3.5.2 Colorectal cancer cell proliferation in 3D 
In order to test the effect of matrix density on cancer cell behaviour, we chose to 
construct ACMs with two different collagen densities; 3% and 10% collagen using 
both HT29 and HCT116 cells lines. The alamarBlue assay was used to assess the 
proliferation rate of HT29 and HCT116 cell lines in the 3% matrix tumouroids over a 
14-day period. The growth rates of HT29 and HCT116 cultures, varied slightly. 
HT29 cells cultured within 3% matrix tumouroids were characterized by a steady 
decrease in proliferation up to day 14. This decrease in cell proliferation could be 
explained by the migration and aggregation of cells to form cell aggregates within 
the ACM. In contrast, HT29 cells cultured in 10% matrix tumouroids did not exhibit 
the same decrease in proliferation and the cell number increased steadily until a 
plateau was reached at day 14. Light microscope analysis of the interface between 
the ACM and the stromal surround revealed moderately – poorly differentiated 
glandular structures, which formed over a 21-day period. Furthermore, the 
alamarBlue assay may not have been able to penetrate the newly formed aggregates, 
which may have resulted in an overall decrease in the readings obtained from the 
cultures. The problem of transferring 2D end-point assays to 3D cell culture has been 
highlighted before in detail[156]. It is also important to note the presence of 
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proliferative heterogeneity present within aggregates of cells, even as small as few 
hundred microns in diameter. A recent study by Laurent and colleagues investigated 
the expression of Ki67, a proliferative marker, in spheroids of different sizes. It was 
found that the expression of Ki67 was localized to the outer periphery of the 
spheroids with a diameter of 500µm, whereas the core of these spheroids contained a 
high proportion of quiescent hypoxic cells[157].  
On the other hand, the HCT116 cultures had a much different proliferation profile 
than the HT29 cultures. Surprisingly, the proliferation readings appeared to drop 
transiently between day 3 and day 7 in both 3% and 10% matrix tumouroids. While 
there was no concomitant reduction in the size of cellular aggregates, the 
biochemical changes reflected within the alamarBlue readings may describe a short 
state of quiescence, which did not affect gross cellular behaviour. Similarly to the 
HT29 cultures, the drop and rise in the proliferation readings could indicate an 
inability of the alamarBlue to penetrate into the cellular aggregates. It is also possible 
that the cells are entering a brief state of quiescence as they become accustomed to 
the different microenvironmental change from 2D to 3D. Furthermore, there was no 
significant differences in the sizes of the these aggregates between HT29 and 
HCT116 cell lines indicating they may have a similar growth pattern in 3D culture, 
or other factors such as oxygen and nutrients limited their growth. 
 
3.5.3 Colorectal cancer cell invasion from the ACM is cell specific  
The morphology and cell distribution of cancer cells in 3% matrix tumouroids was 
examined using H&E staining. Cell aggregate formation was visible by day 7 in both 
HT29 and HCT116 tumouroids. These aggregates appeared to migrate to the edge of 
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the ACM and into the surrounding low-density collagen stromal surround. The 
formation of aggregates, or spheroids, is influenced by the density of the matrix the 
cells are cultured in[137]. This will be discussed in more detail later in the discussion.  
The greatest differences between HT29 and HCT116 cell lines become more visible 
by day 14. At this time point, cell aggregates began to invade outwards from the 
ACM into the stromal surround. HT29 cells invaded the stroma as tightly bound 
compact aggregates whereas HCT116 cells, which also formed aggregates, invaded 
as epithelial cell sheets contiguous from the ACM. H&E staining revealed cell-
specific morphological features. HT29 cells formed a highly concentrated network of 
budding glandular structures at the migrating front. This type of invasion resembles 
tumour budding and is often in histological sections in vivo[158]. Zlobec and 
colleagues strongly correlated the presence of budding with both vascular invasion 
and distant metastasis, which resulted in overall poor prognosis and tumour 
aggressiveness. Interestingly, they also investigated a small cohort of patients with 
metastatic colorectal carcinoma treated with anti-EGFR therapy and found that all 
patients with a KRAS mutation and/or high-grade tumour budding were found to be 
non-responsive to cetuximab and penitumumab. This does raise the prospect of using 
KRAS status alongside tumour budding grade to determine the suitability for anti-
EGFR therapy. 
On the other hand, cancer epithelial cell sheet migration such as that observed in 
HCT116 cells is not commonly detected in histological samples of colorectal cancer. 
In a systematic review of the histological characteristics of colorectal cancer, 
Fleming et al. characterized the presence of epithelioid neoplastic cell sheets at the 
tumour-stroma boundary in medullary carcinomas, which have an occurrence rate of 
5-8 cases for every 10,000 colorectal cancers diagnosed[159]. Kitamura and colleagues 
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have also characterized the presence of collective invasion in a cis-Apc+/Δ716 
Smad4+/- mutant mouse model of colorectal cancer[160]. It was found that the over-
expression of MMP2 and MMP9 by immature myeloid cells at the invasive front 
promotes this collective invasion. However, we have also identified similar 
mechanisms of collective migration within our tumouroids, which lack an immune 
component, suggesting that an immune component is not essential for this type of 
invasion. 
To further characterize cancer invasion, light microscopy was used to evaluate the 
distance migrated by cellular aggregates and cell sheets in both cell lines. This was 
carried out on live cultures as histological processing can occasionally shrink the 
hydrogel stromal surround and affect the evaluation of the distance migrated. In 
HT29 tumouroids, there was no correlation between the time and distance migrated 
of cellular aggregates within the low-density stroma. This is evident by some 
cultures at day 14 travelling a further distance than those cultured for 21 days 
(2,866.1µm2 ± 1,606.9µm2 vs. 2,592.2µm2 ± 812.8µm2). This indicates that once cell 
aggregates detach from the ACM and invade, their migration is not limited and they 
are free to travel easily within a low-density collagen gel. It is also interesting to note 
that this mechanism of invasion i.e. a whole spheroid/aggregate detaching and 
invading from the primary ACM or spheroid has not been shown before in any 2D or 
3D in vitro models of cancer. It is observed exclusively at the invading front of in 
vivo tumours. 
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3.5.4 Extracellular matrix density and composition of the stroma enhances 
cancer invasion 
Tumour stiffness composition and the effect on cancer invasion has often been 
poorly studied, particularly within 3D in vitro cancer models. To date, most of the 
studies to date have not displayed control over ECM composition or concentration 
like the model presented in this thesis. Previous studies have focused on invasive in 
vitro models using either a single ECM protein such as collagen[161] or Matrigel[139] 
where the precise quantity of each basement membrane extract protein is 
unknown[162]. The objective of this Chapter was to further assess cancer invasion 
with a known surrounding matrix density and specific ECM composition. We 
incorporated a dense ACM (10% collagen) into a surrounding stroma of the same 
density, which included laminin, the bulk component of the BM.  
Overall, HCT116 cells were much more invasive than HT29 cells. Interestingly, the 
addition of laminin to the stroma did not induce any morphological changes in HT29 
and HCT116 cells, although it did enhance the invasion profile in comparison to the 
collagen only stromal surround. The incorporation of laminin also appeared to 
increase the overall size of invaded HT29 cellular aggregates in the stromal 
surround. This difference in size is most likely due to the earlier onset of migration 
into the stroma whereby cells migrate to regions of higher nutrients and oxygen 
concentrations and continue to proliferate. Differences in distances travelled of these 
aggregates demonstrated interesting migration patterns of clusters of cells. It 
appeared that once cellular aggregates migrate out from the ACM, they are able to 
migrate up to 3mm within 24 hours of detachment, indicating a highly motile 
phenotype of these cells in a low-density collagen stroma. Laminins are major 
regulators of cell adhesion, migration and proliferation[117,163]. They regulate these 
cellular processes via specific integrin binding. Moreover, the laminin-5 γ2 chain has 
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been implicated as an adhesion substrate for epithelial cells and is expressed in a 
wide variety of invasive carcinomas[164,165]. This is consistent with other findings in 
the literature. Pirilä et al. first demonstrated that the laminin-5 γ2 chain is 
proteolytically degraded by various MMPs into an 80 kDa form that reveals a cryptic 
site necessary for enhanced epithelial cell migration[91]. Another landmark study 
published in 2001 by Hlubek and colleagues correlated the expression of the γ2 chain 
of laminin-5 to the invasive front of colorectal carcinomas[166]. The authors also 
showed that nuclear accumulation of β-catenin in invasive cancer cells was present in 
primary tumours, however its expression was transient due its absence in metastases, 
which was also associated with a reduced expression of laminin γ2. They suggested 
that external influences from the surrounding ECM environment regulated the 
intracellular distribution of β-catenin and consequently activating its target genes. 
There have been other reports implicating laminin-5 modulation by the local 
microenvironment[167]. Laminin also significantly enhanced the invasion rate of 
HCT116 cells irrespective of the density of the stromal surround. Notably, the rate of 
migration differed. In the low-density collagen stroma, cells appeared to migrate in a 
linear fashion, particularly after 10 days in culture indicating the ability of the cells 
to remodel and migrate easily through this mechanically weak matrix[168]. An 
increase in stromal density revealed a gradual slowdown in HCT116 cell invasion by 
day 21. This decrease in migration speed could be attributed to the steric hindrance 
caused by the stiff surrounding stroma. 
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3.5.5 The presence of invasive leader cells corresponds with EMT and ECM 
remodelling 
An analysis of the invading cells is essential to determining how these migratory 
cues and processes are regulated. The objective of these experiments was to 
morphologically analyze the invading cells and to determine whether changes at the 
molecular level that drive invasion. All of the following experiments were done in 
tumouroids with a dense surrounding stroma.  
We observed three independent morphologies of invading HT29 cells and two for 
HCT116 cells. We found polarized collective migration was present in HT29 cells, 
which was evident by the aligned directional migration of cell sheets in non-aligned 
collagen gels indicating a high level of proteolytic degradation by cells to migrate. 
Previous studies have suggested that cancer invasion is dependent primarily on the 
loss of cell polarity, which drives the random migration of cancer cells[169]. However, 
we have found that this is not a necessary event for cancer invasion. Interestingly, we 
also observed leading elongated cells with a mesenchymal morphology at the edge of 
the invading cell sheet, forming cellular protrusions. These ‘leader cells’ often guide 
the following cells that compose the main body of the cell sheet. The collective 
migration of these cells did not appear to be driven in a single direction, with the 
presence of many leader cells migrating in random directions and appearing non-
polarized. Several recent studies have highlighted the importance of these leader 
cells and their presence on the invasive front, and it is thought that they are 
phenotypically different from follower cells[50,150]. Cheung and colleagues recently 
demonstrated in 3D organoid model of breast cancer that collective invasion was led 
by genotypically distinct cells that were defined by their expression of the basal 
epithelial genes K14 and p63[170]. They showed that knockdown of either K14 or p63 
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was sufficient enough to block collective invasion. The genotype of leading invading 
cells in tumouroids will be discussed in more detail in Chapter 4.  
Although, the behaviour of leader cells is inadequately studied in cancer, it may 
mimic TGFβ stimulated collective migration present during the wound healing 
process[50]. The presence of these leader cells in our tumouroid model also highlights 
the heterogeneity of cancer cells cultured in 3D for extended periods of time.  
Furthermore, the upregulation in expression of the EMT marker vimentin and MMP7 
suggests that invasion is an active process dependent on the proteolysis of the 
surrounding ECM. Interestingly, Remy et al have demonstrated that MMP7 
degradation of the β3 chain in laminin-5 enhanced the migration of colorectal 
adenocarcinoma[150]. The expression of MMP7 has been shown to be differentially 
expressed in a small cohort of patients with colorectal tumours in different stages 
with the highest levels of expression associated with advanced disease[51]. It is likely 
the upregulation of MMP7 coupled with the addition of laminin in the stroma is 
responsible for the enhanced migration of both HT29 and HCT116 cells in the 
collagen-laminin cultures. Interestingly, in the majority of epithelial tumours such as 
those of the bowel or breast, cells typically tend to migrate collectively as outlined 
previously in Section 1.1.3[171]. In situ, invasive cells typically upregulate EMT 
markers such as vimentin, however this change in expression is not always 
associated with a spindle shaped mesenchymal phenotype. HT29 cells which invaded 
the dense stroma as aggregates and sheets, upregulated the expression on vimentin 
highlighting the heterogeneity in cell migration utilized by cancer cells. Using 3D 
reconstructions of the cancer-host interface, Bronsert et al. found that while invading 
buds exhibited changes in the expression of EMT markers, they rarely changed to a 
spindle-shape morphology. 
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3.6 Conclusion 
In summary, we have described the development of a 3D in vitro cancer model with 
controllable parameters in both the matrix density and composition of both the 
tumour compartment and the stroma. The results presented in this Chapter have 
demonstrated distinct invasive mechanisms of CRC cells driven by matrix density 
alone i.e. from aggregates of cells to cell sheets. This model is the first to date to 
replicate the collective budding migration observed in histological sections at the 
invasive front of invading tumours. Furthermore, it appears that the invasion process 
is driven by several mechanisms simultaneously as seen by the presence of glandular 
structures, polarized collective migration and cell sheets driven by elongated leader 
cells. The addition of specific ECM proteins, such as laminins, can help further 
elucidate the interaction between cancer cells and the basement membrane, which 
acts as the primary barrier during invasion. We have found this to be particularly 
relevant for the migration of CRC cells in collagen gels. This migratory process is 
also driven by molecular cues as evident by the upregulation in ECM degradation 
proteins MMP7 and EMT marker vimentin, which contributes to a migratory 
phenotype. The development of sophisticated 3d in vitro cancer models such as the 
one presented here, aim to mimic the early steps of the metastatic process and are 
proving a vital step toward the understanding and development of therapies to 
prevent or reverse or block the switch to an invasive phenotype.  
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Chapter 4 Engineering a 
biomimetic stroma 
 
Chapter Four 
 
Engineering a biomimetic stroma 
 
4.1 Introduction 
While metastasis is the leading cause of mortality in patients with CRC[40], studies 
have only recently started investigating the ‘normal’ components of a tumour such as 
the tumour stroma. The stromal cell types present in the in vivo tumour 
microenvironment consist mainly of fibroblasts, ECs and inflammatory cells. 
Although many of these cells will initially confer tumour-suppressing properties to 
the adjacent tumour, the stroma typically changes over time and eventually promotes 
growth, invasion and metastasis. This process is driven by the constitutive expression 
of certain tumour-derived cytokines such as TGF- β that transforms normal healthy 
fibroblasts into cancer-associated fibroblasts (CAFs). In recent years, it has become 
evident that cross-talk between tumour cells, CAFs and the surrounding ECM 
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contribute heavily to the initial metastatic cascade, mainly by fibroblast mediated 
degradation of the ECM to facilitate cancer invasion[118,172–174]. 
The presence of ECs in the stroma correlates to the high levels of pro-angiogenic 
factors released by cancer cells, which recruits them to the tumour site. Tumour 
induced angiogenesis is caused by an imbalance or pro and anti-angiogenic factors 
that results in ‘leaky’ vasculature. Many of these pro-angiogenic factors are released 
by fibroblasts, which compose the bulk cellular component surrounding a tumour.  
Therefore, the objective of this Chapter was to investigate the effect of a reactive 
tumour stroma on cancer invasion and the ability of ECs to form primitive vascular 
networks within the stromal component of 10% matrix tumouroids. Due to the 
complex nature of co-culturing many types of cells together, only healthy fibroblasts 
and ECs were incorporated into the stroma. The presence of the BM was also 
hypothesized to be a critical component required for vasculogenesis and was 
included as it enhanced the invasion profile of CRC cells in the Chapter 3.   
 
4.2 Materials and methods 
4.2.1 Cell maintenance 
In this Chapter, only the HT29 colorectal cancer cell line was used. Primary HDF 
and HUVECs were incorporated into the stromal surround. All cells were maintained 
routinely in culture and the appropriate cellular concentrations were prepared for the 
experiments described below. 
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4.2.2 Fabrication of biomimetic tumouroids 
10% matrix tumouroids were fabricated as described in Section 2.8 with slight 
modifications. HT29 ACMs were created with a density of 50,000 cells per ACM 
(208,000 cells/ml). Once these were returned to the incubator, HDF and HUVECs 
were detached using trypsin and counted to give a cellular concentration of 25,000 
HDFs and 50,000 HUVECs (per ml) per single well for the three cell co-cultures. 
The cell volumes in terms of cell density were seeded with a ratio of 8:2:1 for HT29, 
HUVEC and HDF cells respectively prior to removal of interstitial fluid. The stromal 
surround cell populations are based on ratios determined in a previous study 
investigating the effect of laminin as a promoter to form vascular networks[117,142]. 
The appropriate cell numbers were added to neutralized collagen containing laminin 
at a concentration for 50µg/ml. This was mixed carefully to ensure HDFs and 
HUVECs were mixed thoroughly and no bubble formation occurred in the gels. 
Briefly, 500µl of the HDF-HUVEC-collagen-laminin mixture was added to a 24 
plate and allowed to gel for 5 minutes on a plate heater set at 37ºC. HT29 ACMs 
were then placed on top before 500µl of HDF-HUVEC-collagen-laminin solution 
was added to fully immerse the ACM. This was allowed to gel for a further 10 
minutes at 37ºC before the hydrophilic absorbers removed the interstitial fluid within 
the gel. Finally, 1ml of DMEM and EGM (1:1) was added to each well and returned 
to the incubator immediately set at 37ºC (5% CO2/air and 95% humidity). From this 
point onwards, the HT29, HDF and HUVEC co cultures will be referred to as the 
‘biomimetic tumouroids’. 
Some experiments were carried out in physiological hypoxia. Physiological hypoxia 
is also known as ‘in situ normoxia’ and is representative of the normal oxygen 
pressure present within tissues. This can typically range from 4-14% O2 in a variety 
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of different tissues such as the brain, bowel and liver[175]. A separate incubator was 
used and set at 37°C (5% CO2, 5% O2 and 90% humidity).  
 
4.2.3 Live dead assay 
The live/dead viability/cytotoxicity kit (Invitrogen, Paisley, UK) was used to assess 
the viability of the biomimetic tumouroids as stated in the manufacturers protocol. 
Briefly, 5µl of calcein AM and 20µl of ethidium homodimer-1 was added to 10ml 
distilled PBS (DPBS) and tube was inverted several times to mix the solution. Cell 
culture medium was aspirated and the cultures were washed 3 times in PBS very 
briefly. The live/dead solution was then added to each well and returned to the 
incubator at 37ºC for 45 minutes. Biomimetic tumouroids were then imaged using an 
EVOS FL imaging microscope (Invitrogen). 
 
4.2.4 Immunofluorescent staining of biomimetic tumouroids 
Immunofluorescent staining of biomimetic tumouroids was carried out as described 
in Section 3.2.5. Briefly, tumouroids were fixed using 10% formalin for 30 minutes 
and washed three times for 5 minutes with PBS. After permeabilising with 0.2% TX-
100 for 30 minutes, the gels were washed thoroughly with PBS (3 x 5 minutes) and 
blocked with 1% BSA for 30 minutes. After washing with PBS (3 x 5 minutes), the 
gels were incubated with either a CK20 rabbit primary antibody (D9Z1Z from New 
England Biolabs, Herts, UK), an anti-CD31 mouse primary antibody (JC70/A from 
Abcam, Cambridge, UK) or a vimentin mouse primary antibody (sc-6260 from Santa 
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Cruz, CA, USA) overnight at 4ºC. Following incubation, the gels were washed 3 
times in PBS for 5 minutes and incubated with an Alexa Fluor 488 goat anti mouse 
igG secondary antibody (Invitrogen, Paisley, UK) and DyLight 594 goat anti-rabbit 
igG secondary antibody (Vector labs, Peterborough, UK) for 2.5 hours at room 
temperature. The gels were then washed with PBS thoroughly (3 x 10 minutes) and 2 
drops of NucBlu (Invitrogen, Paisley, UK) was added to the PBS in each sample. 
Tumouroids were imaged in 24 well plates using an inverted EVOS FL imaging 
microscope. 
 
4.2.5 Vascular network analysis 
The formation of vascular networks in the stromal surround was analyzed and 
quantified using the ImageJ software (NIH, v1.43). The length, width, number of 
branches, junctions and loops were all quantified. The cell counter plugin was used 
for ImageJ. Figure 4.1 demonstrates how the length of each branch was measured 
and was traced over using the freehand line tool (yellow line). The numbers in the 
images below signify how the number of branches (number 1), the number of 
junctions (number 2) and the number of loops (number 3) were counted. The width 
of each vascular branch was measured using the straight-line tool and was used to 
draw across the width of each vascular branch within the image. Six images were 
analyzed per condition and all tubules, junctions and loops were quantified. 
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Figure 4.1: ImageJ analysis of vascular networks. The number of branches, junctions, length and 
width of vascular networks was analyzed using ImageJ. The numbers in the images signify how the 
number of branches (number 1), the number of junctions (number 2) and the number of loops (number 
3) were counted. (n=6) Scale bar – 100µm. 
 
 
 
 
 
 
 
 
 
 
 87 
4.3 Results 
4.3.1 Viability of cells in HDF and HUVEC co-cultures  
The objective of these experiments was to investigate the cell viability of cells in 
HDF and HUVEC co-cultures. It has been demonstrated before in collagen hydrogels 
that ECs do not survive when co-cultured with fibroblasts[108,117]. ECs are typically 
found in close proximity to the basement membrane in the in vivo scenario and it is 
thought to promote EC survival so it was added to all experiments unless stated 
otherwise. HDF and HUVECs were co-cultured together and seeded in 10% collagen 
gels containing laminin. Following 10 days of growth, the live/dead assay was 
carried out as outlined in Section 4.2.3. Interestingly, HDF and HUVEC co-cultures 
had relatively few dead cells and could be distinguished at lower magnifications 
(Figure 4.2 – left panel), as some ECs appeared to take cobblestone morphology. 
This was evident by the clustering of cells together to form small sheets throughout 
the gel. On the other hand, fibroblasts appeared disorganized throughout the gel.  
 
Figure 4.2: Live/dead stain of HDF and HUVEC co cultures. HDFs and HUVECs were co-
cultured in 10% collagen gels containing laminin. Cell viability was assessed after 10 days of culture 
using a live (green)/dead (red) assay. Scale bar (left) – 1mm, (right) – 100µm. 
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4.3.2 Vascular network formation in HDF and HUVEC co cultures 
The previous section determined that HUVECs survived in high numbers when co-
cultured with HDFs. Therefore, the objective of these experiments was to further 
investigate the morphology and behaviour of HUVECs in the absence of cancer cells 
but in the presence of stromal cells that would be present within the tumour 
microenvironment, namely HDFs. HDFs and HUVECs were co-cultured for up to 21 
days in both normoxia (21% O2) and physiological hypoxia (5% O2) and their 
morphology was investigated using immunofluorescence of CD31 and vimentin. 
HDFs and HUVECs co-cultured in normoxia in the absence of laminin formed end-
to-end vascular networks (Figure 4.3). These vascular networks were longer and 
wider, but not as interconnected as the HDF-HUVEC co-cultures in the presence of 
laminin (Figure 4.4). Vascular networks without laminin had an average length and 
width of 290.3µm ± 120.7µm and 35.9µm ± 15.4µm whereas the presence of laminin 
leads to the formation of vascular networks with a length and width of 197.5µm ± 
87.5 and 19.1µm ± 8.1µm respectively (Figure 4.4). The length and width were both 
statistically significant (p<0.05). However, an interesting observation is that co-
cultures without laminin formed significantly higher numbers of ECs with a 
cobblestone morphology in comparison to presence of laminin. HDF and HUVECs 
cultured in physiological hypoxia with laminin had a similar length and width to the 
normoxia cultures (215.2µm ± 79µm and 21.4µm ± 7.2µm respectively). Moreover, 
the presence of laminin in the normoxia cultures appeared to produce much more 
significantly interconnected vascular networks as signified by the large number of 
branches, loops and junctions (p<0.05) in comparison to the co-cultures in the 
absence of laminin and in hypoxia in the presence of laminin (Figure 4.5).  
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Figure 4.3: Endothelial cell morphology in HDF and HUVEC co-cultures. HDFs and HUVECs 
were co-cultured for 21 days under normoxia (21% O2) in 10% collagen gels with and without 
laminin and in physiological hypoxia (5% O2) with laminin only. HUVEC morphology was assessed 
using immunofluorescence of CD31 (green) and DAPI (blue). Scale bar – 100µm. 
 
 90 
 
Figure 4.4: Analysis of vascular network length and width in HDF and HUVEC co-cultures. 
ImageJ was used to quantify the length and width of vascular networks in HDF and HUVEC co-
cultures. Normoxia cultures without laminin formed longer and wider networks than either normoxia 
with laminin or hypoxia with laminin. Data is presented as mean ± SD (n=6). * p < 0.05; ** p < 0.01, 
*** p < 0.0001. 
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Figure 4.5 Analysis of the number of branches, loops and junctions in HDF and HUVEC co-
cultures. ImageJ was used to quantify the number of branches, loops and junctions in HDF and 
HUVEC co-cultures. The normoxia cultures with laminin had a significantly higher number of 
branches, loops and junctions in comparison to normoxia without laminin and hypoxia with laminin. 
Data is presented as mean ± SD (n = 6). * p < 0.05, ** p < 0.01 
 
The morphology of the HDFs was also investigated in the HDF and HUVEC co-
cultures. HDFs were stained for the mesenchymal marker vimentin, which stains the 
intermediate filaments in mesenchymal cells such as fibroblasts. HDFs stained 
positively for vimentin after 21 days in culture and had an elongated morphology 
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(Figure 4.6). HDFs also appeared to form a sheet as they appeared in the same plane 
and were appeared to align together in a single direction. This was not evident in the 
fluorescent images in the live/dead stain in Figure 4.2, which stains both cell 
populations simultaneously. 
 
Figure 4.6: Immunofluorescent analysis of HDFs in HDF and HUVEC co-cultures. HDFs and 
HUVECs were co-cultured for 21 days in normoxia in the presence of laminin. HDFs were stained for 
vimentin (red) and DAPI (blue). Scale bar – 100µm. 
 
 
4.3.3 Cell viability in biomimetic tumouroids 
The objective of these experiments was to investigate cell viability in the three cell 
biomimetic tumouroids. Biomimetic tumouroids were fabricated as described in 
Section 4.2.2 and cultured for up to 21 days and the live/dead assay performed at day 
10 and 21. Dead cells were not observed at either time point indicating an ability of 
the three cell populations to remain alive in culture together (Figure 4.7). 
Interestingly, cancer cells invaded at day 5 in a cellular stroma in comparison to day 
10 in an acellular stroma (Table 4.1). Cell aggregates and sheets invaded from the 
ACM and were both visible within the cellular stroma. Again, at day 10, cells had an 
elongated morphology similar to the fluorescent images in Figure 3.11. However, by 
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day 21, there were visible gaps within the invading cell sheet (Figure 4.7, white 
arrow) mimicking microlumens, which are often seen in epithelial tubulogenesis.  
 
Figure 4.7: Cell viability of biomimetic tumouroids. Biomimetic tumouroids were cultured for up 
to 21 days and cell viability was assessed by the live (green)/dead (red) assay. HT29 cell sheets 
invaded as cell sheets with an elongated morphology. By day 21, there were visible gaps within the 
invading sheet indicating epithelial tubulogenesis (white arrows). Scale bar – 100µm. 
 
 
4.3.4 Cancer invasion in biomimetic tumouroids 
In Chapter 3, we investigated the effect of stromal matrix composition and density on 
cancer invasion (Section 3.4.2). These experiments aimed to investigate the effect of 
a cellular stroma on the timeline of cancer invasion in addition to the size of the 
invaded cellular aggregates. In biomimetic tumouroids, HT29 cancer cells invaded at 
day 5 whereas (Table 4.1) under the same conditions without a cellular stroma they 
invaded at day 10 (Table 3.1). Although, HT29 aggregates invaded the cellular 
stroma at day 5, the size of the aggregates was not statistically significant from the 
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acellular stroma aggregates (Figure 4.8) At day 21, aggregates in the acellular stroma 
and cellular stroma were 164,497.7µm ± 49,132.9µm and 182,726.7µm ± 
78,708.4µm respectively. 
 
Stromal surround composition         Day of Invasion 
        HT29 cells 
Acellular stroma (10% collagen + laminin stroma)   Day 10 
Cellular stroma (10% collagen + laminin stroma)    Day 5 
Table 4.1: The invasion timeline of HT29 cells in both an acellular and cellular stroma. 
 
 
Figure 4.8: Invaded cell aggregate size in HT29 tumouroids. Tumouroids were cultured for up to 
21 days. HT29 cells formed cellular aggregates and invaded into either an acellular or cellular stroma. 
Data is presented as mean ± SD (n = 6). 
 
 
4.3.5 Vascular network formation in biomimetic tumouroids 
The previous experiments in this Chapter have confirmed the viability of HUVECs 
and their ability to form ‘tube-like’ structures when co-cultured with HDFs. The next 
step was to investigate cancer cell invasion and the presence of cancer cells on 
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vascular network formation. Biomimetic tumouroids were fabricated and cultured for 
up to 21 days either in normoxia or physiological hypoxia. Light microscope analysis 
of the morphology at the invading edge of biomimetic tumouroids cultured in 
normoxia proliferated much faster as evident by the greater amount of cells present 
in comparison to hypoxia and due to the inability of light to penetrate through the 
ACM (Figure 4.9a). HT29 cells invaded the biomimetic stroma as cell aggregates 
and cell sheets in the normoxia cultures. In hypoxia, cells exclusively invaded as cell 
aggregates. Cell aggregates invaded first at day 5 for both conditions, followed by 
cell sheet invasion by day 7. 
To further investigate cell morphology and the formation of vascular networks, 
HT29 cells were stained for the colorectal cancer epithelial marker CK20 and 
HUVECs were stained with CD31. CK20 is a type I cytokeratin expressed mainly in 
the gastric and intestinal mucosa[176]. CK20 was expressed uniformly throughout the 
ACM while CD31 stained positively for HUVECs in the stroma indicating viable 
ECs present within the stroma (Figure 4.9b). 
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Figure 4.9: Morphological analysis of biomimetic tumouroid invasion and vascular network 
formation in normoxia and physiological hypoxia. HT29, HDF and HUVECs were co-cultured 
together over a 21-day period. Light microscope analysis confirmed HT29 aggregate and sheet 
invasion. CK20 (red) stained positively for HT29 cells while CD31 (green) established the presence 
of vascular networks in the cellular stroma. In hypoxia, cells invaded exclusively as aggregates 
whereas in normoxia, cell aggregates and sheets were present in the stromal surround. Scale bar (top) 
– 200µm, (bottom) – 100µm. 
 
 
In normoxia, HUVECs formed tubule branches with a length and width of 456.8µm 
± 136µm and 24.2µm ± 7µm in comparison to 388µm ± 124.5µm and 20.7µm ± 
4.5µm for the hypoxic cultures (Figure 4.10). Although there were no significant 
differences in the length or width of the vascular networks, the number of tubule 
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branches, which had formed between normoxia and hypoxia, were significant 
(p=0.0031).  
 
 
Figure 4.10: Vascular network analysis in biomimetic tumouroids. Biomimetic tumouroids were 
cultured for up 21 days, stained for the endothelial cell marker CD31 and quantified using ImageJ. 
Data is presented as mean ± SD (n = 6). *p = 0.0031. 
 
 
Interestingly, the addition of HT29 cancer cells also led HUVECs to aggregate in a 
cobblestone pattern within the stroma of the normoxia cultures. In addition to the 
cobblestone morphology, HUVECs also formed disconnected, lengthy vascular 
branches (Figure 4.11). Cobblestone cells formed in large sheets on the apical side of 
the collagen gel forming a monolayer and strongly expressed membrane bound 
CD31. The cobblestone morphology of HUVECs is similar to the morphology 
routinely observed when expanding and culturing ECs in 2D monolayers[177]. On the 
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other hand, vascular networks contained a uniform intracellular expression level of 
CD31 throughout the entire tubule branch. Interestingly, the vascular networks 
observed were composed of multicellular structures, which appeared to wrap around 
in a three-dimensional configuration instead of simple end-to-end joining of single 
ECs (Figure 4.11, bottom right) 
 
Figure 4.11: Endothelial cell morphologies in biomimetic tumouroids. HUVECs formed two 
distinct morphologies, cobblestone and end to end vascular networks, in the stroma as confirmed by 
immunofluorescence of CD31 (green). HT29 cells were stained for CK20 (red). (n=6). Scale bar – 
100µm. 
 
Once the stromal component was optimized, HT29 cancer cells were added to the 
tumouroid model and this illustrated key differences in the formation of end-to-end 
vascular networks within our tumouroids. While we observed vascular network 
formation in both the HDF-HUVEC co-cultures and the HT29-HDF-HUVEC co-
cultures, there are striking differences between them. Figure 4.12 illustrates that the 
interactions of stromal cells with cancer epithelial cells in our tumouroids leads to 
the formation of significantly longer tubules than in the HDF and HUVEC co-
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cultures alone (456.8µm ± 136µm compared to 197.4µm ± 87.5µm) (p<0.0001). 
While these tubules were over 2 times as long, they were significantly less 
interconnected (p<0.0001).  
 
Figure 4.12: A comparative analysis of vascular network formation in HDF-HUVEC co-cultures 
and HT29-HDF-HUVEC co-cultures. ImageJ analysis was used to quantify and compare 
differences in vascular network formation in the presence and absence of cancer cells in HDF and 
HUVEC co-cultures. Data is presented as mean ± SD (n=6) *p < 0.0001. 
 
4.3.6 Vascular network interaction with invading cancer cells  
The metastatic cascade is initiated through a series of interactions between tumour 
cells and the nearby endothelium. While there is no functioning endothelium within 
our tumouroids, the same cell-cell interactions that take place within the in vivo 
microenvironment between cancer cells and ECs are present. Therefore, these 
experiments attempted to visualize some of these cell-cell interactions. HT29 cells 
and HUVECs were stained for CK20 and CD31 respectively. Figure 4.13 illustrates 
cell-cell specific interactions between the vascular networks and the cancer cells. 
While the vascular networks in the biomimetic tumouroids did not contain many 
junctions or highly branches networks, they appeared to fork into separate or 
diverging tubules that appeared to grow into the invading cell sheet (Figure 4.13, 
inset). Similarly, the vascular networks had a tendency to migrate towards the 
invaded cell aggregates within the stroma (Figure 4.13, bottom panel). 
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Figure 4.13: Cancer cell interaction with vascular network. Biomimetic tumouroids were cultured 
for up to 21 days and were stained for CK20 (red), CD31 (green) and DAPI (blue). Vascular networks 
appeared to migrate towards the aggressive invading cancer cell sheet edge where they diverged 
(white arrow, top right panel). Singular tubule branches also migrated towards the invaded aggregates 
within the stroma (white arrow, bottom panel). Scale bar – 100µm. 
 
4.3.7 Loss of CK20 expression 
While evaluating the interactions between cancer cells and the surrounding vascular 
networks, we observed the loss of CK20 in some of the invading cell sheets within 
the same tumouroid. However, this was strictly limited to the invaded epithelial 
sheets that had migrated the furthest distance from the ACM (Figure 4.14). HT29 
aggregates within the ACM still expressed strong levels of CK20, highlighting the 
heterogeneity of protein expression within the same tumouroid (Figure 4.14, top left) 
Using ImageJ, we found that the loss of CK20 correlated strongly with the overall 
distance of invasion. CK20 negative sheets invaded an average distance of 516.6µm 
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± 224.3µm whereas HT29 cells that retained CK20 expression invaded 254.9µm ± 
84.3µm (p=0.0089).  
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Figure 4.14: Loss of CK20 expression in biomimetic tumouroids. Biomimetic tumouroids were 
cultured for up to 21 days, fixed and stained for CK20 (red), CD31 (green) and DAPI (blue). The 
white dotted lines denote the boundary of the ACM and the stromal surround. The loss of CK20 
correlated with the overall distance migrated of the invading epithelial cell sheet. Scale bar (top) – 
1000µm, (bottom) – 100µm. Data is presented as mean ± SD (n = 6). *p = 0.0089. 
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4.4 Discussion 
The work described in this Chapter explores the effect of the tumour stroma on 
cancer invasion and the effect of cancer cells on vascular network formation. Our 
laboratory has previously demonstrated the ability to direct ECs to form end to end 
vascular networks in collagen hydrogels[117,142]. The same research demonstrated that 
ECs do not survive when co-cultured with fibroblasts in plastically compressed 
collagen gels. Therefore, using a different method of removing the interstitial fluid of 
collagen hydrogels (via biocompatible absorbers), we aimed to investigate the effect 
of EC morphology within this dense collagen matrix. The hypothesis under test was 
that cancer cells would promote the development of lengthy ‘leaky’ irregular 
vascular networks, analogous to the in vivo scenario[178]. Furthermore, a large body 
of evidence demonstrated that the tumour stroma actively promotes the invasion of 
cancer cells[118].  We investigated the effect of stromal cells on cancer invasion. 
 
4.4.1 The effect of stromal co-cultures on EC survival 
There are various reports of EC co-cultures with different cell types. These can range 
from smooth muscle cells[179], astrocytes[125] to mesenchymal stem cells (MSCs) and 
fibroblasts[180]. For our tumouroid model we chose fibroblasts due to their significant 
presence within the local tumour microenvironment[181]. One of the main issues with 
co-cultures is optimizing the correct cell ratios of the different cell types without 
compromising cell phenotype, survival and cell behaviour[182]. It is important to 
ensure there are an adequate number of supplementary cells that release the correct 
range of concentration growth factors. While there is no general consensus on the 
optimum cell ratios, it will depend on each specific study. One study in 2013 which 
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investigated this was carried out by Rao and colleagues[183]. ECs and MSCs were co-
cultured at a range of different ratios and the authors found that there was a 
threshold, which below MSC growth factors were inadequate to generate a sufficient 
cellular response. Therefore, the seeding densities and ratios should be carefully 
planned for each experiment. The ratio chosen for stromal component (2:1, ECs to 
fibroblasts) was adopted from previous work involving EC and fibroblast co-cultures 
in collagen hydrogels[142]. Contrary to previous reports, we found that ECs and 
fibroblasts survived in high numbers when co-cultured together in collagen gels. 
However, this could be due to the method of removal of interstitial fluid from 
collagen hydrogels to produce dense collagen matrices. Velazquez and colleagues 
demonstrated that the presence of fibroblasts promotes the survival, migration and 
differentiation of ECs into capillary networks via upregulation of some angiogenic 
factors[184]. They hypothesized that the differentiation of ECs into pre-mature vessels 
is not entirely mediated by VEGF/KDR pathway and that anti-apoptotic signals are 
provided by the fibroblasts in the co-cultures. 
 
 
4.4.2 Normal fibroblasts promote cancer cell invasion 
Fibroblasts are mainly responsible for the bulk synthesis, deposition and remodeling 
of the ECM within the surrounding stroma of a tumour[185]. It was originally thought 
that fibroblasts had a passive role in cancer but they are now recognized as having a 
well-established role in both the initiation and the progression of cancer[118,173,181]. 
Fibroblasts provide a large source of paracrine factors to both epithelial and 
endothelial cells. These factors include fibroblast growth factor (FGF), insulin-like 
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growth factor (IGF), EGF, hepatocyte growth factor (HGF) and the transforming 
growth factor-β (TGF-β) which contribute to an invasive phenotype[186,187].  
In our tumouroids we observed that the presence of a cellular stroma (fibroblasts and 
ECs) enhanced the invasion of HT29 cells. In an acellular stroma, HT29 cells 
invaded at day 10 and in a cellular stroma invasion occurred at day 5. Interestingly, 
although the fibroblasts used in this study were healthy primary HDFs, we found that 
they still promoted the invasion of HT29 cells from the ACM. Other groups have 
reported similar findings. A recent study in 2015 by Knuchel and colleagues tested 
the invasive capacity of cancer cells co-cultured with CAFs, normal healthy colon 
fibroblasts and dermal fibroblasts[188]. The authors showed that similarly to CAFs, 
healthy fibroblasts induced cancer cell elongation, migration and invasion through 
direct cell-cell contact. This invasion was mediated via fibroblast cell surface 
associated FGF-2 and FGF receptors and integrin αVβ5 - SRC dependent signaling in 
cancer cells. Assessing the genetic profile between freshly isolated CAFs and normal 
colonic fibroblasts could identify novel biomarkers identifying specific genetic 
patterns between invasive and non-invasive tumours. 
 
4.4.3 Normal and tumour vasculogenesis 
In the previous Chapter, laminin was added to the stromal component to investigate 
the effect of the basement membrane on cancer invasion. During metastasis, cancer 
cells degrade the surround ECM and basement membrane before they reach the 
vascular supply to travel to distant organs. Therefore, it was decided that the 
incorporation of laminin is a vital constituent, due to the prerequisite for enhanced 
cancer invasion and the close proximity of ECs to the basement membrane in 
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vivo[189]. In the stromal only cultures, ECs formed extensive, highly branched end-to-
end vascular networks whereas cultures without laminin formed significantly less 
interconnected vascular networks. This highlights the importance of matrix 
composition in regulating vasculogenesis. Stamati and colleagues demonstrated end-
to-end networks in a model of vasculogenesis in collagen hydrogels using HUVECs 
and human bone marrow derived stem cells (HBMSCs)[117]. The authors identified an 
important link between increased VEGFR2 production on ECs, regulated by 
HBMSCs, which lead to key aggregation patterns in collagen gels in the presence of 
basement membrane components. It is likely that while no HBMSCs were used in 
this study, the HDFs provided the ECs with a cocktail of angiogenic growth factors 
to generate end-to-end networks. It is also interesting to note that laminin was not 
essential in producing vascular networks in the stromal cultures alone. Its absence 
lead to significantly longer and wider networks in comparison to the laminin and 
physiological hypoxia cultures. This could be due to the lack of interconnectivity in 
comparison to the laminin cultures that leads to longer tubule branches. The 
differences in width can be attributed to the mixed EC morphology within the 
collagen only cultures. ECs formed both cobblestones and end-to-end networks. 
In biomimetic tumouroids, there were significant differences in the formation of end-
to-end networks in comparison to the stromal cultures alone. Firstly, the presence of 
cancer cells leads to the formation of significantly longer networks in the stroma, 
albeit considerably less interconnected. These disorganized and broken up vascular 
tubules mimic the ‘leaky’ vasculature that is often present within a tumour and the 
surrounding microenvironment[71]. An interesting observation in biomimetic 
tumouroids was the reduced multicellular ‘wrapping’ morphology that was observed 
in the stromal cultures alone. This is comparable to the structural differences 
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between normal and tumour vasculature where tumour vessels have highly irregular 
diameters[190]. This indicates one of two things, or a combination of both; that there 
are specific cell-cell interactions between the cancer cells which signals ECs to form 
longer ‘leaky’ vessels or a chronic overexpression of pro-angiogenic factors secreted 
by the cancer cells into the surrounding microenvironment that drives these 
differences in tubule formation. Further work could investigate the release of growth 
factor release and quantify this in comparison to the absence of cancer cells to 
identify the exact mechanistic differences between tubule formation. Some groups 
have made progress in this field[191,192]. Pepin and colleagues have genetically 
profiled distinct expression profiles between two distinct tumour vasculature 
subtypes. They identified three genes, MET, ITGAV and PDGFRβ in one subtype 
and KDR/VEGFR2 in the other subtype that were upregulated. The authors were 
able to derive a vascular signature between these two distinct tumour vasculature 
subtypes that was associated to overall disease outcome[192]. 
Similar to the stromal cultures, two distinct EC morphologies were observed in both 
the biomimetic tumouroids – cobblestones and end-to-end networks. These two 
morphologies mimic developmental mechanisms for tubulogenesis[193]. The 
cobblestone morphology has several tubules that appear to grow out of the EC sheet 
as evident in the high magnification images in Figure 4.3. From a developmental 
perspective, this morphology is similar to budding whereby a group of cells from an 
existing sheet migrate out and form a new tube as the bud extends. On the other 
hand, the presence of laminin in both normoxia and physiological hypoxia appears to 
mimic either cell or cord hollowing. In both of these cellular processes, vacuoles or 
vesicles are involved in creating the lumen of the tubules[193]. In cell hollowing, 
vacuoles are present in the intracellular spaces between individual cells whereas 
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vacuoles in cord hollowing are found in the extracellular space of cells. Ultimately, 
the vacuoles fuse to form a luminal structure. These processes have been studied 
extensively by a number of groups both in vitro and in vivo[194,195]. It was not 
possible to observe whether the vascular networks either in the biomimetic 
tumouroids or the stromal cultures alone had hollow lumens. Real time imaging of 
ECs, may be sufficient enough to delineate the exact mechanism of end-to-end EC 
aggregation in 3D collagen gels. Interestingly, the biomimetic tumouroids cultured in 
normoxia had a mixed EC morphology within the stroma, again both cobblestones 
and end-to-end networks. Although it was not studied, it could be due to the 
upregulation of VEGF by cancer which our lab has previously shown in tumouroids 
cultured at lower matrix densities[145]. It is highly likely the chronic exposure to pro-
angiogenic factors released by the cancer cells leads to the deregulation of the neo-
vascularization process where mixed signals are sent to the ECs to form new blood 
vessels using any possible mechanism.  
Biomimetic tumouroids cultured at physiological hypoxia showed no evidence of EC 
cobblestones. Differential gene expression by EC in the presence of limited oxygen 
conditions has been shown before indicating transcriptional activation of important 
angiogenic genes such as HIF-1α, HIF-2α, VEGF-A, Tie2, iNOS and 
PDGFRβ[196,197]. It is worthwhile noting that biomimetic tumouroids were cultured at 
physiological hypoxia which is 5% O2, whereas these studies used 1% and 0.5% O2 
which is more closer to the in vivo hypoxia levels of a tumour. 
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4.4.4 Fibroblast self alignment in 3D collagen 
The assembly of collagen type I hydrogels largely produces a randomly oriented 
fibril network. One of the disadvantages of using PC collagen includes a lack of 
control of this collagen fibril network. As a tumour develops, the surrounding ECM 
becomes deregulated and highly disorganized[198]. Cancer cells often lose their 
differentiation state, cell polarity and as they grow and migrate, come into contact 
with the surrounding stromal cells. This often leads to acquired mutations in the 
stroma that promotes the invasion of cancer cells. Our hypothesis was that the 
fibroblasts within the stromal compartment would be disorganized similarly to the in 
situ biomechanics of a tumour. We investigated the morphology of fibroblasts in the 
stromal component of our tumouroids. Fibroblast morphology appeared highly 
disorganized by day 10 as observed in the live/dead stain. However, by day 21, the 
expression of vimentin showed that fibroblasts appeared highly aligned. While this is 
surprising, this is not the first instance of cellular self-alignment in collagen gels. 
Georgiou et al. described the generation of self-aligned collagen gels with a 
stabilization step involving the removal of interstitial fluid for the development of 
engineered neural tissue[154]. The development of anisotropic biomaterials is highly 
desirable in nerve regeneration as it contributes to the nerve repair process. Although 
the presence of aligned fibroblasts was present in the stromal component, it is worth 
noting that the cell population used was healthy human dermal fibroblasts. Future 
work to investigate cellular alignment in our tumouroids would focus on using 
CAFs, which are known to have a rapid proliferation rate, enhanced collagen 
production and an upregulation of MMPs involved in ECM degradation[41,174]. The 
use of CAFs coupled with second harmonic generation (SHG) imaging may provide 
new insights into the deregulation of the ECM in tumours. 
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4.4.5 Tumour heterogeneity in tumouroids 
As solid tumours grow in a 3D spatial configuration, the cells within a tumour are 
exposed to varying levels of oxygen and nutrients. This leads to physical and 
chemical stresses that regulate differential gene expression in cells in different 
regions within the same tumour. This intratumoural heterogeneity is more analogous 
to the in vivo situation where diffusion limitations result in regions of hypoxic and 
proliferating cells[199]. We investigated the expression of CK20 as a CRC marker, 
which is involved in the identification of normal intestinal epithelium and 
adenocarcinomas and is used routinely in the clinic[200]. In our HT29 tumouroids, we 
observed a loss of CK20 expression in the invading epithelial cell sheets. This 
strongly correlated with the overall distance migrated of the invading sheet 
indicating that loss of CK20 was associated with tumour aggressiveness. This has 
been recently observed before in a panel of CRC tumours which were 
immunohistochemically analyzed[201]. Kim and colleagues investigated the 
pathological and molecular features of microsatellite unstable CRC tumours with 
different CDX2/CK20 expression statuses. Caudal-type homeobox 2 (CDX2) is 
another highly specific marker for intestinal epithelial tumours and is involved in 
proliferation and differentiation of intestinal epithelial cells[202]. The authors found 
the loss of either CDX2, CK20 or the simultaneous loss of both was significantly 
related with poor survival between patients with MSI colorectal cancer. Interestingly, 
while the loss of CK20 is associated with a higher tumour grade and poor 
differentiation, this does not always imply a worse survival rate as some patients 
have moderately good prognosis. Lugli and colleagues found the loss of CK20 was 
associated with a greater number of intratumoural lymphocytes, which have a more 
favourable prognosis that CK20 positive CRC without intratumoural 
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lymphocytes[203]. This contradictory nature of The expression of CK20 as a 
prognostic marker needs to be examined further to determine its specific role in 
patient outcome, particularly in CRC metastases that may sometimes exhibit a CK20 
positive phenotype[204]. 
While replicating tumour heterogeneity is one of the main aims of reproducing in 
vitro grown tumours, this is often poorly studied within cancer research. Although, 
the use of 3D cancer models is growing, very few studies have been able to 
recapitulate the heterogeneity observed within the same cultures. Most studies have 
focused on differences between cancer cells cultured in 2D and 3D[87,205,206]. This 
piece of work is the first to observe quantifiable and phenotypic differences in 
expression of proteins within the same population of cancer cells cultured for 
prolonged periods of time. While cell lines were only used, it still highlights the 
usefulness of using the tumouroid model as a suitable platform for intratumoural 
studies investigating tumour heterogeneity. 
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4.5 Conclusion   
The results presented in this Chapter aimed at optimizing growth of the stromal 
component and investigating its effect on both cancer invasion and vasculogenesis. 
According to previous reports, ECs do not survive in co-culture with HDFs when 
cultured in low-density collagen gels. We have demonstrated that ECs survive in 
high numbers in dense collagen gels, reflecting the importance of matrix density on 
cell viability and function. The presence of laminin, the main constituent of the BM, 
significantly increased and produced the formation of interconnected end-to-end 
vascular networks in dense collagen gels. As expected, the addition of cancer cells 
disrupted the interconnectivity of these networks and produced end-to-end networks 
twice as long as in the stromal co-cultures, mimicking ‘leaky’ vasculature observed 
in vivo.  Surprisingly, the invading HT29 cell sheets into the cellular stroma lost the 
expression of CK20, which correlated significantly with the overall distance of 
invasion. Clinical studies have demonstrated that the loss of CK20 by CRC cells 
corresponds to a higher tumour grade and ultimately a worse prognosis for patients. 
These results are the first to recapitulate these findings in a tissue-engineered 3D in 
vitro model of CRC. 
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Chapter 5 Therapeutic 
treatment in tumouroids 
 
Chapter Five 
 
Therapeutic treatment in tumouroids 
 
5.1 Introduction 
While the majority of preclinical therapeutic testing is carried out in reductionist 2D 
monolayers, this does not typically mimic the in vivo tumour microenvironment 
scenario accurately. This is particularly relevant for gene expression profiles, which 
can affect drug efficacy, and oxygen and nutrient gradients that control drug 
pharmacokinetics. This Chapter outlines the therapeutic efficacy of the EGFR 
inhibitor cetuximab in HT29 and HCT116 cells cultured both in 2D monolayers and 
in 10% matrix tumouroids. EGFR is highly upregulated in a variety of solid tumours, 
particularly in the bowel[20]. The therapy used to target this receptor, the monoclonal 
antibody cetuximab raised against EGFR, is used extensively in the clinic to treat 
patients with CRC with relative success[25]. 
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The two colorectal cancer cell lines used for therapeutic, HT29 and HCT116 have 
known mutational status, which affects the efficacy of cetuximab. HT29 cells, which 
are KRAS wild type, have been shown to respond to cetuximab therapy while 
HCT116 KRAS mutant are non-responders[207]. This is reflected in patients with 
KRAS mutant status[26,207,208]. 
The objective of this Chapter was to validate the use of tumouroids as a suitable 
drug-screening platform by choosing responder and non-responder cell lines in both 
2D and 3D cultures. The expression of EGFR was investigated as a biomarker and 
compared between monolayers and tumouroids. Furthermore, the objective was to 
investigate whether the presence of an active stroma influenced the efficacy of 
cetuximab treatment.  
 
5.2 Materials and Methods 
5.2.1 Immunofluorescence  
The morphology of HT29 and HCT116 cells was evaluated in 10% matrix 
tumouroids using immunofluorescence of the cytoskeletal proteins F-actin and 
tubulin. Briefly, 20,000 cells were seeded in tumouroids and cultured for 14 days. 
Tumouroids were fixed in 4% paraformaldehyde for 30 minutes and washed 
thoroughly in PBS (3 washes for 5 minutes each). The cultures were permeabilised 
with 1% Triton X-100 (TX-100) for 15 minutes and again washed thoroughly with 
PBS. This was followed by incubation with an anti-tubulin primary antibody solution 
(Abcam, Cambridge, UK; at 1:200 in a blocking solution of PBS containing 1% BSA 
and 0.2% TX-100) or CD44 antibody (Abcam, Cambridge, UK; 1:200) overnight at 
4ºC.  The samples were then washed 3 times in PBS for 5 minutes each and 
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incubated with a Cy3 conjugated secondary antibody (Jackson Immunoresearch, PA; 
1:200), Alexa Fluor 488 conjugated Phalloidin (Invitrogen, Paisley, UK; 1:40) and 
DAPI diluted in the blocking solution for 2.5 hours at room temperature. The 
cultures were then washed 3 times with PBS for 5 minutes each and imaged using an 
Olympus IX71 inverted fluorescent microscope fitted with a Prior z-focus drive. 
EGFR expression was also investigated in cells cultured in 2D. Briefly, 350,000 and 
300,000 cells/well were seeded in a 6 well plate. Cells were cultured for 48h and 
fixed using 4% paraformaldehyde for 30 minutes at room temperature. As EGFR is a 
membrane bound receptor cells were not permeabilised. The staining process is the 
same as mentioned above for tumouroids. EGFR (Abcam, Cambridge, UK) was used 
at a concentration 1:1000 as per the manufacturers instructions and the secondary 
antibody was an Alexa Fluor 488 antibody used at 1:1000. 
 
5.2.2 Cell culture and drug treatment in 2D monolayers and tumouroids 
Cells were maintained and routinely passaged as previously described in Section 2.2. 
For 2D monolayer experiments, HT29 and HCT116 cells were seeded at a density of 
32,000 and 30,000 cells/cm2, respectively. Cells were allowed to grow overnight 
before being serum-starved for 24h in serum free DMEM. 10% matrix tumouroids 
were seeded at a density of 20,000 cells (1.96 x 106 cells/ml) for both HT29 and 
HCT116 cell lines. Tumouroids were cultured for 6 days before being serum-starved 
24h prior to cetuximab treatment (on day 7). This was done to give the cells time to 
acclimatize to the new environment and for cellular aggregates to form. Cetuximab 
(Merck, Darmstadt, Germany) was diluted in serum-free DMEM over a range of 
concentrations (0.034 – 340nM) immediately prior to treatment and kept on ice. 2D 
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monolayers were incubated for 48h, while tumouroids were incubated for 72h and 
144h in cetuximab. Tumouroids that were treated for 144h had fresh cetuximab 
added after the first 72h. Controls were treated with serum-free DMEM only.  
Biomimetic tumouroids were produced in the same manner as those outlined in S 
Section 4.2.2 and cetuximab treatment was carried out as summarized above. 
 
5.2.3 Gene expression analysis 
Gene expression levels of EGFR were measured with one-step quantitative 
polymerase chain reaction (qRT-PCR) using a LightCycler system (Roche, 
Hertfordshire, UK). Tumouroids were seeded at 100,000 cells per well (n=4). Cells 
were collected from 3D collagen gels by digestion in 100-units/ml collagenase (from 
Clostridium histolyticum) in Tris buffer (Sigma Aldrich, Dorset, UK) for 2 hours. 
RNA was extracted from cells in either 2D or 3D after 3 days in culture using the 
RNeasy mini kit (Qiagen, Crawley, UK) according to the manufacturer’s 
instructions. Total RNA was quantified using a nanodrop spectrophotometer 
measuring at 260/280nm. The EGFR and GAPDH primers that were used are shown 
in the table below (Table 5.1). 
 
Primer name Length  
(Base pairs) 
Primer sequence (5’ to 3’) Melting point 
(°C) 
GC content 
(%) 
EGFR sense 16 ATCGCAAAGGGCATGA 61.5 50 
EGFR 
antisense 
19 CCAGCCCAAAATCTGTGAT 62.5 47.3 
GAPDH sense 20 AGATCATCAGCAATGCCTCC 64.2 50 
GAPDH 
antisense 
21 AGTGATGGCATGGACTGTGGT 66.8 52.3 
Table 5.1: Details and sequences of the primers used for qRT-PCR. 
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5.3 Results 
5.3.1 Cancer cell morphology in tumouroids 
The morphology of cells cultured in 10% matrix tumouroids was assessed by 
immunofluorescence of the cytoskeletal proteins F-actin and tubulin. Tubulin is 
involved in regulating microtubule based cellular functions such as cell division and 
intracellular trafficking while the actin filaments primarily drive cellular processes 
such as cell motility and the maintenance of cell junctions[209]. Figure 5.1 illustrates 
strikingly distinct morphological features between the cellular aggregates of HT29 
and HCT116 cells. HT29 cells formed well-defined tightly bound aggregates with a 
distinct expression of F-actin at the cell-cell junctions. On the other hand, HCT116 
cells formed consistently loose clusters of aggregates with a ‘grape-like’ phenotype 
with poor cell-cell adhesion in comparison to HT29 aggregates. The expression of 
tubulin within HCT116 aggregates was localized to the spindle fibers of dividing 
cells. The expression of the actin filaments was quantified and revealed a greater 
level of expression in HT29 aggregates in comparison to HCT116 aggregates (Figure 
5.1) which further supports the compact morphology of the HT29 aggregates. 
 
Figure 5.1: Immunofluorescent analysis of cytoskeletal proteins on colorectal cancer cultures. 
HT29 and HCT116 cells in 3D cultures were maintained for 14 days, fixed and stained for tubulin 
(red) and F-actin (green – phalloidin). Nuclei were stained with DAPI (blue). Scale bar – 50µm. 
 
 118 
5.3.2 Over-expression of EGFR in tumouroids compared to 2D monolayers 
Prior to cetuximab treatment, quantitative RT-PCR was carried out on the target 
receptor, EGFR to investigate any significant differences in mRNA levels between 
both cell lines cultured in 2D and in tumouroids. As the cells were seeded at different 
concentrations, which was both cell line dependent and 2D vs. 3D dependent, the 
EGFR mRNA copy numbers were standardized to 50,000 copies of G6PDH to 
ensure that likely differences in cell numbers did not interfere with expression levels. 
EGFR mRNA levels of cells cultured in 2D showed that HCT116 cells expressed 
double the EGFR level of the HT29 cells (Figure 5.2). This difference was further 
demonstrated in tumouroids cultured for 3 days, as EGFR expression levels were 
significantly upregulated in comparison to 2D monolayers. HT29 tumouroids 
expressed roughly twice the levels of EGFR in comparison to their monolayer 
counterparts (p<0.05). Similarly, HCT116 tumouroid EGFR expression increased 
approximately 3-fold in comparison to 2D (p<0.01). 
Further analysis of EGFR expression was carried out using immunofluorescence to 
investigate whether the EGFR mRNA is translated to protein and expressed. 
Immunofluorescent analysis demonstrated in 2D that HCT116 cells expressed more 
EGFR than HT29 cells (Figure 5.2). Although this was also carried out in 
tumouroids, the staining was not successful after several attempts (Figure 5.2). As 
the mRNA levels confirmed that EGFR levels were significantly higher in 
tumouroids in comparison to 2D monolayers, these experiments aimed at comparing 
the translated protein levels of EGFR in both monolayers and tumouroids. While the 
immunofluorescent staining was successfully carried out in 2D monolayers, there 
were technical issues with the staining process in the tumouroids. HT29 and HCT116 
cells were cultured in 10% matrix tumouroids for 14 days and immunofluorescently 
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stained for EGFR. The antibody failed to adequately stain both cell lines and was 
repeated on three separate occasions. Possible reasons for this are explained later in 
the discussion. 
 
 
 
 
Figure 5.2: Quantitative RT-PCR analysis of EGFR mRNA levels in colorectal cancer cells and 
immunofluorescent expression of EGFR. HT29 and HCT116 cells were cultured for 3 days in either 
2D or in 3D cultures. RNA was extracted, quantified and qRT-PCR was performed using G6PDH as a 
housekeeping gene. EGFR expression was also examined using immunofluorescence in 2D and 
tumouroids. HCT116 EGFR expression was higher than HT29 cells in monolayers while EGFR 
expression was not detected in tumouroids. Data is presented as the mean ± SD (n=3). * p < 0.05; ** p 
< 0.01. Scale bar – 100µm. 
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5.3.3 Cetuximab treatment in 2D monolayers and tumouroids 
To determine cetuximab efficacy, HT29 and HCT116 cells cultured in 2D and in 
tumouroids were treated for 48h and 72h respectively and growth inhibition was 
assessed by the alamarBlue assay. The difference in time between treatments in 2D 
and 3D is due to the differences in pharmacokinetics of drugs on a flat monolayer of 
cells in comparison to a 3D structure, which acts as a physical barrier to the drug. It 
has also been shown previously that this timeline is the optimum time to instigate the 
maximum effect of the drug, particularly in 3D cultures[210]. 
In 2D monolayers, a concentration of 0.34nM of cetuximab resulted in a 60% 
reduction in proliferation of HT29 cells compared to untreated controls (p<0.001), 
while HCT116 cells appeared to be non-responsive (Figure 5.3). Interestingly, at 
higher concentrations (3.4nM), HCT116 cell proliferation increased slightly in 
response to cetuximab treatment; however this was not statistically significant. 
Cetuximab was significantly less effective in HT29 tumouroids demonstrating a 
maximum of 40% reduction in proliferation at 3.4nM (p<0.01) while again HCT116 
tumouroids were non-responsive at all concentrations (Figure 5.4)  
As a secondary measure response to cetuximab treatment, the sizes of cellular 
aggregates within the ACM were measured after treatment to assess the impact on 
cell proliferation (Figure 5.4). A dose dependent decrease in the surface area of 
cellular aggregates broadly correlated with treatment efficacy as measured by 
alamarBlue. At a concentration of 3.4nM, HT29 cellular aggregates were 35% 
smaller in size (p<0.05) in comparison to untreated controls. HCT116 aggregate size 
remained largely unaffected by cetuximab at any of the concentrations. 
 
 121 
 
Figure 5.3: The efficacy of cetuximab on HT29 and HCT116 cells cultured in 2D. HT29 and 
HCT116 cells were treated with cetuximab at a range of concentrations for 48h and their proliferation 
was assessed by alamarBlue. Data is presented as the mean ± SD (n=4). *** p<0.001. 
 
 
 
 
Figure 5.4: The inhibitory effect of cetuximab in tumouroids. HT29 and HCT116 tumouroids were 
cultured for 7 days before being treated with cetuximab for 72h with increasing concentrations of 
cetuximab. Tumouroids were then fixed and the surface area of 10 random cellular aggregates was 
measured using the ImageJ software and calculated as a percentage of the control. Data is presented as 
the mean ± SD. * p < 0.05, ** p < 0.01. 
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5.3.4 Drug treatment in biomimetic tumouroids 
As HCT116 cells are KRAS mutant and resistant to cetuximab treatment, the 
following experiments were carried out in HT29 tumouroids with a cellular surround 
containing HDF and HUVEC cells. Biomimetic tumouroids were created as outlined 
in Section 4.2.2.  
Biomimetic tumouroids were cultured for 6 days prior to 24h serum starvation and 
72h and 144h cetuximab treatment. Cetuximab had a maximum inhibitory effect of 
12% at 340nM (Figure 5.5) at 72h while the longer exposure at 144h had resulted in 
an overall of 7% reduction in proliferation. Although this appeared statistically 
significant (p<0.0001), cetuximab was largely ineffective at instigating a similar 
effect to the cancer cell only tumouroids in Section 5.3.3. The resistance of HT29 
cells in this instance to cetuximab was further supported by the absence of dead cells 
at all concentrations (3.4nM-340nM) following a live/dead stain post treatment for 
72h. 
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Figure 5.5: The effect of cetuximab on cellular stromal surround tumouroids. Tumouroids were 
treated with cetuximab for 72h or two consecutive doses of cetuximab for 72h and the metabolic 
activity was assessed by alamarBlue (n=8). A live/dead (green/red) stain was then used to further 
assess the inhibitory effect of tumouroids after treatment with cetuximab for 72h. Data is presented as 
the mean ± SD. Scale bar – 100µm. * p < 0.05; ** p < 0.0001 
 
 
5.3.5 Cetuximab resistance in HT29 cells and overexpression of CD44 in 
tumouroids in comparison to 2D monolayers 
Due to a lack of inhibition by cetuximab in Section 5.3.4, drug treatment was 
repeated again in 2D monolayers where there previously was a 60% inhibition of 
proliferation. Cetuximab failed to produce a similar inhibitory effect when treated at 
the same concentrations as Section 5.3.3 (Figure 5.6). Although the experiments 
were carried out at different times, it should still be expected to instigate a similar 
effect. Inhibition of proliferation by cetuximab between the concentrations 3.4nM – 
340nM resulted in a maximum of 12% inhibition, which appeared to be statistically 
significant.  
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In order to further investigate the newly acquired resistance of HT29 cells to 
cetuximab, the expression of CD44 was explored as a possible mechanism of 
resistance due to its function as a cancer stem cell marker (Figure 5.6). CD44 was 
expressed in HT29 cells in both 2D and in tumouroids. However, there was a higher 
expression level in tumouroids in comparison to 2D. There was also a heterogeneous 
level of expression of CD44 within individual aggregates indicating different 
subpopulations of cancer stem cells residing within the tumouroids. 
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Figure 5.6: Cetuximab resistance in HT29 monolayers. (a) HT29 cells treated with cetuximab at 
3.4nM – 340nM for 48h displayed and the alamarBlue assay was used to measure response to drug 
treatment. (b) The expression of CD44 was also investigated (green) in HT29 cells in 2D and 3D as a 
marker for cancer stem cells and cetuximab resistance. Data is presented as the mean ± SD (n=8). * p 
< 0.05; * p < 0.01. Scale bar – 100µm. 
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5.4 Discussion 
The work in this Chapter focuses on translating the tumouroid model into a platform 
for testing anti-cancer therapeutics. The principal aim is to have an amenable, 
complex in vitro tumour model, which bridges the gap between 2D reductionist cell 
culture and animal models. Using these 3D tumour models will allow us to mimic 
certain in vivo parameters such as the stiffness of tumour microenvironment while 
maintaining the simplicity of in vitro cultures. 
 
5.4.1 Invasive and non-invasive morphologies in colorectal cancer tumouroids 
Prior to drug testing, the morphologies of both HT29 and HCT116 cells in 10% 
matrix tumouroids was evaluated by immunofluorescently staining the cytoskeletal 
proteins tubulin and F-actin. This was done to evaluate the organization of the actin 
filaments, which is involved in cell clustering during cell aggregate formation and 
also to establish whether these morphologies in EGFR positive cells play a role in 
cetuximab resistance. 
HT29 and HCT116 cells formed moderately distinct cellular aggregates. HT29 cells 
formed tight compact cellular aggregates characterized by disorganized nuclei and 
strong cell-cell adhesion while HCT116 cells formed loosely bound clusters of cells 
with poor cell-cell adhesion. These two types of morphologies cells have been 
previously observed in a recent study investigating breast cancer cell morphology in 
3D[211]. The authors cultured an extensive panel of breast cancer cell lines in 3D and 
characterized 4 distinct morphologies; round, mass, grape-like and stellate. In this 
instance the HT29 and HCT116 cells formed mass and grape-like morphologies 
respectively. The expression of tubulin was localized to the outer periphery of the 
 127 
HT29 cellular aggregates, indicating a more heterogeneous expression than HCT116 
cells. However, this may represent an inability of the antibody to penetrate 
thoroughly into the cellular aggregates, as they appear tightly bound. The penetration 
of antibodies and large molecules in both 3D in vitro culture systems and in situ 
tissues has always poised significant issues. Xiang et al. have investigated this 
extensively by treating a spheroid model of mesothelioma with a fluorescently 
labeled SS1P immunotoxin antibody and tracked its penetration over 16h. They 
reported the restricted penetration of SS1P, which was localized to the outer 
periphery of the spheroids following the first 4h of treatment, indicating inadequate 
infiltration to the core. 
Kenny and colleagues found that eight of the nine breast cancer cells that formed a 
grape-like phenotype similar to the HCT116 cells were isolated from invasive 
tumour metastases. This indicates an acquired ability to metastasize to other tissues 
over the course of their evolution. This supports the reported invasive behaviour of 
HCT116 cells in comparison to HT29 cells[146]. This is further supported by the 
presence of cellular protrusions in HCT116 aggregates which are involved in cell 
migration[212]. Occasionally these migratory fronts are driven by chemotactic 
responses that can stimulate intracellular pathways such as EGFR. A recent study by 
Patsialou et al. determined macrophage dependent invasion of breast cancer cells in a 
mouse model driven by an EGF/CSF-1 paracrine loop between cancer cells and 
macrophages[213]. The implication of these cellular protrusions in our 3D tumouroid 
model may signify underlying autocrine signaling pathways involved in the 
migration of HCT116 cells in stiff collagen matrices. 
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5.4.2 EGFR overexpression in tumouroids 
When cetuximab was first developed, it was assumed that the expression of EGFR 
would be taken as pre-requisite for cetuximab therapy. It is now known that this is 
not the case[26]. However, the mRNA and protein levels of EGFR were still evaluated 
in our tumouroids and in 2D monolayers. HT29 and HCT116 (low and high 
expressing cell lines respectively) mRNA expression of EGFR were compared and 
were greatly enhanced in 3D culture in comparison to 2D monolayers. This was also 
confirmed by immunofluorescence of EGFR in 2D. Immunofluorescence of EGFR 
in tumouroids was not possible due to an inability of the antibody to stain the cells 
and ultimately did not show up any expression.  
These results suggest that in 3D, the EGFR levels are upregulated due to intrinsic 
features present within the microenvironment of the tumouroids. This may be due to 
the strong presence of cell-cell or cell-matrix interactions in addition to the presence 
of hypoxia that may stimulate a signaling cascade to upregulate EGFR levels in 
response to low oxygen conditions to encourage cell proliferation. There have been 
conflicting results with regards to EGFR expression in 2D and 3D cultures. One such 
study by Franovic et al. demonstrated tangible increases in EGFR levels in 3D 
compared to 2D dependent on both the use of 3D cultures and oxygen levels in a 
range of brain, prostate and breast cancer cell lines[214]. Another study carried out by 
Luca and colleagues in colorectal cancer cells found that several genes involved in 
proliferation were downregulated in 3D including EGFR[205]. The authors postulated 
this could be due to microenvironmental factors impairing the expression of 
proliferation genes such as those of the EGF family. While these differences exist 
and there is no clear solution, it is important to note that cetuximab efficacy is not 
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dependent on EGFR expression and this should be taken into consideration prior to 
cetuximab treatment[215]. 
 
5.4.3 Cetuximab efficacy in tumouroids and 2D monolayers 
In order to explore the therapeutic potential of tumouroids for drug screening, 
tumouroids were cultured as described in Section 5.2.2 and treated with increasing 
concentrations of cetuximab. Alongside the proliferation assay, alamarBlue, the 
surface area of cellular aggregates was used a secondary measure of drug efficacy. 
We have already determined that HT29 and HCT116 cells express low and high 
levels of EGFR respectively. The next step was to evaluate their response to the anti-
EGFR therapy, cetuximab. 
In recent years it has become more apparent KRAS mutant status is a much more 
effective indicator of response to cetuximab treatment[26]. The HT29 cell line has a 
positive EGFR status and wild-type KRAS status whereas the HCT116 cell line is 
KRAS mutant. As expected, cetuximab was effective on HT29 cells in both 2D and in 
tumouroids displaying a maximum 60% inhibition in 2D and 40% in 3D. However 
the inhibitory effect was limited at high concentrations under both conditions. This 
could be due to several reasons. It has been suggested that cetuximab functions 
through immune dependent mechanisms, which increases the overall efficacy of 
cetuximab in vivo[216]. Therefore, the reported efficacy of cetuximab here may be 
lessened due to the lack of a functional immune component within the tumouroids. 
Hsu et al. demonstrated in a xenograft model of non-small cell lung cancer that 
increased cetuximab toxicity was driven by an immune dependent mechanism known 
as antibody dependent cellular cytotoxicity (ADCC). They postulated that it was due 
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to complement-dependent cytotoxicity, which releases anaphylatoxins such as C5a 
that increases the recruitment and activation of effector cells to the tumour site. 
Interestingly, therapeutic treatment in both 2D monolayers and in tumouroids 
illustrates that cetuximab does not follow a conventional linear drug inhibition curve 
with drug inhibition limited at increasing concentrations. This is well established and 
has been previously observed in both clinical trials and in vitro studies[24,217]. While 
there is no reason given for the in vitro scenario, it has been postulated that 
cetuximab follows non-linear, dose dependent pharmacokinetics due to reaching 
saturation levels in the serum. EGFR antibodies such as cetuximab and panitumumab 
are subject to a saturable antigen-specific elimination process based on the 
internalization of the EGF ligand-receptor complex and are subsequently removed 
from circulation[218].  
As anticipated, cetuximab was less effective in 3D than in 2D. Drug 
pharmacokinetics plays an important role in the delivery mechanism of most anti-
cancer therapeutics, particularly within 3D cultures and in vivo tumour models. 
Tumouroids displayed a degree of ‘resistance’ to drug treatment in comparison to 2D 
monolayers. The formation of 3D cellular structures in the tumouroids can function 
to obstruct the penetration of large molecules and antibodies into the core of the 
aggregates, mimicking the in vivo drug barrier present in tissues. Hence, improving 
the penetration or relying on more targeted treatments such as nanoparticles will be 
vital in maximizing the therapeutic potential while minimizing the toxicity of these 
agents to surrounding healthy tissue[87,219]. 
In line with the KRAS mutant status, HCT116 cells were resistant in both 2D 
monolayers and tumouroids to cetuximab treatment. Interestingly, at 0.34nM, 
cetuximab appeared to stimulate the proliferation of HCT116 cells in tumouroids. 
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However, this growth was very limited and did not appear to be statistically 
significant. The increases were not substantial enough to lead us to investigate this 
further, however this may be due to paradoxical activation of the MAPK pathway. 
Normally, in BRAF (V600E) tumours, inhibitors of the MAPK pathway block 
downstream signaling and prevent cell proliferation decreasing overall tumour 
growth. A recent study by Hatzivassiliou and colleagues showed that RAF inhibitors 
used in KRAS mutant tumours activate the RAF-MEK-ERK pathway in a RAS 
dependent manner thus increasing tumour growth in some models of cancer[220]. This 
was due to direct conformational changes of inhibitors on the RAF kinase domain, 
which in some instances can have the opposite of intended effect. It is interesting to 
note, there was no such pattern observed in the 2D HCT116 cultures, highlighting 
further potential advantages of using more relevant 3D in vitro models. 
 
5.4.4 Drug treatment in biomimetic tumouroids and resistance to cetuximab 
The following experiments were carried out only in the HT29 cell lines due to the 
non-responsive nature of HCT116 cells to cetuximab. Tumouroids were constructed 
using the HT29 cell lines in the ACM and HDF and HUVEC cells in the stromal 
surround as outlined in Section 4.2.2. The aim of these experiments was to 
investigate whether the presence of a biomimetic stroma influenced the efficacy of 
drug treatment. Tumouroids were allowed to mature for 7 days before either 72h or 
144h treatment of cetuximab at increasing concentrations. Although the initial 
response to cetuximab was promising, these more recent results provide some 
conflicting data. Treatment with cetuximab for 72h displayed high levels of 
resistance at all concentrations with a maximum of 12% inhibition at the highest 
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concentration (340nM). This was further supported by the absence of dead cells in 
live/dead stain carried out on treated cultures in addition to prominent invasion 
witnessed at day 10. The next step was to investigate the effect of long-term drug 
exposure (144h) on tumouroids. This is particularly difficult in 2D monolayer due to 
fast growing nature of cells as they reach confluency in a much shorter period due to 
contact inhibition. Surprisingly, cetuximab treatment at 144h elicited less of a 
response than 72h with a maximum inhibition of 7%. Although this appeared 
statistically significant, this is most likely due to a high number of repeats which 
appeared to skew the p values below 0.05. To ensure this was not an artifact caused 
by the presence of stromal cells, cetuximab treatment was repeated in 2D monolayers 
to ensure efficacy in HT29 cells. Again, HT29 cells were resistant in 2D indicating a 
newly acquired mechanism of resistance within these cells independent of 2D or 3D 
culture.  
There could be several reasons due to this new mechanism of cetuximab resistance. 
Firstly, HT29 cells are a BRAF V600E mutation cell line, which has been shown to 
be associated with a lack of response in wild type KRAS tumours in patients with 
colorectal cancer[25,30,221]. It is important to note that the cetuximab sensitive and 
resistant experiments were carried out at different times during the course of this 
work and over time the cell line may have mutated to become more resistant. In 
contrast to the presence of the V600E mutation, there have been numerous groups, 
which have reported HT29 response to cetuximab[24,222]. Although this data is 
conflicting, there has been no hypothesis put forward to the contrasting nature of 
cetuximab in HT29 cells.  
The next step was to investigate a mechanism, which may contribute to the resistance 
of HT29 cells to cetuximab. CD44 was investigated as a possible biomarker of 
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resistance due to its functional role as an important cancer stem cell marker[223]. It is 
regulated via the β-catenin/Tcf-4 signaling pathway and is particularly upregulated in 
colorectal cancer precursor legions indicating a role in intestinal tumourigenesis and 
EMT induction[224]. We found that CD44 was expressed in HT29 cells both in 2D 
and in tumouroids. However, it is interesting to note that CD44 was highly expressed 
in tumouroids, particularly within specific sub-populations of cellular aggregates. La 
Fleur and colleagues investigated the emergence of drug resistance in a model of 
head and neck squamous cell carcinoma (HNSCC) by identifying CD44low, 
CD44high/EGFRhigh and CD44high/EGFRlow cell sub-populations[225]. The authors 
found that CD44high/EGFRlow expressing cells displayed a degree of resistance to the 
anti-EGFR therapies cetuximab and gefitinib. It was postulated that the cells with 
this phenotype modulate cell signaling by the BCR/ABL and Src family tyrosine 
kinases due to their sensitivity to dasatinib. While it is important to reiterate this 
work was carried out in HNSCC, it is likely that the same mechanism may contribute 
to cetuximab resistance in HT29 cells. 
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5.5 Conclusion 
The results presented in this Chapter describe and validate the use of our tissue-
engineered tumouroids as a suitable drug-screening platform. Cancer cells form 
tumour-like cellular aggregates with visible cell-cell junctions in vitro, similarly to 
the in vivo scenario. The expression of the biomarker, EGFR, was examined and 
found to have significantly elevated mRNA levels in tumouroids in comparison to 
monolayers. HT29 and HCT116 cells responded to cetuximab treatment in 
accordance with their KRAS status. Cetuximab treatment was more effective in 2D 
monolayers than in 3D tumouroids. When the cellular stroma containing fibroblasts 
and ECs was incorporated, HT29 cells became resistant to cetuximab treatment. 
However, this appeared to be attributed to the reported BRAF mutant status of HT29 
cells in addition to the upregulation of the CSC marker CD44 that contributes 
significantly to cetuximab resistance in CRC. 
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Chapter 6 Conclusions 
 
 
Chapter Six 
 
Conclusions 
 
The research presented in this thesis has made significant contributions in developing 
a biomimetic 3D in vitro tumour model. While 2D cell culture remains the current 
gold standard for delineating biochemical and molecular mechanisms of cancer cells, 
it does not factor in the vital role of the ECM in cancer progression. Although our 
tumouroids lack the full complexity of animal models, this model is cost and time 
effective, allows for easy manipulation of cell and matrix densities and exhibits 
characteristics of the native in vivo tumour microenvironment. The research 
presented here shows for the first time behavioural characteristics of cancer cells in 
physiologically relevant collagen matrices. Furthermore, the presence of a reactive 
stroma populated with both fibroblasts and ECs incorporates the influence of the 
stroma in both cancer invasion and the formation of vascular networks.  
This research investigated the effect of ECM density and composition on cancer 
invasion. The novelty of this tumour model is its compartmentalization, mimicking 
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both the cancer mass and the stroma of a tumour. The research presented here is the 
first to investigate the migration of cancer cells from a ‘dense’ cancer mass of 
collagen I into an engineered stroma composed of collagen I of varying densities and 
known concentrations of basement membrane components. We are the first to 
describe changes in the invasion pattern of cancer cells, from spherical cell 
aggregates to cell sheets, dependent upon the stromal composition and density. These 
changes in cell morphology were associated with an epithelial to mesenchymal 
transition of cancer cells. 
Furthermore, the incorporation of a cellular stroma highlights the importance of the 
presence of ‘healthy’ cells in the local tumour microenvironment. The development 
of a vascular network, although non-functioning in this instance, is essential to a 
growing tumour. The presence of normal HDFs was shown to promote the formation 
of these vascular networks. We have shown here for the first time, differences in the 
aggregation of ECs driven by both matrix composition and the presence of cancer 
cells. Cancer cells lead to disconnected end-to-end vascular networks with irregular 
diameters, mimicking leaky vasculature, often a defining characteristic of in vivo 
tumour vasculature. The loss of expression of important colorectal epithelial markers 
such as CK20 by invading cancer cells also highlights the heterogeneity of the 
tumouroids. The loss of CK20 is observed widely in the clinic and to date, this model 
is the only one to recapitulate sophisticated cellular behaviours and to correlate it 
with tumour aggressiveness. 
Targeting tumours in a 3D environment is one of the main goals of developing more 
biomimetic in vitro models. Investigating the effect of therapeutic agents on cancer 
cells in a 3D spatial configuration is vital to developing more targeted and efficient 
therapies. Using cetuximab, we have shown major differences in the efficacy 
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between 2D monolayers and 3D tumouroids, independent of EGFR expression 
levels. This hindrance of the stiff collagen matrix in addition to the cell aggregates 
may have acted as a barrier to hinder the penetration of cetuximab mimicking the in 
vivo drug barrier in tissues.  
Further development of the tumouroid model would include the incorporation of an 
immune component. It has become increasingly that certain immunotherapies are 
more effective when cells such as lymphocytes are present. While cell lines provide 
an invaluable amount of information, the use of patient derived cells would also help 
to recapitulate the in vivo scenario even more closely. This could include the effect 
of CAFs and their function in promoting cancer invasion. Delineating the molecular 
mechanisms of end-to-end aggregation of ECs will also provide new information to 
possibly target the tumour vasculature by developing inhibitors that may disrupt 
neovascularization mechanisms hijacked by cancer cells during tumourigenesis.  
In summary, the work presented in this thesis has positively contributed to our 
understanding of the ECM and its role in cancer progression. Establishing the 
foundation of cancer cell behaviour in a biomimetic environment will prove 
fundamental in paving the route for personalized medicine as a realistic alternative in 
cancer therapy. 
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Introduction
Cancer is one of the leading causes of death worldwide 
with an estimated 12.6 million people diagnosed in 2008, 
accounting for approximately 7.6 million deaths glob-
ally.1 Cancer prognosis would improve with better thera-
peutic regimens, particularly when tumours cannot be 
managed by surgical resection alone and require subse-
quent chemo- or radiotherapy. The majority of current 
models for therapeutic and pharmacological investiga-
tions are carried out in either two-dimensional (2D) 
reductionist in vitro cell culture or severe combined 
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Abstract
The preclinical development process of chemotherapeutic drugs is often carried out in two-dimensional monolayer 
cultures. However, a considerable amount of evidence demonstrates that two-dimensional cell culture does not 
accurately reflect the three-dimensional in vivo tumour microenvironment, specifically with regard to gene expression 
profiles, oxygen and nutrient gradients and pharmacokinetics. With this objective in mind, we have developed and 
established a physiologically relevant three-dimensional in vitro model of colorectal cancer based on the removal of 
interstitial fluid from collagen type I hydrogels. We employed the RAFT™ (Real Architecture For 3D Tissue) system for 
producing three-dimensional cultures to create a controlled reproducible, multiwell testing platform. Using the HT29 
and HCT116 cell lines to model epidermal growth factor receptor expressing colorectal cancers, we characterized 
three-dimensional cell growth and morphology in addition to the anti-proliferative effects of the anti–epidermal 
growth factor receptor chemotherapeutic agent cetuximab in comparison to two-dimensional monolayer cultures. 
Cells proliferated well for 14 days in three-dimensional culture and formed well-defined cellular aggregates within the 
concentrated collagen matrix. Epidermal growth factor receptor expression levels revealed a twofold and threefold 
increase in three-dimensional cultures for both HT29 and HCT116 cells in comparison to two-dimensional monolayers, 
respectively (p  <  0.05; p  <  0.01). Cetuximab efficacy was significantly lower in HT29 three-dimensional cultures in 
comparison to two-dimensional monolayers, whereas HCT116 cells in both two-dimension and three-dimension were 
non-responsive to treatment in agreement with their KRAS mutant status. In summary, these results confirm the use 
of a three-dimensional in vitro cancer model as a suitable drug-screening platform for in vitro pharmacological testing.
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immunodeficient (SCID) animal models. It is, however, 
becoming increasingly apparent that microenvironmental 
factors play an important role in controlling both the pro-
gression of cancer and the chemotherapeutic response to 
treatment.2 Although highly useful, 2D in vitro cell mod-
els lack the sophistication of cellular orientation and cell–
matrix interactions, while animal models often overlook 
host factors that are typically involved in disease progres-
sion such as the immune system.3 Both types of investiga-
tions are routinely used by pharmaceutical companies, but 
efficiency of drug discovery and clinical translation 
remain suboptimal. For example, this holds true for the 
family of Endothelin A receptor antagonists, for example, 
atrasentan. Despite encouraging preclinical data, the 
agents failed to demonstrate a benefit in clinical trials and 
therefore have not progressed to the clinic.4 To address the 
gap between 2D culture systems and in vivo models, 
three-dimensional (3D) cell culture systems such as mul-
ticellular tumour spheroids and scaffold-based approaches 
have been used as a bridge to further our understanding of 
cancer biology, particularly how the cells may respond to 
treatment in a 3D environment. Of the available 3D in 
vitro models, spheroid assays are widely used for thera-
peutic testing;5 however, they are inherently limited by 
their size (400–600 µm) resulting from nutrient and O2 
deficiency. Spheroids develop a necrotic core surrounded 
by a rim of viable cells (100–300 µm) in the periphery.6 
Due to the absence of a matrix, cancer cells have restricted 
mobility, a key parameter in the development of microme-
tastases in vivo. More recent approaches have utilized 
natural or synthetic scaffolds. Natural scaffolds include 
extracellular matrix (ECM) proteins such as collagen, 
laminin or hyaluronic acid.7,8 They are largely malleable 
by cell behaviour, typically as a result of ECM degrading 
proteins such as matrix-metalloproteinases (MMPs). This 
is remarkably helpful for modelling the complex dynamic 
nature of tumours. Natural scaffolds are also appealing 
due to their biocompatibility and orientation that allows 
cell surface receptors such as integrins and discoidin 
domain receptors to interact with natural matrix proteins. 
Hyperhydrated gel systems such as collagen consist of 
cross-linked macromolecular networks of hydrophilic 
polymers.9 However, this hyperhydration (~99% water) is 
not physiologically representative of any tissue in the in 
vivo environment, and ultimately, more biomimetic mod-
els are needed to model tumours accurately. Synthetic 
scaffolds such as polyethylene glycol (PEG) and polygly-
colic acid (PGA) are biodegradable scaffolds that function 
to mimic the macromolecular structures of the ECM.10,11 
Compared to natural scaffolds, they are mechanically 
stiffer and therefore suitable for modelling the dense 
tumour microenvironment. However, they are not without 
their disadvantages, often having to undergo surface mod-
ifications to improve cell attachment, migration and scaf-
fold degradation.12
In this article, we describe for the first time the creation 
and use of a 3D collagen-based multiwell platform for 
therapeutic validation into colorectal cancer. Tissue-
engineered 3D cultures are generated by the RAFT™ 
(Real Architecture For 3D Tissue) technology, a process 
based on the removal of water from hyperhydrated colla-
gen hydrogels.13 This controlled removal of water provides 
a structurally and physiologically relevant matrix. We 
chose colorectal as the demonstrator cancer and used the 
HT29 and HCT116 cancer cell lines to create 3D cultures 
and monitored growth, morphology and response to tar-
geted treatment. The cell lines were chosen for their KRAS 
mutant status – HCT116 mutant and HT29 wild-type.14 
The expression of the epidermal growth factor receptor 
(EGFR) was investigated as a biomarker and compared to 
2D monolayer expression levels. EGFR was targeted for 
treatment using cetuximab, the monoclonal antibody 
raised against the EGFR receptor. These preclinical data 
demonstrate the use of our 3D cultures as a simple, fast 
and consistent model for drug testing. We propose this as a 
suitable in vitro model to help bridge the gap between con-
ventional 2D monolayer studies and complex in vivo ani-
mal models.
Materials and methods
Cell maintenance
The HT29 human colorectal adenocarcinoma cell line and 
the HCT116 human colorectal carcinoma cell lines (both 
from the European Collection of Cell Cultures, Sigma–
Aldrich, Dorset, UK) were used. HT29 and HCT116 cells 
were routinely cultured in 2D monolayers in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 
1 g/L glucose, 10% fetal bovine serum (FBS), 100 units/
mL penicillin and 100 µg/mL streptomycin (all from 
Invitrogen, Paisley, UK) at 37°C in standard cell culture 
conditions (5% CO2/air and 95% humidity).
Preparation of 3D cultures
The 3D cultures were prepared using the RAFT™ 3D cell 
culture system in 96-well plates as detailed by the manufac-
turer’s instructions (TAP Biosystems, Royston, UK). In 
brief, 2.8 mL of Minimal Essential Medium (MEM 10×) 
was added to 22.4 mL of rat-tail collagen type I. This solu-
tion was neutralized by 1.6 mL of the neutralizing solution 
provided, before 1.2 mL of the cell suspension was added 
(1.96 × 106 cells/mL). The collagen–MEM–cell solution 
was mixed gently and aliquoted into the 96-well plate 
(240 µL per well) and placed on a plate heater (37°C) for 
15 min, initiating collagen fibrillogenesis to produce a cell-
populated collagen hydrogel. While still on the heater, bio-
compatible hydrophilic RAFT™ absorbers were placed on 
the hydrogels and left for 15 min (Figure 1). This process 
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removes some interstitial fluid while preserving cell viabil-
ity and creates a more physiological matrix (9.59% ± 0.64% 
collagen as measured by freeze drying to determine the wet 
and dry weight). Fully supplemented medium was added to 
each well, and the plates were placed in the incubator, under 
standard culture conditions.
Cell proliferation and morphology
HT29 and HCT116 cultured in 3D were seeded at a den-
sity of 1.96 × 106 cells/mL per 3D culture. Preliminary 
cell density studies indicated that this was the optimum 
cell density for growth and ease of imaging (data not 
shown). Metabolic activity was assessed over 14 days 
using the alamarBlue® assay according to the manufactur-
ers’ protocol (Invitrogen). AlamarBlue measures the 
chemical reduction of resazurin to resorufin by mitochon-
drial activity and provides an indicator of metabolic activ-
ity. DMEM without phenol red (Invitrogen) was used to 
minimize saturation of the fluorescent dye. In brief, 
100 µL of alamarBlue solution (10% solution in fully sup-
plemented DMEM) was added to each well. The samples 
were incubated for 4 h at 37°C and the solution transferred 
to a black-bottom 96-well plate to obtain a fluorescent 
reading at excitation of 530 nm and emission 620 nm. Cell 
morphology was also monitored in real time by live-cell 
phase-contrast imaging using a Nikon, Eclipse TE300 
microscope.
Immunofluorescence
Cell morphology was confirmed by immunofluorescence. 
The 3D cultures were fixed in 4% paraformaldehyde for 
30 min and washed thoroughly in phosphate-buffered 
saline (PBS) (three washes for 5 min each). The cultures 
were permeabilized with 1% Triton X-100 (TX-100) for 
15 min and again washed thoroughly with PBS. This was 
followed by incubation with an anti-tubulin primary anti-
body solution (Abcam, Cambridge, UK; at 1:200 in a 
blocking solution of PBS containing 1% bovine serum 
albumin (BSA) and 0.2% TX-100) overnight at 4°C. The 
samples were then washed three times in PBS for 5 min 
each and incubated with a Cy3 conjugated secondary anti-
body (Jackson ImmunoResearch, West Grove, PA, USA; 
1:200), Alexa Fluor 488 conjugated Phalloidin (Invitrogen; 
1:40) and 4′,6-diamidino-2-phenylindole (DAPI) diluted 
in the blocking solution for 2.5 h at room temperature. The 
cultures were then washed three times with PBS for 5 min 
each and imaged using an Olympus IX71 Inverted 
Fluorescent Microscope fitted with a Prior z-focus drive.
Gene expression analysis
Gene expression levels of EGFR were measured with one-
step quantitative reverse transcription polymerase chain 
reaction (qRT-PCR) using a LightCycler® system (Roche, 
Hertfordshire, UK). Cells were collected from 3D collagen 
gels by digestion in 100 units/mL collagenase (from 
Clostridium histolyticum) in Tris buffer (Sigma–Aldrich) 
for 2 h. RNA was extracted from cells in either 2D or 3D 
after 3 days in culture using the RNeasy Mini Kit (Qiagen, 
Crawley, UK) according to the manufacturer’s instruc-
tions. Total RNA was quantified using a nanodrop spectro-
photometer measuring at 260/280 nm. All experiments 
were performed in triplicate.
Drug treatment in 2D and 3D
For 2D monolayer experiments, HT29 cells and HCT116 
cells were seeded at a density of 18,000 and 17,000 cells/
cm2, respectively. Cells were allowed to grow overnight 
before being serum-starved for 24 h in serum-free DMEM. 
The 3D cultures were seeded at a density of 20,000 cells 
(1.96 × 106 cells/mL) for both cell lines. The 3D cultures 
were maintained for 6 days before being serum-starved for 
24 h prior to treatment. This was carried out to give the 
cells time to acclimatize to the new environment and for 
cellular aggregates to form. Cellular aggregates in this 
context are defined by the migration and adhesion of can-
cer cells to each other to form cell clusters. Cetuximab 
(Merck, Darmstadt, Germany) was diluted in serum-free 
DMEM over a range of concentrations immediately prior 
Figure 1. A schematic diagram of how 3D cultures are created.
3D: three-dimensional.
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to treatment and incubated for 48 h (2D monolayers) or 
72 h (3D cultures). Controls were treated with serum-free 
DMEM only. Metabolic activity was measured using the 
alamarBlue assay and was considered an indicator of cell 
viability.
Evaluation of cell aggregate size
The surface area of 3D cellular aggregates (n = 10) was 
quantified using measurements based on their circumfer-
ence using the ImageJ software (version 1.46v). The line 
tool was used to trace around the cellular aggregates, and 
the area was calculated using a predetermined scale that 
was set in ImageJ.
Statistical analysis
Data were presented as means and standard deviations of 
each group. Statistical analysis was carried out using a 
one-way analysis of variance (ANOVA) with post hoc 
Dunnett’s test. Significance was accepted at and below 
0.05. Results were shown on occasion as percentages for 
ease of presentation. However, all statistical analyses were 
carried out on the original data.
Results
Cancer cell proliferation and morphology
To assess the metabolic activity of HT29 and HCT116 
cells in 3D culture, the alamarBlue assay was used. Since 
the assay is non-toxic, multiple readings over a timescale 
were measured for each well. Increases in metabolic activ-
ity, taken as an indicator of cell proliferation, and therefore 
increases in cell number were determined over 14 days for 
both cell lines (Figure 2(a)). HT29 cells displayed a steady 
increase in cell number that appeared to plateau at day 14. 
Morphologically, the cellular aggregates appeared to grow 
in size consistently over the 14-day period, in line with the 
proliferation measurements. On the other hand, although 
HCT116 cultures exhibited an overall growth pattern over 
14 days, there was a significant drop in the proliferation 
readings at day 7 indicating a quiescent state. However, 
phase-contrast images of HCT116 cellular aggregates 
showed no reduction or a slower rate of apparent growth 
between day 3 and day 7 (Figure 2(b)); therefore, any state 
of biochemical quiescence did not result in a concomitant 
morphological change.
The morphology of cellular aggregates was further 
determined by immunofluorescent analysis of the cytoskel-
etal proteins tubulin and F-actin. Tubulin is involved in 
regulating microtubule dynamics during cell division, 
while the actin filaments are involved in many processes 
including cell motility and the maintenance of cell junc-
tions.15 Figure 3 demonstrates the different morphological 
phenotypes of cellular aggregates of the two cancer cell 
lines in 3D culture. HT29 cells formed irregularly shaped 
aggregates of cells with a defined expression of F-actin 
visible at cell–cell junctions. HCT116 cell aggregates 
demonstrated a more ‘grape-like’ phenotype with the cells 
apparently forming loose clusters with poor cell–cell adhe-
sion in comparison to HT29 cells.16 Semi-quantitative 
analysis of the phalloidin stain demonstrated a twofold 
increase in fluorescent intensity of HT29 cells in compari-
son to HCT116 cells (data not shown). Expression of tubu-
lin was limited to the outer edges of HT29 aggregates, 
while HCT116 expression was localized to the spindle 
fibres of dividing cells throughout the aggregate.
Over-expression of EGFR in 3D compared to 
2D monolayer cultures
To determine gene expression levels, total EGFR messen-
ger RNA (mRNA) expression was assessed in HT29 and 
HCT116 cells cultured in 2D and in 3D by qRT-PCR. 
EGFR mRNA copy number was standardized to 50,000 
copies of G6PDH to ensure that possible differences in cell 
number did not interfere with expression levels. Analysis 
of EGFR mRNA levels on cells cultured in 2D showed that 
HCT116 cells expressed double the EGFR level of the 
HT29 cells (Figure 4). This difference was illustrated fur-
ther in 3D cultures cultured for 3 days, as EGFR expres-
sion was significantly upregulated in comparison to 2D 
monolayers. HT29 3D cultures expressed roughly twice 
the levels of EGFR in comparison to their monolayer 
counterparts (p < 0.05). Similarly, EGFR gene expression 
in HCT116 3D cultures was also increased approximately 
threefold in comparison to 2D (p < 0.01).
Inhibitory effect of cetuximab on 2D monolayer 
and 3D cultures
To determine the cytotoxicity of cetuximab, HT29 and 
HCT116 cells cultured in 2D and in 3D were treated for 48 
and 72 h, respectively, and growth inhibition was assessed by 
the alamarBlue assay. In 2D monolayers, a concentration of 
0.34 nM of cetuximab in HT29 cells resulted in a 60% reduc-
tion in proliferation in comparison to untreated controls 
(p < 0.001), while HCT116 cells appeared to be non- 
responsive (Figure 5(a)). Interestingly, at higher concentra-
tions, cetuximab appeared to stimulate the growth of 
HCT116 cells; however, this was not statistically significant. 
Cetuximab was less effective in 3D cultures demonstrating a 
40% reduction in HT29 proliferation at 3.4 nM; while again, 
HCT116 cultures were non-responsive (Figure 5(b)) at all 
concentrations. As a secondary measure of response to drug 
treatment, the size of cellular aggregates was measured after 
treatment and compared to untreated controls (Figure 5(c)). 
A dose-dependent decrease in the size of cellular aggregates 
broadly correlated with cetuximab treatment efficacy as 
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measured by alamarBlue. The size of HT29 cellular aggre-
gates reduced by up to 35% in size (p < 0.05) when treated 
with 3.4 nM cetuximab compared to untreated controls, 
while the size of HCT116 cellular aggregates remained 
largely unaffected by treatment at any concentration.
Discussion
Classical 2D monolayer culture provides us with a 
medium to explore basic mechanistic investigations into 
cancer cell behaviour in vitro. However, the simplicity 
of this system does not recapitulate cell–cell and cell–
matrix interactions found within the tumour architecture 
that regulates key tumourigenic pathways.17 The emer-
gence of 3D in vitro cancer models aims to address these 
issues by providing a more biomimetic environment for 
cancer cells. To create our 3D model, we chose collagen 
type I as our basic matrix component. Collagen type I 
hydrogels are particularly useful because they are highly 
biocompatible, malleable by cell behaviour and mimic 
Figure 2. Growth kinetics of HT29 and HCT116 cells in 3D culture. (a) The proliferation profile of HT29 and HCT116 colorectal 
cancer cells cultured in 3D over a 14-day period measured by the alamarBlue assay and (b) morphological analysis of HT29 and 
HCT116 3D cultures over a 14-day period. Single cells are seeded and migrate together over time to form cellular aggregates (scale 
bar – 50 µm).
3D: three-dimensional.
Figure 3. Immunofluorescent analysis of cytoskeletal proteins 
on colorectal cancer cultures. HT29 and HCT116 cells in 3D 
cultures were maintained for 14 days, fixed and stained for 
tubulin (red) and F-actin (green – phalloidin). Nuclei were 
stained with DAPI (blue) (scale bar – 50 µm).
3D: three-dimensional; DAPI: 4′,6-diamidino-2-phenylindole.
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the basic ECM composition of the natural tumour micro-
environment.18,19 Our previous work reported the devel-
opment and characterization of a model of colorectal 
cancer based on plastic compression of collagen hydro-
gels.20 The model was created with distinct compart-
ments: a plastically compressed collagen gel populated 
by cancer cells which was nested in uncompressed col-
lagen populated with fibroblasts and endothelial cells. 
This manipulation of collagen density for mimicking the 
dense nature of solid tumours was the first use of this 
technique for culturing cancer cells in 3D. The aim of 
this study was to produce and characterize the use of a 
consistent, scaled down 3D model with physiological 
levels of collagen as a potential drug-screening platform 
using two colorectal cancer cell lines and their response 
to EGFR inhibition.
Prior to drug testing, we characterized the growth char-
acteristics of the two chosen colorectal cancer cell lines in 
3D culture. The growth rates of HT29 and HCT116 cul-
tures, as measured by metabolic activity, varied slightly. 
HT29 cultures exhibited a gradual increase in proliferation 
and appeared to plateau between days 10 and 14. 
Morphologically, the cells did not stop increasing in size or 
number between these time points, implying an inability of 
alamarBlue to penetrate into the tight cellular aggregates. 
This problem of transferring 2D end-point assays to 3D 
cell culture has been highlighted before in detail, and cell 
morphology was investigated as a secondary assay of 
growth.21 Equally, HCT116 cultures proliferated well over 
the 14-day period; however, at day 7, the proliferation pro-
file appeared to drop transiently (Figure 2(a)). There was 
no concomitant reduction in the size of cellular aggregates, 
suggesting that the biochemical changes (reflected in the 
alamarBlue readings) may describe a short phase of quies-
cence, which did not affect gross cellular behaviour. HT29 
and HCT116 cultures formed morphologically distinct cel-
lular aggregates. Immunofluorescent staining of tubulin 
and F-actin demonstrated different expression levels for 
both cytoskeletal proteins. HT29 cultures exhibited a 
slightly lower, more heterogeneous level of expression of 
tubulin; however, this may have been an inability of the 
antibody to penetrate into the cellular aggregates (with 
HT29 appearing to form more tightly packed aggregates 
than HCT116). The penetration of antibodies and large 
molecules has always presented a significant issue in both 
in situ tumours and in vitro tissue-like substitutes. Xiang 
et al.22 treated a spheroid model of mesothelioma with a 
fluorescently labelled SS1P immunotoxin antibody and 
monitored penetration over 16 h. The authors reported that 
the penetration of SS1P was limited to the outer periphery 
of the spheroids following 4 h of treatment indicating inad-
equate penetration to the core of the spheroid. The ‘grape-
like’ morphology of HCT116 has been observed before in 
a panel of breast cancer cell lines cultured in 3D.16 The 
authors found that eight out of nine cells that formed a 
grape-like phenotype were isolated from tumour metasta-
ses indicating an acquired ability of these cells to metasta-
size over the course of their evolution. This supports the 
reported invasive behaviour of HCT116 cells in compari-
son to HT29 cultures.23 Furthermore, the immunofluores-
cent images in Figure 3 show the loosely bound morphology 
of HCT116 cells in addition to the cellular protrusions that 
are typically involved in cell motility.24 These migratory 
fronts are classically driven by chemoattractants that stim-
ulate intracellular pathways such as the EGFR pathway. A 
recent study by Patsialou et al.25 demonstrated that mac-
rophage-dependent invasion of breast tumour cells in a 
mouse model was driven by an epidermal growth factor 
(EGF)/colony-stimulating factor-1 (CSF-1) paracrine loop 
between host tumour cells and macrophages.25 The impli-
cation of these protrusions in our 3D model may indicate 
an autocrine signalling pathway involved in the motility of 
HCT116 cells in physiologically relevant collagen gels.
The expression of EGFR has always been taken as a pre-
requisite for cetuximab therapy. HT29 and HCT116 (low 
and high expressing cell lines, respectively) expressions of 
EGFR were compared and shown to be greatly enhanced in 
3D culture in comparison to 2D. The analysis of cetuximab 
therapy in our 3D model has demonstrated that EGFR 
expression levels do not necessarily correlate with cetuxi-
mab efficacy in vitro. This is consistent with findings in the 
literature.26 Wild et al. measured the EGFR expression lev-
els in 11 human carcinoma xenografts and their responses 
to cetuximab therapy. They revealed a very low correlation 
profile between EGFR expression in xenografts and 
response to cetuximab. However, in recent years, it has 
Figure 4. Quantitative RT-PCR analysis of EGFR mRNA 
levels in colorectal cancer cells. HT29 and HCT116 cells 
were cultured for 3 days in either 2D or 3D cultures. RNA 
was extracted and quantified and qPCR was performed using 
G6PDH as a housekeeping gene. Data are presented as the 
mean ± SD.
RT-PCR: reverse transcription polymerase chain reaction; EGFR: 
epidermal growth factor receptor; mRNA: messenger RNA; 2D: two-
dimensional; 3D: three-dimensional; qPCR: quantitative polymerase 
chain reaction; SD: standard deviation.
*p < 0.05; **p < 0.01.
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emerged that KRAS mutant status is a much more effective 
indicator of response to anti-EGFR therapy.27 The HT29 
cell line was chosen for cetuximab treatment in this case for 
its positive EGFR status and wild-type KRAS status and the 
HCT116 cell line for its KRAS mutant status. Although 
cetuximab was effective on HT29 cells in both 2D and 3D, 
its inhibitory effect was limited at high concentrations. This 
could be due to several reasons. First, HT29 cells are a 
BRAF mutant cell line which has been shown previously to 
lack a sufficient clinical response to cetuximab treatment in 
a small cohort of patients.28 Although the precise mecha-
nisms are not fully understood, it is believed that BRAF and 
KRAS mutant status should be taken together as indicators 
of cetuximab efficacy. Second, it has been suggested that 
immune-dependent mechanisms may contribute to an 
increase in the efficacy of cetuximab.29 However, reduced 
efficacy in vitro may also be attributed to the lack of an 
immune component in our current 3D model. Hsu et al. 
demonstrated for the first time in a xenograft model of non-
small cell lung cancer that increased cetuximab-mediated 
toxicity was driven by an immune-dependent mechanism. 
Complement activation leads to complement-dependent 
cytotoxicity which releases anaphylatoxins, such as C5a, 
that increase the recruitment and activation of effector 
cells. Furthermore, the differences between drug response 
in HT29 cells in 2D and 3D can also be attributed to drug 
pharmacokinetics. Similar to the in vivo scenario, our 3D 
model has displayed a level of ‘resistance’ or non-respon-
siveness to chemotherapeutic treatment in comparison to 
2D cultures. The formation of cellular structures over time 
can function to hinder the penetration of large molecules 
such as cetuximab to the cells in the core, mimicking the in 
vivo drug barrier in tissues. Hence, improving the penetra-
tion of large molecules and drugs will be vital to maximiz-
ing the therapeutic potential of these agents. Finally, 
HCT116 cells either in 2D or 3D were resistant to cetuxi-
mab treatment, in line with their KRAS mutant status. 
Interestingly, exposure to cetuximab appeared to promote 
HCT116 growth by modest, not significant amounts. This 
increase is not sufficient to lead us to investigate whether 
Figure 5. The inhibitory effect of cetuximab on colorectal cancer cells cultured in 2D and 3D. (a) HT29 and HCT116 cells were 
cultured in 2D and treated for 48 h with cetuximab. (b) HT29 and HCT116 3D cultures were cultured for 7 days and treated for 
72 h with increasing concentrations of cetuximab. Cetuximab-treated 3D cultures were then fixed and the (c) surface area of 10 
random cellular aggregates was measured using the ImageJ software and calculated as a percentage of the control (n = 4). Data are 
presented as the mean ± SD.
2D: two-dimensional; 3D: three-dimensional; SD: standard deviation.
*p < 0.05; **p < 0.01; ***p < 0.001.
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this is an example of paradoxical activation of the mitogen-
activated protein kinase/extracellular signal-regulated 
kinase (MAPK/ERK) pathway. However, it is interesting 
that no such pattern was observed in 2D HCT116 cultures, 
highlighting potential differences and usefulness of 3D 
models.
The work described here is the first to investigate the 
use of a 3D model of cancer with physiological concentra-
tions of collagen for pharmacological testing. To date, the 
preclinical drug development process has focused mainly 
on the use of monolayer cell culture systems while disre-
garding microenvironmental cues that affect cell behav-
iour, gene expression and drug diffusion. Although use of 
spheroid cultures can address drug diffusion, further incor-
poration of ECM components such as collagen can help 
direct signals that facilitate intracellular cascade events 
between intracellular and extracellular spaces that may 
influence drug distribution. This model can be further 
improved by incorporating other components of the ECM 
and cell types that are localized to the tumour stroma such 
as endothelial cells or fibroblasts.
Conclusion
In this study, we have established the use of our simple 
and consistent tissue-engineered 3D model as a suitable 
drug-screening platform. Cells behave similar to the in 
vivo scenario, forming tumour-like cellular aggregates 
with visible cell–cell junctions in vitro. Furthermore, we 
have established that cetuximab efficacy is significantly 
lower in 3D cultures in comparison to 2D monolayers, 
independent of EGFR expression levels. This signifies the 
increasingly important role of matrix density and cellular 
architecture on drug uptake and distribution. This model 
could be used to further elucidate the biological mecha-
nisms and physical limitations of drug penetration into in 
situ tumours.
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 1.  Introduction 
 Solid cancers (malignant tumors) are composed of cancer 
foci within a reactive stroma, which is populated by 
non-cancer cells such as fi broblasts and endothelial cells. 
The relative constituents vary, resulting in the architectural 
heterogeneity typical of cancer. This cancer-stromal relation-
ship is easy to observe histopathologically in the tissues. It is 
less easy to depict when imaging in vivo, either in patients 
or in animal models, as most imaging modalities (computer-
ized tomography, magnetic resonance and positive emission 
tomography) do not have the necessary resolution at the 
micrometer scale. Non-invasive imaging of the tumor micro-
architecture and detection of small disseminated disease foci 
away from the cancer mass boundaries would provide invalu-
able information that can directly inform treatment choices. 
 Nanoparticles (NPs) have the potential to act as tumor-
specifi c markers to enhance the resolution of current imaging 
platforms. Given their relative biologically inert qualities and 
stability, and unique physicochemical properties, GNPs are 
good contenders for enhancing imaging sensitivity. They are 
a reliable contrast medium for use with X-rays due to the DOI: 10.1002/smll.201400194
 In order to maximize the potential of nanoparticles (NPs) in cancer imaging and 
therapy, their mechanisms of interaction with host tissue need to be fully understood. 
NP uptake is known to be dramatically infl uenced by the tumor microenvironment, and 
an imaging platform that could replicate in vivo cellular conditions would make big 
strides in NP uptake studies. Here, a novel NP uptake platform consisting of a tissue-
engineered 3D in vitro cancer model (tumoroid), which mimics the microarchitecture 
of a solid cancer mass and stroma, is presented. As the tumoroid exhibits fundamental 
characteristics of solid cancer tissue and its cellular and biochemical parameters are 
controllable, it provides a real alternative to animal models. Furthermore, an X-ray 
fl uorescence imaging system is developed to demonstrate 3D imaging of GNPs and 
to determine uptake effi ciency within the tumoroid. This platform has implications for 
optimizing the targeted delivery of NPs to cells to benefi t cancer diagnostics and therapy. 
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high atomic number ( Z ). [ 1–3 ] This same attribute can be used 
to enhance the effects of X-ray radiotherapy [ 4–7 ] and proton 
radiotherapy. [ 8 ] Moreover, GNPs have a modifi able surface 
that can be used to increase solubility (to travel through 
the bloodstream) and enhance cell-specifi c uptake. [ 9 ] Addi-
tional coating with polyethylene glycol (PEG), sodium cit-
rate or heparin mitigates any toxicity, prevents initiation of 
blood coagulation and assists in evading the host immune 
system. [ 10 ] Further functionalization with cancer specifi c 
antibodies can enhance targeting and detection as reported 
using in vivo models with typical concentrations of the order 
of 0.01 mgNP/mL taken up by tumors—ten-fold greater 
compared to concentrations in the surrounding tissue. [ 11–14 ] 
In order to maximize their potential in cancer imaging, NP 
uptake mechanisms and impact of tumor environmental con-
ditions must be understood. 
 The cancer-stromal relationship infl uences how cancer 
cells uptake exogenous agents such as NPs. The majority of 
the research on biomarker imaging and NP uptake has been 
carried out in animal models. Although serving as a useful 
fi rst step, animal work does not always allow the delineation 
of the relevant mechanisms at the cellular level and has trans-
lated poorly to humans. The emergence of 3D in vitro cancer 
models [ 15 ] may provide a more direct and reliable method to 
test novel forms of biomarker-coupled imaging. In this paper 
we describe novel application of a 3D in vitro cancer model 
(tumoroid) capable of incorporating GNPs at typical concen-
trations achieved in vivo. The platform is based on a cancer 
model we have developed; previous molecular biology studies 
of the model have been presented to demonstrate biomim-
icry in terms of tumor growth and progression properties. [ 16 ] 
Here we present parallel work that demonstrates application 
of the model as a platform for NP uptake investigations, and 
as an imaging phantom with ability to inform development of 
NP imaging technology. It mimics tumor micro-composition, 
in terms of cell types and spatial positioning to allow specifi c 
investigations of NP uptake by cell types found within solid 
tumors. As a model, it has exciting potential for investigating 
cancer targeted imaging and therapy and can replace a con-
siderable proportion of work carried out in vivo. 
 Alongside the cellular model, a technique to measure 
GNP concentration and distribution is required for uptake 
investigations. The current gold standard technique for 
measuring GNP concentration is inductively coupled plasma 
atomic emission spectroscopy (ICP-AES). However, ICP-
AES is not an imaging technique, and digests cells in nitric 
acid at 110 °C which precludes further analysis. [ 17 ] As well 
as a clinical need for non-destructive measurement methods, 
there is also a requirement for a GNP imaging technology 
that is sensitive to suffi ciently low concentrations. Cur-
rent imaging technologies are lacking in this respect, with 
the lowest measurable concentration of 0.05 mgAu/mL 
using micro-computed tomography. [ 12 ] We have developed 
a novel non-destructive X-ray fl uorescence (XRF) tech-
nique that can be used to improve on NP imaging capa-
bilities lacking in current systems. This technique achieves 
sensitivity more than an order of magnitude greater than 
other reported techniques down to GNP concentrations of 
0.005 mgAu/mL. [ 18 ] XRF enables a greater penetration 
depth than optical techniques (being a higher energy 
modality) and offers potential for simultaneous imaging of 
multiple NP compositions. Our approach shows potential in 
both quantifi cation of and sensitivity to NP concentrations 
typically found in tumors. [ 18 ] 
 2.  Results 
 2.1.  GNP Uptake 
 The fi rst step of tumoroid production was to initiate GNP 
uptake within cell lines of each tumoroid component (artifi cial 
cancer mass: HT29 colorectal cancer cells, stromal component: 
3T3 murine fi broblasts). Uptake of GNPs of diameter 1.9 nm 
was achieved by both cell lines (incubation time 24 h) as dem-
onstrated by TEM ( Figure  1 ), and appeared to be through 
endocytosis (captured in  Figure  2 ). An incubation time of 24 h 
was found to give optimum GNP uptake in order to maximize 
GNP imaging signal per cell. It was observed that incubation 
times greater than 24 h were associated with signs of cell stress 
and apoptosis (up to 10% cell death at incubation time 48 h). 
X-ray microanalysis confi rmed gold presence within the cells; 
this involved a TEM technique that bombarded the sample 
with electrons and detected the emitted X-rays (the energy of 
emission being characteristic to elemental composition). 
 2.2.  GNP Uptake Measurement using X-Ray Fluorescence 
 Before complex tumoroids were constructed, uncompressed 
3D constructs were manufactured in order to test GNP 
uptake over a range of incubation doses. The following 
results enabled relation of GNP incubation dose with uptake 
concentrations for each cell line; this data was subsequently 
used to inform controlled engineering of GNP concentration 
within each tumoroid component (ACM and stroma). 
 2.2.1. Measured XRF Spectra 
 To confi rm sensitivity to gold the XRF system was used to 
obtain emission spectra for two 3D uncompressed HT29 
small 2014, 10, No. 19, 3954–3961
 Figure 1.  TEM image of a 3T3 fi broblast (left) and an HT29 cancer cell 
(right) incubated with 1.9 nm GNPs (incubation time 24 h). The cells 
appear viable; the dark appearance of the cytoplasm indicates presence 
of ground substances and a healthy state; organelles required for healthy 
cell functioning are present (such as the nucleus, endoplasmic reticulum 
and mitochondria). GNPs (black round spheres) appear either dispersed 
or as aggregates, mostly encapsulated in cytoplasmic vesicles. 
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cellular constructs (incubated with 4 mgAu/mL and 
0 mgAu/mL (control);  Figure 3 a). Typical measurement 
times ranged from 40 min for high concentration samples to 
400 min for the lowest concentration. The cell samples incu-
bated with gold present a spectrum with the characteristic 
gold fl uorescence lines, compared with the control samples 
which showed no gold present. 
 2.2.2. Calibration Curve 
 XRF analysis was performed on a range 
of known GNP concentration solutions in 
order to determine the actual GNP con-
centration present in the 3D constructs. 
The resulting calibration curve ranged 
from 0.005 mgAu/mL to 0.03 mgAu/mL 
(Figure  3 b). 
 2.2.3. Gold Concentration per Sample 
 Figure  3 c displays the measured GNP con-
centration found for the 3T3 and HT29 
3D uncompressed constructs. Repeats at 
the incubation dose 4 mgAu/mL gave the 
same fi nal GNP concentration within meas-
urement error. The XRF signal from the 
sample incubated with 4 mgAu/mL was 
four times greater than that incubated at 
1 mgAu/mL (Figure 3c). TEM images quali-
tatively corroborated the XRF technique’s 
fi ndings that uptake was proportional to 
initial GNP dose. Attaining a known GNP 
uptake was shown to be repeatable and 
reproducible well within the standard 
errors of measurement. Percentage uptake 
of initial incubation GNP dose per million 
cells as measured by a non-destructive XRF 
technique was found to range between 
0.3–0.5% and 0.1–0.3% for the 3T3 and 
HT29 cell constructs respectively. An order 
of magnitude estimate of the number of 
GNPs taken up per cell was undertaken 
for the highest measured GNP uptake (the 
3T3 sample given an incubation dose of 
4 mgAu/mL) as follows. The mass of gold 
per cell was estimated: A GNP concentra-
tion of ≈0.015 mgAu/mL was measured for 
this sample using XRF analysis ( Figure 3c); 
cell number was normalized to 1 million 
cells per mL. This corresponds to 0.015 ngAu 
per cell. The mass of one 1.9 nm GNP was 
estimated: Each NP was assumed to be a 
solid sphere of gold of calculated volume 
4.2 nm 3 . The volume was multiplied by the 
density of gold (19.32 g/cm 3 ) to give an esti-
mated mass of 7 × 10 −11 ng per NP. For this 
sample we inferred from XRF emissions that 
≈2 × 10 8 GNPs were present per 3T3 cell. 
 2.3.  Tumoroid Production 
 We implemented a 3D in vitro tissue-engineering technique 
to create a 3D model that incorporates NP cellular uptake: 
where the basic premise was to create a dense artifi cial 
cancer mass (ACM) comprised of HT29 colorectal cancer 
cells set within a dense collagen scaffold, surrounded by 
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 Figure 2.  TEM image of the cell membrane surface of an HT29 cancer cell incubated with 
1.9 nm GNPs (incubation time 24 h). The image has captured each step of endocytosis: 
1) GNP-membrane interaction, 2) membrane invagination to take up GNPs in to the cell, and 
3) resulting endosome transports GNPs towards the lysosomes (4).
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uncompressed collagen populated by non-cancer cells, in this 
case fi broblasts to mimic cancer stroma. [ 19 ] 
 Successful manufacture of a 3D tumoroid (full construct 
dimensions 8 mm diameter, 18 mm height; ACM diameter 4 mm) 
was demonstrated with 0.7 × 10 6 HT29 cells pre-incubated with 
5 mgAu/mL for 24 h (compressed ACM) and 6.3 × 10 6 3T3 
fi broblasts pre-incubated with 2 mgAu/mL for 24 h (uncom-
pressed stromal component). The incubation doses were chosen 
to engineer an ACM GNP concentration of 0.02 mgAu/mL and 
GNP concentration ratios of 5:1 between the ACM and sur-
rounding stroma to resemble conditions achieved in vivo. The 
engineered GNP-loaded tumoroid is displayed in Figure  4 . 
 2.4. 3D  XRF Imaging of Tumoroid 
 3D XRF imaging was performed of several image slices of the 
tumoroid, with a partial reconstruction displayed in Figure  5 . 
All component details were clearly visible with a delineated 
ACM emitting at fi ve times more than the surrounding cel-
lular stroma. The image presented in Figure  5 was taken at 
the Diamond synchrotron source, UK. The log scale amplifi ed 
recognition of the tumor region (red corresponding to 
highest gold concentration), the surrounding background 
(green corresponding to a lower gold concentration) and the 
plastic container (blue corresponding to absence of gold) in 
which the tumoroid was set. A control sample with no GNP 
incubation yielded no gold signal and so the ACM could not 
be distinguished from the surround. 
 3.  Discussion 
 3.1.  Summary of Results 
 We have presented a 3D in vitro cancer model (tumoroid) 
that was successfully used as a platform 
to image GNP uptake and distribution at 
concentrations achieved in human tissue. 
The tumoroid was engineered to have 
distinct tumor and stromal compartments 
mimicking the microarchitecture of solid 
cancers and developed as a more control-
lable replacement to small-animal models 
in order to assess NP delivery to tissue 
under controlled conditions. 
 The uptake of 1.9 nm GNPs into the 
cells used for the uncompressed single 
cell type 3D constructs and the more 
complex tumoroids was passive and 
largely related to the cell surface area, 
with 3T3 cells being larger than HT29 
cells (data not shown). It is likely that 
this passive uptake was facilitated by pro-
tein adsorption on to the GNP surface 
resulting in a protein corona from serum 
proteins found in the growth medium, 
which brings them in prolonged contact 
with the cell membrane and promotes 
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 Figure 3.  Quantitative XRF measurement of GNP concentration within 3D constructs. a) Measured spectra of 4 mgAu/mL GNP incubation dose 
uncompressed HT29 cellular construct and 0 mgAu/mL (control) acquired over 40 mins; b) Calibration curve relating XRF signal to GNP concentration. 
The XRF signal has been normalized to the Compton peak and acquisition time. [ 20 ] A weighted linear fi t (solid line) and boundary levels (dashed lines) 
are shown. The boundary levels were fi t to fully include 95% of the data points and their error bars; the latter calculated using Poisson statistics. 
Measurements were made over a range of known GNP concentration solutions; c) GNP concentrations measured in 3T3 and HT29 3D uncompressed cell-
populated collagen gel constructs over a range of initial incubation doses. The boundary levels of (b) were used to determine the error on each sample 
GNP concentration measurement, which was then added in quadrature to the error in the XRF measurement resulting from statistical fl uctuations.
 Figure 4.  Tumoroid consisting of an artifi cial cancer mass (ACM):stromal surrounding GNP 
concentration ratio 5:1, the ACM of approximate concentration 0.02 mgAu/mL. a) Microscopic 
appearance (TEM) of tumoroid photographed in (b). The boundary between ACM and stroma 
is evident as a difference in collagen density, the greatest difference in collagen greyscale 
mapped as a dashed line to estimate the cancer/stromal boundary; collagen is more dense 
within the ACM (above dashed line) and stromal collagen less dense (below dashed line). 
GNP containing vesicles are visible within the cells.
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endocytosis. [ 20 ] There is huge potential for active targeting 
through conjugation of the NPs to antibodies that target 
tumor biomarkers and provide functional information as 
to the cellular characteristics of the tumor; for example for 
use in mapping hypoxia. 
 Dose dependent uptake was demonstrated at incubation 
times of 24 h. Signs of cytotoxicity were observed for longer 
incubation time. However, evidence for the cytotoxicity of 
GNPs is equivocal and requires further study. [ 11,21,22 ] 
 To our knowledge, no other tissue engineered in vitro 
alternative exists as an imaging platform for research in to 
imaging biomarkers. Our construct is biomimetic in terms 
of cell composition and spatial orientation (cancer mass sur-
rounded by collagen matrix and stromal cells). In particular, 
by using plastic compression, we have increased the density 
of cell-seeded collagen type I hydrogels to ≈7% (w/v), which 
aims to approach densities found in vivo (generally accepted 
as >10%). Cell viability was retained in cells embedded in the 
scaffold during compression (results not shown); a previous 
study showed that the standard compression method results 
in only a 10% reduction in cell viability. [ 23 ] Using a tissue 
engineering approach allows a high degree of modulation 
and reproducibility which is needed to probe how NP uptake 
is infl uenced by controlled introduction of further cell types 
and incorporation of different matrix components according 
to designed spatial positioning within specifi c local matrix 
densities. To the authors’ knowledge, the latter and its impor-
tance in cell uptake behavior within tissues is not addressed 
by any other existing in vitro cancer model. 
 Furthermore we have presented a novel quantitative 
imaging module (XRF) that is sensitive to GNP concentration 
and distribution and can perform non-destructive imaging of 
bulk 3D samples, the latter imperative for NP uptake studies. 
To summarise the important novel charac-
teristics of our imager, achieved through it 
being purpose designed and custom built, 
we can now meet the needs of NP-imaging 
that are required by the community and 
yet to be met in the literature: i) sensitivity 
to low NP concentrations typically found 
in vivo (our system is an order of magni-
tude more sensitive to others reported, 
with a detection limit of 0.005 mgAu/mL), 
ii) ability to quantify NP concentration 
over a 3D matrix: our high energy tech-
nique can measure bulk 3D volumes at 
depth (1–2 cm) currently unachievable by 
NP imaging techniques, iii) contains 3D 
positional information of NPs (with spatial 
resolution better than other technologies 
due to implementation of polycapillary 
optics), iv) does not require destruction 
of the sample unlike gold standard TEM 
and ICP-AES. In addition the module 
has potential for multiparametric imaging 
(simultaneous measurement of multiple 
NP types). We used both XRF imaging 
and the reference standard of TEM to 
observe GNP uptake and distribution in 
our 3D tumoroids. The use of GNPs as a contrast agent ena-
bled micrometer scale tumor detail to be imaged as can be 
observed in Figure  5 . This result demonstrates clinical poten-
tial of GNP-XRF imaging; tumors are not homogeneous, 
regularly shaped tissues and as such require an imaging tech-
nique to fully characterise the cell types and distributions 
within them to fully inform therapy regimens. 
 Our XRF technique was used to perform an order of 
magnitude estimate of the number of GNPs taken up per cell. 
At the highest given GNP dose of 4 mgAu/mL we estimated 
that ≈2 × 10 8 GNPs were present per 3T3 cell. This number 
of NPs per cell is in keeping with previous reports; one study 
quantifi ed NP uptake per cell at a rate that was four orders 
of magnitude lower than our own (3000 per cell) for HeLa 
cells given an incubation dose four orders of magnitude 
lower (0.14 µgAu/mL) with 14 nm GNPs. [ 20 ] A different NP 
size, and GNP stabilized with sodium citrate and different 
cell lines renders the results not directly comparable, but 
indicates that our estimates of number of GNPs per cell is 
appropriate and accurate. 
 3.2.  Clinical Implications 
 We have demonstrated the ability of imaging micrometer 
scale tumor detail using GNPs as a contrast agent and an 
XRF technique sensitive to GNP concentration and distribu-
tion. This holds great potential in the development of plat-
form technology, which relates to: i) testing active targeting 
of GNPs to tumors for a range of tumor characteristics 
under controlled conditions using our model as a platform; 
NP XRF can be used to determine microstructural and func-
tional signals of a range of biomarkers within the tumoroids, 
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 Figure 5.  XRF image of three different cross sections of a tumoroid composed of an ACM 
and surrounding 3T3-embedded collagen gel with a challenging GNP concentration ratio 5:1 
between the ACM and surrounding. The blue-to-red colour scale presents gold concentration 
(red representing the highest gold concentration).
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ii) harvesting and growth of cancer cells from a patient 
within our tumoroids, we can test the tumor characteristics, 
signalling and response to therapies on a patient-by-patient 
basis, delivering potential for true personalized medicine, 
iii) the development of a higher energy XRF system for 
potential to work towards GNP XRF in vivo imaging of 
tumors to guide therapy; the possibility of clinical transla-
tion from synchrotron to bench-top source has been dem-
onstrated previously, [ 18 ] iv) the ability to map specifi c tumor 
characteristics such as hypoxia can be used to inform cancer 
therapy regimens, for example, radiotherapy dose escalation 
to hypoxic regions, and v) NP XRF imaging enables capa-
bility to detect small clusters of infi ltrating cancer cells com-
monly missed by current imaging modalities. 
 GNPs were selected in this study to demonstrate the con-
cept of our platform for nanoparticle uptake and imaging 
studies as they are widely used within the community due 
to their clinical viability and are heavily reported within the 
literature; however our uptake and imaging platform is not 
limited solely to gold and will be used in future studies for 
uptake investigation of a range of clinically relevant metallic 
nanoparticles. 
 3.3.  Future Research 
 This work provides the basic protocol for assessing biofunc-
tionalized NP uptake in 3D in vitro models through the 
development of tumoroids; we shall extend the current work, 
which involved NP uptake in monolayer cultures to investi-
gate the cellular uptake of NPs in 3D cultures to represent 
more realistic in vivo conditions representative of the clinical 
situation. We also aim to make the model more sophisticated 
in terms of adding fl ow components to simulate lymphatic 
drainage and vasculature leakage. 
 The tumoroids provide a more controllable replacement 
to small animal models in order to assess imaging and treat-
ment regimes under modifi able tumor and stromal conditions. 
For example, investigations of the dose enhancing power of 
GNPs in radiotherapy will be undertaken using the models. 
Tumoroid technology has the potential to escalate progress in 
NP applications in cancer imaging and provision of personal-
ized cancer therapy, providing a platform to inform targeted 
drug delivery and uptake, and to assess the effectiveness of 
therapy at the cellular level. We have been developing in 
parallel a model for investigations in to tumor growth and 
progression and for therapeutic screening. [ 16 ] This model has 
demonstrated the formation of a hypoxic core at the centre 
of the ACM and expression of vascular endothelial growth 
factor (VEGF) by cancer cells at the stromal boundary. The 
level of hypoxia is controllable and dependent on the cell and 
extracellular matrix (ECM) density. We aim to implement 
such tissue engineering strategies to investigate the effective-
ness of NPs targeted for hypoxia. We will also use the tumor-
oids to investigate multi-biomarker imaging where different 
molecular targeting biomarkers can be tagged to different 
element NPs each of which will give a specifi c XRF signal 
and allow the sophisticated mapping of disease or response 
to treatment. 
 4.  Conclusions 
 A 3D in vitro colorectal tumoroid, which mimics the micro-
architecture of solid cancers incorporating GNPs at typical 
concentrations achieved in vivo, was developed in order to 
provide a nanoparticle uptake platform in order to develop 
nanoparticle imaging and therapy studies under controlled, 
variable tumor and stromal conditions. 
 Production of the tumoroids involved two stages during 
their development: i) effecting GNP uptake in cells, and 
ii) embedding the cells in a 3D scaffold. The former stage was 
successfully achieved with relative ease, thought to be pas-
sively facilitated by protein adsorption on to the GNP sur-
face of serum proteins found in the growth media. Future 
work will look at different culture media to see if different 
protein corona on the surface of GNPs has an infl uence on 
cell uptake and warrants further investigation. Percentage 
uptake of initial incubation GNP dose per million cells was 
found to range between 0.3–0.5% and 0.1–0.3% for the 3T3 
and HT29 cell constructs respectively. In an in vivo situation 
tumor cells will take up more GNPs than healthy cells due 
to leaky tumor vasculature and poor lymphatic drainage at 
tumor sites. The differential uptake of GNPs between cancer 
and stromal cells may be improved through functionalisa-
tion using specifi c antibodies, growth factors, and targeting 
peptides to meet the overall eventual aim of this project in 
using GNPs as contrast agents to image the distribution of 
bio-parameters of a tumor. TEM images qualitatively cor-
roborated the XRF technique’s fi ndings that uptake was pro-
portional to initial GNP dose, and captured the nanoparticle 
internalisation process of endocytosis. 
 3D-XRF imaging successfully measured a challenging 
GNP concentration ratio of 5:1 between the ACM and 
stroma of the tumoroid and all component details could 
clearly be seen. The current model will be extended in the 
future from GNP incubation in 2D culture towards 3D cul-
ture incubation techniques. Here our aim is to mimic the 
tumor microenvironment through platform technology to 
determine how cell-cell communication, cell-ECM inter-
actions, ECM and cell density, and outside physical and 
mechanical forces found under physiological conditions 
such as shear stress and fl uid fl ow, will affect and infl uence 
the uptake of nanoparticles in cells, making use of the non-
destructive XRF imaging technique to map the time course 
of GNP distributions within the model, which will have 
direct implications in personalized medicine and patient 
healthcare. 
 5.  Experimental Section 
 Gold Nanoparticles : GNPs with a 1.9 nm gold core and water-
soluble organic shell (Aurovist, Nanoprobes Inc., USA) were sus-
pended in phosphate buffered saline (PBS) and/or cell culture 
media to form 10 mgAu/mL stock solution. GNP size quantifi cation 
of these commercially available GNPs was previously measured 
through TEM analysis and found to have a mean particle diameter 
of 2.2 ± 0.2 nm (≈70% of particles ranged between 1.5 nm and 
2.5 nm). [ 24 ] 
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 Cell Culture and GNP Incubation : The human colon adeno-
carcinoma cell line HT29 (passages [p]:30-42) and the mouse 
embryonic fi broblast cell line 3T3 (p:28-32) (ECACC, Sigma-Aldrich, 
Dorset, UK) were cultured routinely under aseptic humidifi ed con-
ditions at 37 °C in 5% CO 2 /95% air, in Hepes buffered Dulbecco’s 
Modifi ed Eagle Medium (DMEM plus 1000 mg glucose/L and 
 l -glutamine, Sigma-Aldrich); and supplemented with foetal calf 
serum (10% FCS, 5129, First Link UK Ltd, Birmingham UK) and 
penicillin/streptomycin (1% P/S, GIBCO, Invitrogen, Paisley UK). 
For GNP experiments, cells were grown in 25 cm 2 fl asks to 75% 
confl uence and incubated with GNPs (0.5–5 mgAu/mL) in order 
to i) relate GNP incubation concentration with cellular uptake 
concentration for each cell line, and ii) to inform engineering of 
tumoroids to allow control of GNP concentration in each compo-
nent (ACM and stroma). Incubation was performed under a range 
of incubation times up to 48 h, under routine conditions, to ascer-
tain an incubation time for optimized GNP uptake within the limits 
of cell viability. After incubation, a strict protocol was followed 
to ensure reproducibility and maximum cell harvesting. The cells 
were washed with PBS (2 × 3 min), PBS-EDTA (1 × 2 min) and enzy-
matically detached using 0.5 mL of 1 mg/mL Trypsin in PBS-EDTA 
(1 min). Cells were resuspended in 5 mL media, 50 µL were 
removed for counting (haemocytometer) and the remaining were 
centrifuged (400 g , 5 min). Cells were resuspended in a fi nal 
0.1 mL or 0.4 mL of media, as appropriate to be used for manufac-
turing of 3D in vitro constructs. 
 Manufacture of 3D Uncompressed Cellular Constructs : 3D 
tissue culture constructs were engineered using HT29 cancer cells 
and 3T3 fi broblasts. All cells had taken up GNPs. The formation of 
collagen type 1 lattices involves fi brillogenesis—a thermodynami-
cally driven fi bril aggregation following neutralization of native 
collagen solution. Resultant collagen hydrogels consist mainly 
(>99%) of water and are therefore of a much lower collagen 
density than that found in vivo. We mixed collagen type I (rat-
tail collagen type I, protein concentration 2.035 mg/mL in 0.6% 
acetic acid, First Link UK Ltd.) and minimum essential medium 
(MEM, 10X with Earle's Salts, without  l -glutamine, sodium bicar-
bonate, GIBCO 21430, Invitrogen) and adjusted the pH to 7-7.7 
(NaOH: 1  m , 5  m ), as judged by indicator colour change. GNP-
containing cells (either HT29 or 3T3) were immediately added 
and the mixture micro-pipetted to ensure even cell dispersion. 
Collagen:medium:cell volume ratios were 8:1:1. The mixture 
(1 mL) was transferred to a polypropylene container (inner/outer 
diameter 8/9 mm, height 45 mm, 1.5 mL volume, Nunc), and the 
gel allowed to set in a humidifi ed incubator, 5% CO2/95% air at 
37 °C for a minimum of 30 min. 
 Manufacture of Tumoroid : A 3D in vitro tissue-engineering 
technique was implemented to create a 3D model that enables 
NP cellular uptake: where the basic premise was to create a dense 
artifi cial cancer mass (ACM), surrounded by uncompressed col-
lagen populated by non-cancer cells, in this case fi broblasts 
to mimic cancer stroma. [ 19 ] Briefl y, for the ACM, collagen type I 
and minimum essential medium (MEM) were mixed and the pH 
adjusted to 7-7.7 (described above). GNP-containing HT29 cells 
were immediately added to the mixture using a micro-pipette, 
and poured into a cuboidal mould resting on a nylon mesh which 
was in turn placed on top of a 165 µm stainless steel mesh and 
absorbent paper and allowed to set into a gel at room temperature for 
30 mins. [ 19 ] The gel was compacted using a standard plastic 
compression protocol modifi ed from [ 18 ] (compression under a 
73.55 g load, for 5 mins). The gel was turned over and the pro-
cess repeated to reduce cell concentration gradients resulting from 
directional fl uid fl ow. This compression results in approximately a 
16–fold increase in collagen density compared to uncompressed 
gels giving a fi nal collagen density for the ACM of 6.7% (w/v). [ 25 ] 
Collagen:MEM:cell volume ratios were 8:1:1 with an overall, pre-
compression volume of 4 mL. The dense ACM cuboid gel was 
divided in to ≈4 mm segments and each segment nested into a 
1 mL uncompressed collagen gel populated with GNP-containing 
3T3 fi broblasts (prepared as above) before placing in the incu-
bator and allowed to set. Full construct dimensions were 8 mm in 
diameter, 18 mm in height, and an ACM diameter of 4 mm. The 
construct was incubated for at least 30 mins before fi xation with 
10% gluteraldehyde (in PBS) for 24 h at room temperature. The 
30 minute incubation times were not suffi cient for cell-mediated 
gel contraction, which habitually starts within a few hours of incu-
bation and can continue to over a week. [ 26 ] 
 Transmission Electron Microscopy (TEM) : Fixed 3D culture 
constructs were dissected using a scalpel blade in to cubes < 2 
mm in thickness, washed in PBS and postfi xed using 1% osmium 
tetroxide/1.5% potassium ferricyanide (BDH, Leicester, UK) for 
1.5 h; washed in distilled water and dehydrated through a 
degrading ethanol series (30% to 100%). They were then placed 
in 50% alcohol/50% Lemix epoxy resin (TAAB Laboratories Equip-
ment Ltd, Reading, UK) mixture overnight (18 h), and the following 
day infi ltrated with 100% Lemix resin for 2 d and fi nally embedded 
in fresh Lemix resin and polymerized at 70°C overnight (18 h). 
Ultrathin sections were cut using a diamond knife (Diatome) and 
collected on 300HS, 3.05 mm copper grids (Gilder). Sections were 
stained with saturated uranyl acetate in 50% ethanol (TAAB) for 
four minutes followed by Reynold's lead citrate for 5 min (BDH). 
Sections were viewed using a Philips CM120 TEM and photo-
graphed with an AMT Digital Camera (Deben UK). 
 X-Ray Fluorescence Technique : A technique based on inducing 
X-ray fl uorescence (XRF) in GNPs was developed to enable non-
destructive quantitative assessment of the GNPs incorporated 
into the 3D constructs. [ 18 ] Here we have extended this 1D meas-
urement technique to enable step and shoot 3D imaging of bulk 
samples. [ 27 ] The system comprised a laminar incident excitation 
X-ray beam to excite the GNPs to fl uoresce, in conjunction with an 
energy-resolving 10 mm 2 silicon drift detector (SDD) coupled to a 
slightly focusing polycapillary optic which allowed collection and 
3D mapping of fl uorescence emissions. [ 28,29 ] The magnitude of the 
XRF signal characteristic to gold was proportional to the concentra-
tion of GNPs in the measurement volume. To calibrate, 1 mL GNP 
solutions were used at 0.005–0.04 mgAu/mL; the concentration 
range covered the range of GNP concentrations retained by the cell 
preparations. 
 GNP Uptake Measurement using X-Ray Fluorescence : Cell cul-
tures (HT29, 3T3) were incubated with GNPs (0.5–4 mgAu/mL) 
for 24 h and used for manufacture of 1 mL 3D uncompressed 
cellular constructs (as above). A maximum of 5 × 10 6 cells/mL 
were embedded into the collagen gel. XRF measurement using a 
clinically available bench-top molybdenum X-ray tube was used to 
determine the internalized GNP uptake effi ciency over a range of 
concentrations. 
 XRF Imaging of Tumoroid : Measurements were made at 
the Diamond Light Source, Oxford, UK. The incident energy was 
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optimized for gold XRF excitation, set to 15 keV (above the edge for 
gold L-fl uorescence of 11.9 keV and 13.7 keV for Lα / Lβ 2 and Lβ 1 
fl uorescence respectively), a compromise between optimum exci-
tation and minimization of the impact of the Compton shoulder 
background on the gold fl uorescence line. The beam, sample 
centre and SDD-optic module were aligned. A CCD camera located 
behind the sample was used to monitor the beam-sample align-
ment. An ionization chamber was used to monitor beam intensity 
in order to normalize the data. The sample was then scanned in 
both the  x -,  y -, and  z -directions to build up a pixellated image. The 
full energy spectrum was obtained at each point. GNP images were 
reconstructed off-line by computing the integral counts under the 
gold  Lα and  Lβ fl uorescence peaks. 
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